State,Payer_Name,Payer_Type,LOB,Drug_Class,Medication_Category,Step_Therapy_Required,Step_1_Requirement,Step_1_Duration,Step_2_Requirement,Step_2_Duration,Quantity_Limit,Contraindication_Bypass,Gold_Card_Available,Gold_Card_Threshold,Policy_ID,Source_Document,Vault_Payer_ID,National_Payer_ID,Vault_Denial_Code,Episodic_Same_As_Chronic,High_Freq_Episodic_Threshold,Episodic_Notes
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans from different chemical families (sulfonamide: sumatriptan/naratriptan vs indole: rizatriptan/zolmitriptan),≥4 weeks each unless early discontinuation for documented adverse effects,N/A",,Standard QL,Yes - CV risk factors (uncontrolled HTN, CAD, CVD) qualify immediately without triptan trial; contraindication to vasoconstrictive agents,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-001,True,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 distinct oral preventive classes (beta-blockers, anticonvulsants, TCAs, SNRIs) at therapeutic doses (propranolol ≥80mg, topiramate ≥100mg, amitriptyline ≥50mg)",≥8 weeks each,,,Aimovig/Ajovy/Emgality; failure = <50% reduction in monthly migraine days OR intolerable side effects,Yes - documented contraindications: depression (TCA unsafe); cognitive impairment (topiramate); CV contraindication (beta-blockers); sedation impacting occupation,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-002,True,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes (same as CGRP requirement); NOTE: does NOT require CGRP mAb failure before Botox - considered equivalent Tier 3 options,≥8 weeks each",,,Chronic Migraine (≥15 HA days/mo for ≥3 months, ≥8 days with migraine features),Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-200-005,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Independence Blue Cross,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans OR documented contraindication; IBX accepts same-class trials if justified (e.g., two sumatriptan formulations for tolerability)",≥3 separate migraine episodes treated with each triptan,,,Standard QL,Yes - CV contraindication; accepts same-class trials with justification,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Gepants Policy effe86e1,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-001,True,,
PA,Independence Blue Cross,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 conventional oral preventives from different classes; IBX UNIQUELY allows SNRIs (venlafaxine, duloxetine) to count as one of two required classes",≥6 weeks each (SHORTER than Highmark 8-week),,,Standard criteria,Yes - teratogenic; CV contraindication; documented intolerance,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX CGRP Policy,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-002,True,,
PA,Independence Blue Cross,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives,≥6 weeks each (shorter than Highmark),,,Chronic Migraine (≥15 HA days/mo for ≥3 months); REQUIRES headache diary documentation for 3-month period prior to PA submission,Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Botulinum Toxins Form,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,UPMC Health Plan,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 DIFFERENT triptans (explicitly requires chemical class distinction),≥4 weeks each unless early discontinuation documented,,,Standard QL,Yes - CV contraindication; contraindication to vasoconstrictive agents,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Pharmacy PA Criteria,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-001,True,,
PA,UPMC Health Plan,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 conventional preventives from different classes (beta-blockers, anticonvulsants, TCAs explicitly listed as preferred first-line)",≥8 weeks each,,,Standard criteria,Yes - documented contraindications/intolerances,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC CGRP Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-002,True,,
PA,UPMC Health Plan,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,,,Chronic Migraine (≥15 HA days/mo for ≥3 months); accepts EITHER headache diary OR physician attestation in clinical notes,Yes - oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Botox Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,UPMC For You,Medicaid MCO,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"≥2 triptans from different chemical classes per PA DHS PDL (pharmacy CARVED OUT to state PDL),≥4-6 weeks each (adequate trial); failure = <50% reduction OR intolerable effects OR contraindication (CV disease, hemiplegic/basilar migraine),N/A,N/A,PA DHS PDL governs; different from UPMC Health Plan commercial",Yes - CV contraindication to vasoconstrictive agents (uncontrolled HTN, ischemic heart, PVD, CVD, hemiplegic/basilar migraine),Act 146 (Medicaid),,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-001,True,,
PA,UPMC For You,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥2 distinct oral preventive classes per PA DHS PDL (beta-blockers: propranolol/metoprolol, anticonvulsants: topiramate/valproic acid, TCAs: amitriptyline/nortriptyline) at therapeutic doses",≥8 weeks each unless discontinued early for documented adverse effects; failure = <50% reduction OR intolerable adverse effects,,,PA DHS PDL governs; most stringent in state,Yes - documented contraindications per PA DHS PDL bypass criteria,Act 146 (Medicaid),,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-002,True,,
PA,UPMC For You,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventives per UPMC For You medical policy (NOT commercial UPMC Health Plan policy),≥8 weeks each",,,Chronic Migraine per ICHD-3 (≥15 HA days/mo for ≥3 consecutive months, ≥8 days with migraine features); must document via headache diary or clinical note for 3-month period preceding PA,Yes - oral preventive contraindications,Act 146 (Medicaid),,UPMC For You Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per PA DHS PDL,≥8 weeks each,,,PA DHS PDL governs; dedicated Migraine Prevention Agents PA form available,Yes - documented contraindications,Act 146 (Medicaid),,AmeriHealth Migraine Prevention Form,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-002,True,,
PA,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,"Failed 'conventional methods' of treatment (best practice: ≥2 oral preventive classes documented),Documented in medical record",,,LCD L38809/DL39909; Chronic Migraine (≥15 HA days/mo for >3 months, ≥8 migraine days); Episodic NOT covered; injection sites + dosages must be documented; JW modifier for waste MANDATORY; Original Medicare = post-service prepayment audits (no pre-service PA); MA plans DO require pre-service PA,Yes - documented conventional therapy failures,No - Federal Medicare,,LCD L38809/DL39909,Pennsylvania_2026_PA_Audit,PA-MAC-NOVITAS,NOVITAS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS DE,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,"Ubrelvy 16/30d, Nurtec 8/30d",Yes - CV contraindication,Yes (Voluntary),90% approval rate,I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-001,True,,
DE,Highmark BCBS DE,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"1 agent from 2 different classes (beta-blocker, antidepressant, anti-epileptic, ARB)",≥8 weeks each,,,Monthly supply,Yes - teratogenic; CV per 18 Del. C. § 3381,Yes (Voluntary),90% approval rate,I-200-005,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-002,True,,
DE,Highmark BCBS DE,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 prophylactic classes,≥6 weeks each,,,155 units/12 weeks,Yes,Yes (Voluntary),90% approval rate,I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS DE,Commercial,Commercial,CGRP mAbs (IV),Preventive IV,Yes,Must justify why SubQ CGRP not appropriate,,Fail SubQ CGRP or document barrier,,Quarterly infusion,Yes - needle phobia; inability to self-inject,Yes (Voluntary),90% approval rate,I-222-007,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS,65093,DENY-GOLD-001,True,,
DE,AmeriHealth Caritas Delaware,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 PDL agents (may be same class unlike Highmark); pharmacy fill history required,Documented + adherence proof,,,DMAP PDL; Emgality/Ajovy often preferred; Brand over Generic = DAW 1; SDOH leverage viable,Yes - teratogenic; cognitive; respiratory,,,DMAP PDL,Delaware_2026_PA_Audit,DE-MCD-AMERIHEALTH,AmeriHealth,DENY-STEP-002,True,,
DE,Delaware First Health,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,PDL limits,Yes per 18 Del. C. § 3381,No,,DE Medicaid PDL,Delaware_2026_PA_Audit,DE-MCD-DELFIRST,65093,DENY-STEP-001,True,,
DE,Cigna,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1 triptan,Trial required,,,Plan dependent,Yes - CV contraindication,Yes (National Gold Card),Voluntary program,Cigna Medical Policy,Delaware_2026_PA_Audit,DE-COM-CIGNA,62308,DENY-STEP-001,True,,
DE,Cigna,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes,Yes (National Gold Card),Voluntary program,Cigna Medical Policy,Delaware_2026_PA_Audit,DE-COM-CIGNA,62308,DENY-STEP-002,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
DE,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 classes; headache diary required,Trial required,,,155 units/12 weeks,Yes,,,LCD L38809,Delaware_2026_PA_Audit,DE-MAC-NOVITAS,MAC-JL,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥30 days per agent,,,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-001,True,,
AL,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventives (beta-blocker, topiramate, divalproex, amitriptyline/venlafaxine)",≥2 months each,Fail Aimovig OR Emgality for non-preferred (Ajovy),,Monthly supply,Yes - teratogenic; CV,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-002,True,,
AL,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,Check Gold Card status first - Advance Notification only if Gold Carded,,,,155 units/12 weeks,Yes,Yes (National Gold Card),≥92% approval x 2 years,UHC Medical Policy,Alabama_2026_PA_Audit,AL-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,Blue Cross Blue Shield Alabama,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 different oral preventive classes,≥8 weeks each,,,⚠️ 87% market share = BCBSAL denial = statewide denial; Source+Rx formulary; Prime Therapeutics; ⚠️ 'Consensus Agreement' = No AI Denial + quasi-Gold Card,Yes - teratogenic; cognitive; respiratory,✓ Voluntary Consensus Agreement,90%,Source+Rx Formulary,Alabama_2026_PA_Audit,AL-COM-BCBSAL,BCBSAL,DENY-STEP-002,True,,
AL,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 conventional preventives; ICD-10 G43.7xx ONLY,Adequate trial,,,155 units/12 weeks; JW modifier required for waste,Yes,,,LCD DL39909 (eff. 2/15/2026),Alabama_2026_PA_Audit,AL-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Blue Cross Blue Shield MI,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes - teratogenic; CV,No,,BCBSMI Medical Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-MICHBCBS,710,DENY-STEP-002,True,,
MI,Priority Health,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-001,True,,
MI,Priority Health,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventives,Trial required,,,Monthly supply,Yes; honors continuity of care,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-002,True,,
MI,Priority Health,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives; no concurrent CGRP unless refractory appeal,Trial required,,,155 units/12 weeks,Yes,Yes (Priority Gold Card),High approval rate,Priority Health Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-PRIORITY,38259,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,1-2 triptans (plan dependent),≥30 days,,,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-001,True,,
MI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes; Aimovig/Emgality preferred,≥6 weeks each,Ajovy requires fail of Aimovig OR Emgality,,Monthly supply,Yes,Yes (National Gold Card),≥92% approval x 2 years,UHC CGRP Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-002,True,,
MI,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives; strict 15 day documentation,Trial required,,,155 units/12 weeks,Yes,Yes (National Gold Card - CPT 64615),≥92% approval x 2 years,UHC Medical Policy,Michigan_2026_PA_Audit_Strategy,MI-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ME,Anthem BCBS Maine,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,Anthem CarelonRx,Maine_2026_PA_Audit_Report,ME-COM-ELEV,47198,DENY-STEP-001,True,,
ME,Anthem BCBS Maine,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2-3 oral preventive classes (beta-blocker, TCA, anticonvulsant)",Trial required,,,Monthly supply,Yes - teratogenic; CV; asthma,No state mandate,,Anthem CarelonRx,Maine_2026_PA_Audit_Report,ME-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
ME,MaineCare,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥1 triptan (PDL requirement),Trial required,,,PDL limits,Yes - CV contraindication,,,MaineCare PDL,Maine_2026_PA_Audit_Report,ME-MCD-MAINECARE,STATE-ME,DENY-STEP-001,True,,
ME,MaineCare,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per PDL requirements,Trial required,,,PDL limits,Yes per 24-A MRSA §4304-B,,,MaineCare PDL,Maine_2026_PA_Audit_Report,ME-MCD-MAINECARE,STATE-ME,DENY-STEP-002,True,,
ME,Community Health Options,Commercial,Exchange,Gepants (Acute),Acute,Yes,≥2 triptans (Express Scripts),Trial required,,,Plan dependent,Yes - CV contraindication; CISP bypass available,No,,CHO/ESI Formulary,Maine_2026_PA_Audit_Report,ME-COM-COMMHEALTH,MHMC1,DENY-STEP-001,True,,
ME,Harvard Pilgrim,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,Ajovy EXCLUDED 2026,,Monthly supply,Yes,No,,Point32Health Policy,Maine_2026_PA_Audit_Report,ME-COM-HARVARD,4271,DENY-STEP-002,True,,
ME,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 conventional preventives; headache diary,Adequate trial,,,155 units/12 weeks; JZ modifier required,Yes,,,LCD L33646,Maine_2026_PA_Audit_Report,ME-MAC-NGS,MAC-JK,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Anthem BCBS New Hampshire,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes,No state mandate,,Carelon Medical,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,NH Healthy Families,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans (Centene PDL),Trial required,,,PDL limits,Yes - CV contraindication,No,,NH.PHAR.476,New_Hampshire_2026_PA_Audit,NH-MCD-GRANITE,68069,DENY-STEP-001,True,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (strict PDL),Trial required,,,PDL limits,Yes,No,,Centene Policy,New_Hampshire_2026_PA_Audit,NH-MCD-GRANITE,68069,DENY-STEP-002,True,,
NH,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 conventional preventives,Adequate trial,,,155 units/12 weeks,Yes,,,LCD L33646,New_Hampshire_2026_PA_Audit,NH-MAC-NGS,MAC-JK,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,NYRx (New York State Medicaid),Medicaid FFS,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"≥1 triptan trial (failure/intolerance/contraindication),Per clinical judgment,N/A",,Nurtec ODT 18-24 doses/30-40d acute; 8 tabs/30d some contexts; Ubrelvy standard QL,Yes - CV contraindication to vasoconstrictive agents (CAD, uncontrolled HTN, PVD) bypasses triptan requirement immediately,N/A - State Medicaid,,NYRx PDL Clinical Criteria,New_York_2026_PA_Audit,NY-MCD-NYRX,NYRX,DENY-STEP-001,True,,
NY,NYRx (New York State Medicaid),Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (Beta-blockers, Anticonvulsants, Antidepressants) - CAPPED at 2 per NY Chapter 20 Laws 2025",≤30 days or per evidence-based guidelines (NY law),,,Emgality 120mg PREFERRED; Nurtec ODT PREFERRED for episodic prevention (EOD dosing); Aimovig/Ajovy/Qulipta NON-PREFERRED require step through preferred,Yes - contraindication/harm; clinical ineffectiveness; stability/continuity of care; best interest (NY Ins Law §4903 override criteria),N/A - State Medicaid,,NYRx PDL / NY Ins Law §4902,New_York_2026_PA_Audit,NY-MCD-NYRX,NYRX,DENY-STEP-002,True,,
NY,Fidelis Care (Centene),Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes (Topiramate, Propranolol, Amitriptyline) - CAPPED at 2 per NY Chapter 20,≥2 months each (but ≤30 days if adverse event per NY law),N/A",,155-200 units/12 weeks; Chronic Migraine (≥15 HA days/mo, ≥8 migraine days, ≥4 hours duration) for ≥3 months; reauth requires ≥7 day reduction or functional improvement,Yes - cognitive slowing (topiramate); hypotension (beta-blockers); adverse event discontinuation valid regardless of duration per NY Ins Law §4902,N/A - Medicaid MCO,,Centene CP.MP.162/CP.FC.05,New_York_2026_PA_Audit,NY-MCD-FIDELIS,13551,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Fidelis Care (Centene),Medicaid MCO,Medical Benefit,CGRP mAbs (IV),Chronic Migraine,Yes,"≥2 oral preventive classes,≥2 months each",≥1-2 SC CGRPs (Aimovig/Emgality) OR Botox,Documented failure/intolerance,J3032; Non-Preferred; Site of Care restriction - non-hospital settings preferred unless medical necessity (severe infusion reaction history, difficult venous access),Yes - inability to self-inject; GI malabsorption (bioavailability argument); SC injection failures,N/A - Medicaid MCO,,Centene CP.FC.05 Vyepti,New_York_2026_PA_Audit,NY-MCD-FIDELIS,13551,DENY-QL-001,True,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 different triptans (sumatriptan, rizatriptan, etc.),≥4 weeks each,N/A",,Qulipta/Nurtec Tier 2 (oral-forward formulary); Ubrelvy Tier 3/4; standard QL enforcement,Yes - CV risk factors (CAD, PVD, uncontrolled HTN) = triptan contraindicated = immediate bypass per NY Ins Law §4903,Pending (S7470),N/A - pending legislation,Empire Select Drug List 2026,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-001,True,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1-2 oral preventive classes (Beta-blockers, Anticonvulsants) - plan rider dependent; CAPPED at 2 per NY law",≤30 days or per guidelines,,,Qulipta/Nurtec/Emgality/Aimovig Tier 2 PREFERRED; Ajovy Tier 3/4 Non-Preferred; Empire is 'oral-forward' - favorable for patients preferring oral over injection,Yes - asthma/bradycardia (beta-blocker contraindication); cognitive impairment (topiramate); teratogenic bypass,Pending (S7470),N/A - pending legislation,Empire CGRP Policy,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-002,True,,
NY,Empire BCBS,Medicare Advantage,Part B,Neurotoxins,Chronic Migraine,Yes,Per NGS LCD L33646,Adequate trial,,,155 units/12 weeks,Yes,,,LCD L33646,New_York_2026_PA_Audit,NY-MA-EMPIREBCBS,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,UnitedHealthcare (Oxford),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥4 weeks each,,,Nurtec ODT 8 tabs/30d acute (15-16 tabs if approved for prevention); Ubrelvy 10-16 tabs/30d; aggressive QL enforcement; MOH monitoring,Yes - CV contraindication; reauth requires NO medication overuse headache + clinical improvement documented,Yes (Voluntary),92% approval rate on specific codes - check UHC Provider Portal for eligibility,UHC PA-Notification-Nurtec-Qulipta-Ubrelvy-Zavzpret,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-001,True,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes - strict step therapy enforcement via Designated Specialty Programs,≥8 weeks each,,,Aimovig/Emgality PREFERRED; Ajovy EXCLUDED or Non-Preferred (must fail preferred first); Qulipta/Nurtec gated behind oral preventive failures,Yes - teratogenic; CV contraindication; documented intolerance,Yes (Voluntary),92% approval rate on specific codes,UHC PA-CGRP-Receptor-Antagonists,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-002,True,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥3 oral preventive classes (Antidepressants, Anticonvulsants, Beta-blockers) - ⚠️ POTENTIALLY NON-COMPLIANT with NY 2-drug cap law",≥8 weeks each,,,Chronic Migraine (≥15 HA days/mo for >3 months); 50% REDUCTION in frequency/intensity required for reauth - higher bar than 'clinical improvement'; precise documentation required,Yes - documented specific failures; APPEAL 3rd drug requirement citing NY Chapter 20 Laws 2025 (N.Y. Ins. Law §4902),Yes (Voluntary),92% approval rate on specific codes,UHC Policy 2026T0004W,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Always requires Preauthorization; Medical Benefit; clinical improvement for reauth; emphasize 'impact on essential job functions' for City employees,Yes - documented oral preventive failures/intolerances,Pending (S7470),N/A - pending legislation,EmblemHealth Medical Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 conventional preventives; ≥15 days/month x 3 months,Adequate trial,,,155 units/12 weeks; 12-week interval strict,Yes,,,LCD L33646,New_York_2026_PA_Audit,NY-MAC-NGS,MAC-JK,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 standard oral preventive class (Beta-blockers: propranolol, Anticonvulsants: topiramate, Antidepressants: amitriptyline)",≥8-12 weeks,,,Aimovig/Emgality PREFERRED; Ajovy requires step through preferred (unless latex allergy); ValueScript CLOSED formulary - non-listed drugs require Formulary Exception,Yes - intolerance; contraindication; latex allergy for autoinjector devices,Yes (SB 7016),>90% approval in 2025,Policy 05-70-068,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-STEP-002,True,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes,≥8 weeks each",,,Aimovig/Emgality PREFERRED on Advantage formulary; Vyepti requires Part B Step Therapy (fail SC CGRP first) for MA patients,Yes - teratogenic; CV contraindication; physical barrier to self-injection (severe arthritis, cognitive impairment),Yes (SB 7016),Internal Gold Card + FL state mandate,UHC CGRP Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-002,True,,
FL,Sunshine Health,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 different oral preventive classes (Beta-blocker AND Anticonvulsant) - stricter than commercial 1-class requirement,≥8 weeks each; adherence verified via claims refill history,,,Aimovig/Emgality historically preferred; Ajovy requires PA; bound by AHCA PDL (quarterly updates),Yes - documented intolerances; contraindications; EPSDT override for pediatric (must use phrase 'Medically necessary under EPSDT guidelines'),Yes (SB 7016),Statutorily required for Medicaid,AHCA PDL / Sunshine Clinical PA,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-002,True,,
FL,Aetna,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 oral preventive classes (strictest),Trial required,,,155 units/12 weeks,Yes,No,,Aetna CPB 0113,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,First Coast Service Options,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD; ASC PA demonstration expansion,Adequate trial,,,155 units/12 weeks,Yes,,,FCSO LCD,Florida_2026_PA_Audit,FL-MAC-FCSO,MAC-JN,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (Beta-blockers, TCAs, Anticonvulsants)",≥8 weeks each,,,"PREFERRED (Tier 3): Aimovig, Emgality; NON-PREFERRED/RESTRICTED: Ajovy (especially on Essential formulary), Vyepti; requests for non-preferred require failure/intolerance to preferred documented; 'Net Results' formulary uses aggressive 'Value PA' steering to generics",Yes - teratogenic; CV contraindication; documented intolerance,HB 434 - pending,80% threshold,BCBS NC CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-002,True,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (beta-blockers, anticonvulsants, antidepressants)",≥8 weeks each,,,"PREFERRED: Aimovig, Emgality; ⚠️ Vyepti = STEP 3 agent: requires failure of 2 OTHER CGRP mAbs (e.g., Aimovig AND Emgality) before approval - higher hurdle than Medicaid",Yes - teratogenic; CV contraindication; documented intolerance,ACTIVE Gold Card,92% threshold,UHC CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-002,True,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"⚠️ ≥3 prophylactic classes (aligned with Medicaid, STRICTER than BCBS 2-class)",≥8 weeks each,,,Medical Benefit Drug Policy 2026D0017AN eff Jan 1 2026; Chronic Migraine (≥15 days/mo); Botox = preferred neurotoxin (Dysport/Xeomin/Myobloc off-label/unproven for migraine = generally denied),Yes - oral preventive contraindications,ACTIVE Gold Card,92% threshold for CPT 64615,UHC Policy 2026D0017AN,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CT,Anthem BCBS CT,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes,No state mandate,,CarelonRx Policy,Connecticut_2026_PA_Audit,CT-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CT,ConnectiCare/Molina,Exchange,Exchange,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,No,,Molina Policy,Connecticut_2026_PA_Audit,CT-COM-CTCARE,13551,DENY-STEP-001,True,,
CT,ConnectiCare/Molina,Exchange,Exchange,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes; Ajovy/Emgality/Qulipta/Nurtec preferred,≥2 months each,Aimovig Non-Preferred (fail 2 preferred),,Monthly supply,Yes; Dual Therapy clause for refractory,No,,Molina Policy 17/18,Connecticut_2026_PA_Audit,CT-COM-CTCARE,13551,DENY-STEP-002,True,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans from Balanced Drug List,≥4 weeks each,N/A",,"Ubrelvy 16/30d, Nurtec 8/30d (Tier 3 PA/QL)",Yes - CV contraindication (ischemic heart disease, uncontrolled HTN, cerebrovascular disease),Yes (HB 3459/HB 3812),90% approval on 5+ requests; annual evaluation,Balanced Drug List 2026,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-001,True,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"""≥2 oral preventive classes (Beta-blocker, Anticonvulsant, TCA, SNRI)"",≥3 months each (stricter than UHC 2-month)",,,Monthly supply; Aimovig/Emgality preferred; Ajovy steeper hurdles,Yes - adverse events (cognitive slowing/paresthesia for topiramate, hypotension/bradycardia for beta-blockers); teratogenic bypass,Yes (HB 3459/HB 3812),90% approval on 5+ requests; annual evaluation,Prime Therapeutics ST Policy,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-002,True,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes,≥3 months each",,,155-200 units/12 weeks; Chronic Migraine only (15+ days/mo, 8+ migraine days),Yes - oral preventive contraindications; dual therapy requires partial response documentation (30% reduction) + additional benefit (>50%),Yes (HB 3459/HB 3812),90% approval on 5+ requests,Medical Policy I-200-005,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans (sumatriptan, rizatriptan, naratriptan) - 180-day pharmacy claims lookback",≥4 weeks each,,,Tier 2/3; strict QL enforcement; SmartPA auto-denial if no triptan claims history,Yes - CV contraindication; new-to-plan patients must manually document prior triptan use,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,OptumRx Step Therapy Migraine,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-001,True,,
TX,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral prophylactic classes,≥2 months each (shorter than BCBSTX 3-month),,,Aimovig/Emgality Tier 2 Preferred; Ajovy excluded or Step 2 (fail preferred first),Yes - injection site reaction; lack of efficacy on preferred agents,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,OptumRx CGRP Policy,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-002,True,,
TX,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥3 oral preventive classes (Antidepressant, Antiepileptic, Beta-blocker) - MORE STRINGENT",≥8 weeks each; must specify drug/dose/duration in chart notes,,,200 units max/12 weeks; vague notes like 'tried oral meds' insufficient,Yes - documented specific failures with drug/dose/duration,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,UHC Medical Policy Botox,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Superior HealthPlan,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans per Texas VDP,≥4 weeks each,,,9 tabs/month max; >9 requires MOH exclusion documentation,Yes - CV contraindication; MOH evaluation required for QL override,No (Medicaid excluded HB 3459),,Superior Clinical Edit Triptans,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-001,True,,
TX,Superior HealthPlan,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per VDP criteria,≥8 weeks each,,,Non-Preferred on PDL; Clinical PA required proving standard treatment failure,Yes - teratogenic bypass; CV contraindication,No (Medicaid excluded HB 3459),,Superior Clinical PA CGRP,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-002,True,,
TX,Cigna Healthcare of Texas,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,Tier 2/3; high scrutiny on quantity overrides; ESI formulary restrictions,Yes - CV contraindication,Yes (HB 3459/HB 3812),Biannual notifications,ESI Migraine DQM Policy,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-001,True,,
TX,Cigna Healthcare of Texas,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥3 months each,,,Emgality/Aimovig Tier 2 Preferred; most restrictive exclusion lists; rebate-driven,Yes - teratogenic; CV contraindication,Yes (HB 3459/HB 3812),Biannual notifications,ESI CGRP PA Policy,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-002,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
TX,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in medical record,,,"155-200 units/12 weeks per LCD DL39909; J0585; Chronic Migraine (>15 days/mo, ≥8 migraine days); objective scales (MIDAS/HIT-6) required",Yes - documented in chart with specific ICD-10 (G43.709/G43.719),No (Federal Medicare exempt),,LCD DL39909,Texas_2026_PA_Audit,TX-MAC-NOVITAS,,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Naratriptan) - Code I checks 180-day claims history",≥4 weeks each,,,Nurtec 8/30d acute; 16/30d preventive requires separate PA; Ubrelvy requires triptan history in Medi-Cal system; Reject Code 75 if no triptan claims,Yes - CV contraindication (vasoconstrictive agents unsafe); non-vasoconstrictive mechanism bypass,No (State Medicaid),,Form 61-211 / CDL Code I,California_2026_PA_Audit,CA-MCD-MEDICALRX,,DENY-STEP-001,True,,
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥1-2 oral preventive classes (Antiepileptics: Divalproex/Topiramate, Beta-blockers: Propranolol/Metoprolol, Antidepressants: Amitriptyline/Venlafaxine)",≥8 weeks each at therapeutic dose,,,Code I PA Required; Chronic Migraine (≥15 HA days/mo) or Episodic (≥4 HA days/mo); Emgality has Labeler Restriction (Eli Lilly NDCs only); 2026 grandfathering reset,Yes - teratogenic bypass for females of childbearing potential (Valproate/Topiramate FDA Cat D/X); CGRP has favorable safety profile,No (State Medicaid),,Form 61-211 / Medi-Cal Rx CDL,California_2026_PA_Audit,CA-MCD-MEDICALRX,,DENY-STEP-002,True,,
CA,L.A. Care Health Plan,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes (Beta-blockers, Anticonvulsants, TCAs)",≥8 weeks each,,,"Medical Benefit (pharmacy carved to Medi-Cal Rx); Chronic Migraine (≥15 HA days/mo, ≥8 migraine days) for ≥3 months; Episodic NOT covered; IPA delegation creates variability",Yes - oral preventive contraindications; attach L.A. Care Clinical Policy to IPA submissions,No (Medicaid),,L.A. Care Medical Policy,California_2026_PA_Audit,CA-MCD-LACARE,LACAR,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Kaiser Permanente,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥3 oral preventive classes (Beta-Blocker: Propranolol/Atenolol, TCA: Amitriptyline/Nortriptyline, Anticonvulsant: Topiramate/Divalproex) - MOST RESTRICTIVE",≥6-8 weeks each,,,Tier 4/Non-Preferred; CGRPs behind formidable wall of generic failures; Vyepti reserved as 'last resort' requiring SC CGRP failure first,Yes - significant functional impairment (MIDAS Grade IV); beta-blocker contraindicated due to asthma/bradycardia; TCA contraindicated due to sedation/arrhythmia risk; topiramate cognitive slowing/paresthesia,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser CGRP PA Form,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-002,True,,
CA,Kaiser Permanente,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans from Kaiser formulary,≥4 weeks each,,,Tier 4/Non-Preferred; closed formulary; internal referral system,Yes - CV contraindication; vascular risk factors,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Internal Guidelines,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-001,True,,
CA,Anthem Blue Cross,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,≥4 weeks each,,,Step therapy automated at POS - checks 180-day claims for 2 unique triptan fills; new-to-plan patients submit PA immediately citing prior triptan failure,Yes - established CV disease; uncontrolled hypertension explicitly allows triptan bypass,SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem CG-DRUG Gepants,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-001,True,,
CA,Anthem Blue Cross,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive agents (BB, TCA, Anticonvulsant classes)",≥2 months each (less restrictive than Kaiser 3-class),,,Emgality/Ajovy Preferred; Aimovig Non-Preferred (step through preferred); Combination Ban: Botox + CGRP prohibited unless refractory chronic migraine with individual failures,Yes - contraindication to Beta-Blockers (Asthma/Bradycardia); history of kidney stones (Topiramate); partial responder documentation,SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem Aimovig Policy PHARM_ALL,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CA,Blue Shield of California,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥1 preferred triptan (Sumatriptan, Rizatriptan, Naratriptan, Zolmitriptan) - MORE LENIENT than Anthem",≥4 weeks,,,Max 16 tablets/30 days; Value-Based Tiering formulary,Yes - CV contraindication; vascular risk factors,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Nurtec/Ubrelvy Policy,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-001,True,,
CA,Blue Shield of California,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 standard prophylactic drug (BB, TCA, Anticonvulsant) - RELAXED from 2 failures eff 2024",≥8 weeks,,,Aimovig/Emgality Preferred; Ajovy may require step through preferred; Vyepti requires fail 2 SC CGRPs + Nurtec preventive; Feb 2026: Vyepti cannot combine with other CGRP,Yes - teratogenic contraindication; CV contraindication; documented intolerance,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield CGRP Policy PRV_Aimovig,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-002,True,,
CA,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,,,"155-200 units/12 weeks; LCD DL39909 replacing L35170 eff 1/1/2026; strict ICD-10 (G43.709/G43.719 required - R51.9 autodeny); headache diary mandate (≥15 HA days, ≥8 migraine features); 12-week frequency strict; HOPD PA mandatory CPT 64615",Yes - documented in medical record with specific diagnosis codes and headache diary metrics,No (Federal Medicare),,LCD DL39909,California_2026_PA_Audit,CA-MAC-NORIDIAN,,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,Blue Cross Blue Shield of Arizona,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,6-8 weeks,,,"PREFERRED: Aimovig, Emgality; Ajovy excluded (step-within-step); ⚠️ DUAL THERAPY BAN",Yes - teratogenic; cognitive; respiratory,✓,80%,BCBSAZ Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,BCBSAZ,DENY-STEP-002,True,,
AZ,Blue Cross Blue Shield AZ,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; may require CGRP trial first,Trial required,,,155 units/12 weeks,Yes; Dual therapy via AHS Consensus appeal,No state mandate,,BCBSAZ Medical Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,86052,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-STEP-001,True,,
AZ,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,Ajovy excluded/Tier 3; Qulipta may require injectable step,,Monthly supply; Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-STEP-002,True,,
AZ,UnitedHealthcare Arizona,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 SC CGRP mAbs (Aimovig AND Emgality),≥3 months EACH,,,J3032; Exception: inability to self-inject bypasses SC step,Yes - arthritis; cognitive; needle phobia,✓,CPT-specific,UHC Vyepti,Arizona_2026_PA_Audit,AZ-COM-UHC,87726,DENY-QL-001,True,,
AZ,AHCCCS Fee-For-Service,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥6 weeks each,,,"PREFERRED: Aimovig, Emgality; Policy 310-V override",Yes - teratogenic; cognitive; respiratory; HB 2449 mental health,,,AHCCCS 310-V,Arizona_2026_PA_Audit,AZ-MCD-AHCCCS,AHCCCS,DENY-STEP-002,True,,
AZ,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per AHCCCS FFS PDL + administrative layers,Trial required,,,PDL limits,Yes,No,,UHC Community Plan Policy,Arizona_2026_PA_Audit,AZ-MCD-UHC,87726,DENY-STEP-002,True,,
AZ,Cigna Healthcare AZ,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Strict QL,Yes - CV contraindication,No state mandate,,Cigna Medical Policy,Arizona_2026_PA_Audit,AZ-COM-CIGNA,62308,DENY-STEP-001,True,,
AZ,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909; WISeR pilot protocols,Adequate trial,,,155 units/12 weeks; specific ICD-10 codes only,Yes,N/A (Federal),,LCD DL39909,Arizona_2026_PA_Audit,AZ-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Nevada Medicaid,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥1 triptan (Single PDL 2026),Trial required,,,"Nurtec 16/30d preferred, Ubrelvy non-preferred",Yes - CV contraindication,No,,Single PDL (sPDL),Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-001,True,,
NV,Nevada Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class,Trial required,Fail preferred CGRP before Ajovy/Vyepti,,Aimovig/Emgality preferred,Yes,No,,Single PDL (sPDL),Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-002,True,,
NV,Nevada Medicaid,Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 different oral prophylactic classes; rule out MOH,Trial required,,,155 units/12 weeks,Yes,No,,NV Medicaid MSM Ch 1200,Nevada_2026_PA_Audit_Report,NV-MCD-NVMEDICAID,STATE-NV,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (Fail 2 strict),Trial required,,,Plan dependent,Yes - CV contraindication,Yes (AB 463),2 business days,UHC Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-001,True,,
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,6+ weeks each,Qulipta may require injectable step first,,Aimovig/Emgality preferred,Yes - needle phobia bypass,Yes (AB 463),2 business days,UHC Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-002,True,,
NV,UnitedHealthcare/Health Plan of Nevada,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives; Dual therapy denied (cite AHS Consensus),Trial required,,,155 units/12 weeks,Yes,Yes (AB 463),2 business days,UHC Medical Policy,Nevada_2026_PA_Audit_Report,NV-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Anthem Blue Cross Blue Shield NV,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Nurtec preferred; Ubrelvy may require Nurtec step,Yes - CV contraindication,Yes (AB 463),2 business days,Anthem Policy,Nevada_2026_PA_Audit_Report,NV-COM-ELEV,47198,DENY-STEP-001,True,,
NV,Anthem BCBS Nevada,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,≥1 month each,,,Emgality/Ajovy may be preferred (varies); Nevada Select list may exclude high-cost brands,Yes - teratogenic; cognitive; respiratory,,,Anthem Nevada,Nevada_2026_PA_Audit,NV-COM-ELEV,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
NV,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD L35170,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD L35170,Nevada_2026_PA_Audit_Report,NV-MAC-NORIDIAN,MAC-JE,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Presbyterian Health Plan,Commercial/Medicaid,Commercial/Medicaid,CGRP mAbs (SC),Preventive,Yes,1-2 oral classes,2-3 months,,,Aimovig/Emgality typically preferred; Vyepti requires SC failure first,Yes - teratogenic; cognitive; respiratory,⚠️ NMAC 13.10.31.12,90%,Presbyterian Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBYNM,Presbyterian,DENY-STEP-002,True,,
NM,Presbyterian Health Plan,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,Per closed formulary; Stanson Health/Evolent delegation,Trial required,,,155 units/12 weeks,Yes,No state mandate,,Presbyterian Medical Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBYNM,90787,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 categories (e.g. Anticonvulsant AND Beta-blocker),≥2 months each,,,Tier 3 PA; ⚠️ UM outsourced to Carelon/EviCore Jan 2026,Yes - teratogenic; cognitive; respiratory,⚠️ NMAC 13.10.31.12,90%,BCBSNM Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-STEP-002,True,,
NM,BCBS New Mexico,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; J0585 requires NDC and exact units,Trial required,,,155 units/12 weeks; JW modifier for wastage,Yes,No state mandate,,BCBSNM Medical Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Molina Healthcare New Mexico,Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 classes (Topiramate/Propranolol),Documented,,,⚠️ Smart PA lookback 180d; new members = history invisible = immediate manual PA required; strict FDA labeling,Yes - teratogenic; cognitive; respiratory,,,Molina Policy,New_Mexico_2026_PA_Audit,NM-MCD-MOLINA,Molina,DENY-STEP-002,True,,
NM,Presbyterian Turquoise Care,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Strict 2026 Statewide PDL compliance,Trial required,,,PDL limits,Yes,No,,NM Statewide PDL,New_Mexico_2026_PA_Audit,NM-MCD-PRESBYHEALTH,90787,DENY-STEP-002,True,,
NM,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD L38809,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD L38809,New_Mexico_2026_PA_Audit,NM-MAC-NOVITAS,MAC-JH,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,BCBS Oklahoma,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,Per HCSC Step Therapy; cannot be more restrictive than OHCA PDL,Trial required,,,Monthly supply,Yes,No (HB 3190/1808 transparency),,BCBSOK Medical Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,621,DENY-STEP-002,True,,
OK,BCBS Oklahoma,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; JW/JZ modifier required,Trial required,,,155 units/12 weeks; specific muscle groups listed,Yes,No (HB 3190/1808 transparency),,BCBSOK Medical Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Oklahoma Complete Health,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per OHCA Unified PDL; MCOs cannot be more restrictive,Trial required,,,PDL limits,Yes; 60-day continuity mandate for plan changes,No,,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-OKCOMPLETE,68069,DENY-STEP-002,True,,
OK,Aetna Better Health,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per OHCA Unified PDL,Trial required,,,PDL limits,Yes; PA valid 6 months-3 years for chronic conditions,No,,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,60054,DENY-STEP-002,True,,
OK,Humana Healthy Horizons,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per OHCA Unified PDL,Trial required,,,PDL limits,Yes; PA valid 6 months-3 years for chronic conditions,No,,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-HUMANA,61101,DENY-STEP-002,True,,
KY,Anthem (Elevance) KY,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes,No state mandate,,Anthem KY Policy,Kentucky_2026_PA_Audit,KY-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
KY,Humana Kentucky,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,Documented,,,⚠️ Voluntary Gold Card pioneer - reducing friction vs Anthem's restrictions,Yes - teratogenic; cognitive; respiratory,✓ Voluntary Gold Card,90%,Humana KY Formulary,Kentucky_2026_PA_Audit,KY-COM-HUMANA,61101,DENY-STEP-002,True,,
KY,Humana,Medicare Advantage,Part B,Neurotoxins,Chronic Migraine,Yes,Botox preferred; Myobloc non-preferred (fail Botox first),Trial required,,,155 units/12 weeks,Yes,Yes (7-day rule compliance),High approval rate,Humana MA Policy,Kentucky_2026_PA_Audit,KY-MA-HUMANA,61101,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KY,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes for ≥2 months; specific agents listed,≥2 months each,,,Monthly supply,Yes,Yes (National Gold Card),≥92% approval rate,UHC CGRP Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-002,True,,
KY,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,Smart Edits - auto-bypass if 2 triptan claims in history,30 days each,,,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication,Yes (National Gold Card),≥92% approval rate,UHC Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-001,True,,
KY,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,12-week frequency strict; 10-11 week injections denied,Trial required,,,155 units/12 weeks,Yes,Yes (National Gold Card - CPT 64615),≥92% approval rate,UHC Medical Policy,Kentucky_2026_PA_Audit,KY-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 oral preventive class (Beta-blocker, TCA, or Anticonvulsant)",≥2 months,Intra-class step: Aimovig often NON-PREFERRED (Tier 4) - requires step through Emgality or Ajovy,Documented failure,Emgality/Ajovy PREFERRED; Aimovig requires step through preferred agents,Yes - intolerance; contraindication; teratogenic bypass,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Performance Drug List,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-002,True,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,J0585 + 64615; Chronic Migraine (≥15 days/mo); PA via Availity or Carelon; dual therapy (Botox+CGRP) HIGH RESTRICTION - cite AHS Consensus Statement for refractory,Yes - oral preventive contraindications; dual therapy requires 'partial responder' documentation,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,UnitedHealthcare Illinois,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Part B Step: Fail ≥1 self-injected CGRP (Aimovig/Emgality) before IV Vyepti; PLUS Site of Care restriction - HOPD routinely DENIED,Documented SC failure + Site of Care review,J3032; Site of Care: Home Infusion or freestanding Infusion Center PREFERRED; HOPD exception requires 'difficult venous access requiring ultrasound guidance' OR 'history of syncope/anaphylaxis requiring hospital-level resuscitation',Yes - needle phobia; inability to self-administer (arthritis/cognitive impairment); difficult venous access,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Part B Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-QL-001,True,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"⚠️ ≥3 DISTINCT oral preventive classes (e.g., Topamax + Propranolol + Amitriptyline) - STRICTER than BCBSIL 2-class",≥8 weeks each at maximum tolerated dose; chart must explicitly state 'Trial duration: 8 weeks at maximum tolerated dose',,,Chronic Migraine (≥15 days/mo); frequency STRICT every 12 weeks - claims <84 days = automated denial; P2P focus on 'trial duration',Yes - document specific drug/dosage/duration/reason for discontinuation for EACH of 3 classes,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Botulinum Toxins A and B,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per HFS PDL,≥8 weeks each,,,⚠️ CRITICAL 2026 RESTRICTION: 'One CGRP at a time' rule - blocks concurrent Nurtec (preventive 16 tabs/mo) + Botox; WORKAROUND: prescribe Nurtec as ACUTE (8 tabs/mo) to bypass preventive duplicate logic OR submit medical necessity appeal for refractory status,Yes - teratogenic; CV contraindication; documented intolerance,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Policy,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-002,True,,
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per HFS PDL,≥4 weeks each,,,Ubrelvy PREFERRED with PA confirming triptan failure; ⚠️ STRICT QL: 16 tablets/30 days - exceeding requires 'medical necessity' review (rarely approved without severe rebound documentation),Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-001,True,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes (varies by specific plan - National vs Select); verify plan formulary,≥8-12 weeks,,,Emgality/Ajovy generally PREFERRED (plan dependent); Aimovig may be non-preferred/higher copay,Yes - teratogenic; CV contraindication; documented intolerance,SB 5 - Jan 1 2026 implementation,90% threshold,Anthem CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; ⚠️ Dual Therapy (Botox+CGRP) classified as 'duplicative therapy' - will DENY second agent; appeal requires 'partial responder' + AHS Consensus Statement reference,Yes - oral preventive contraindications; dual therapy requires refractory documentation,SB 5 - Jan 1 2026 implementation,90% threshold for CPT 64615,Anthem Botox Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,UnitedHealthcare Georgia,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Aimovig/Emgality often PREFERRED; Ajovy frequently excluded or Tier 3/4,Yes - teratogenic; CV contraindication; documented intolerance,UHC National Gold Card ACTIVE,92% threshold,UHC CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-002,True,,
GA,Peach State Health Plan,Medicaid CMO,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per Unified PDL,≥8-12 weeks each per PDL,,,Unified PDL criteria via DCH,Yes - per PDL contraindication criteria,SB 5 - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-PEACHSTATE,68069,DENY-STEP-002,True,,
GA,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Fail standard care (implies ≥2 oral preventive classes),Documented in medical record,,,LCD L33458; Chronic Migraine STRICT: ≥15 HA days/mo; ≥8 migraine days/mo; duration ≥4 hours/day; 12-week frequency RIGID (>84 days or denial); ICD-10: G43.709; CPT 64615 + J0585,Yes - documented failures with specific adverse events,No - Federal Medicare (SB 5 does not apply),,LCD L33458,Georgia_2026_PA_Audit_Strategy,GA-MAC-PALMETTO,PGBA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans (sumatriptan/rizatriptan preferred),≥2 acute episodes each,,,"Nurtec 8/30d, Ubrelvy 16/30d",Yes - CV contraindication; hemiplegic migraine,Pending (HB 2292),,MP-RX-2026-MIGRAINE,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-001,True,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes at therapeutic dose (beta-blocker ≥80mg propranolol, anticonvulsant ≥100mg topiramate, TCA ≥25mg amitriptyline, SNRI ≥75mg venlafaxine)",≥8 weeks each,,,Monthly supply per label,Yes - teratogenic contraindication (females); CV contraindication for beta-blockers; cognitive impairment for topiramate,Pending (HB 2292),,MP-RX-2026-CGRP,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-002,True,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each at therapeutic dose,,,155-200 units/12 weeks,Yes - oral preventive contraindications documented,Pending (HB 2292),,MP-MED-2026-BOTOX,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BCBSKANSAS,47171,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans from formulary,≥4 weeks each,,,Plan-dependent QL,Yes - CV contraindication triggers automatic bypass,Pending (HB 2292),,UHC-MIGRAINE-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-001,True,,
KS,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes - standard contraindication language accepted,Pending (HB 2292),,UHC-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-002,True,,
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥3 oral preventive failures (Elevance UM guidelines - stricter than commercial),≥8 weeks each,,,Monthly supply per Medicaid PDL,Yes - standard contraindication bypass,No,,HEALTHYBLUE-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-002,True,,
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥3 oral preventive classes (Elevance guidelines),≥8 weeks each,,,155 units/12 weeks,Yes - documented intolerances/contraindications,No,,HEALTHYBLUE-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Centene guidelines),≥8 weeks each,,,Monthly supply,Yes - teratogenic/CV bypass,No,,SUNFLOWER-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-002,True,,
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"""≥2 oral prophylactic classes (Beta-blockers, Anticonvulsants, Antidepressants)"",≥8 weeks each",,,Aimovig/Ajovy/Emgality; NO combination with other CGRP antagonists allowed; dual therapy (Botox+CGRP) = guaranteed initial denial,Yes - intolerance (cognitive slowing for topiramate, fatigue for beta-blockers) bypasses 8-week trial,MN §62M.07 Platinum Card,Chronic condition auth does not expire,BCBSMN CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-002,True,,
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 oral prophylaxis classes (Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,,,"155-200 units/12 weeks; Chronic Migraine (≥15 HA days/mo, ≥8 migraine days); RENEWAL requires ≥7 day reduction OR ≥100 hour reduction documented",Yes - oral prophylaxis contraindications; vague 'doing better' notes will be denied,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Policy II-16-010,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,≥6 weeks each,Vyepti requires fail preferred injectable CGRPs,,Aimovig/Emgality preferred,Yes,Yes (UHC National + Platinum Card),≥92% approval rate,UHC CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-UHC,87726,DENY-STEP-002,True,,
MN,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; No concurrent CGRP without appeal,Trial required,,,155 units/12 weeks,Yes - cite refractory status for dual therapy,Yes (UHC National + Platinum Card),≥92% approval rate,UHC Medical Policy,Minnesota_2026_PA_Audit,MN-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,HealthPartners,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per DHS PDL,≥8 weeks each,,,Integrated P&T; calcium channel blockers accepted as step therapy class per commercial policy,Yes - intolerance; CV contraindication,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS PDL + HealthPartners Policy,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-002,True,,
MN,HealthPartners,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 preventive drug categories,≥8 weeks each,,,Chronic Migraine; Medical Benefit; no concurrent CGRP,Yes - documented failures with calcium channel blocker alternative,MN §62M.07 Platinum Card,Chronic condition auth does not expire,HealthPartners MCD Botox,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,,,155-200 units/12 weeks; LCD L33646/DL39909; strict ICD-10 (G43.709/G43.719 required - G43.909 autodeny); 12-week frequency strict; JW/JZ modifiers mandatory 2026,Yes - documented in medical record with specific diagnosis codes,No (Federal Medicare),,LCD L33646/DL39909,Minnesota_2026_PA_Audit,MN-MAC-NGS,,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,Highmark BCBS WV,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans + 1 other acute,Trial required,,,Plan dependent,Yes - CV contraindication bypass,Yes (SB 833 - Procedures Only),Drugs excluded from Gold Card,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-001,True,,
WV,Highmark BCBS WV,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,First-Line (No oral step required per 2026 policy),,,,Monthly supply,N/A - first-line per Highmark 2026,Yes (SB 833 - Procedures Only),Drugs excluded from Gold Card,Highmark Commercial National Select,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-002,True,,
WV,Highmark BCBS WV,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,Fail CGRP or Oral Preventives; Dual Therapy Allowed (J-1207),Trial required,,,155 units/12 weeks,Yes - partial response doctrine,Yes (SB 833 - Procedures Only),90% approval rate,Highmark J-1207,West_Virginia_2026_PA_Audit,WV-COM-HIGHBCBS,65093,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Naratriptan),Documented,,,Non-Preferred; MCOs contractually bound to BMS PDL,Yes - CV contraindication,,,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-001,True,,
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,≥3 months,,,"PREFERRED: Aimovig, Emgality (locked behind Step 1); NON-PREFERRED: Ajovy, Vyepti (require preferred CGRP failure); ⚠️ NO AHS First-Line adoption",Yes - teratogenic (female childbearing potential); cognitive; respiratory,,,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-002,True,,
WV,West Virginia Medicaid (BMS),Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,,,Chronic (15/8); headache diary required by MCOs (Aetna Better Health/The Health Plan),Yes - oral contraindications,,,BMS PDL,West_Virginia_2026_PA_Audit,WV-MCD-BMS,WV-BMS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,The Health Plan,Commercial/Medicaid,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes (Fail BB + Topiramate); 720-day lookback,Trial required,,,Tier 3/4 placement,Yes,Yes (SB 833 - Procedures Only),Drugs excluded,The Health Plan Policy,West_Virginia_2026_PA_Audit,WV-COM-HEALTHPLAN,THPWV,DENY-STEP-002,True,,
WV,The Health Plan,Commercial/Medicaid,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes + Chronic Dx,Trial required,,,155 units/12 weeks,Yes,Yes (SB 833 - Procedures Only),Drugs excluded,The Health Plan Medical,West_Virginia_2026_PA_Audit,WV-COM-HEALTHPLAN,THPWV,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,CareSource,Marketplace,ACA Exchange,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Plan dependent,Yes,No Gold Card,Standard PA,CareSource WV Policy,West_Virginia_2026_PA_Audit,WV-ACA-CARESOURCE,CARES,DENY-STEP-002,True,,
WV,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909; Mandatory HIT-6/MIDAS Scores,Adequate trial,,,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),,LCD DL39909,West_Virginia_2026_PA_Audit,WV-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Regence BlueCross BlueShield,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes - CV; teratogenic,No (HB 3134 stripped Gold Card),,Regence Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-002,True,,
OR,Regence BlueCross BlueShield,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No (HB 3134 stripped Gold Card),,Regence Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-001,True,,
OR,Regence BlueCross BlueShield,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No (HB 3134 stripped Gold Card),,Regence Medical Policy,Oregon_2026_PA_Audit,OR-COM-CAMBIA,93093,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Providence Health Plan Oregon,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,Aimovig/Ajovy Tier 3/4; Emgality often NON-PREFERRED (Tier 4 or Non-Formulary); ⚠️ Part B Step Therapy may require Part D drug first,Yes - teratogenic; cognitive; respiratory,,,Providence Policy,Oregon_2026_PA_Audit,OR-COM-PROVIDENCE,Providence,DENY-STEP-002,True,,
OR,Moda Health,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes,No (HB 3134),,Moda Policy,Oregon_2026_PA_Audit,OR-COM-MODA,MODAOR,DENY-STEP-002,True,,
IA,Wellmark BCBS,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes - CV; teratogenic,No state mandate,,Wellmark Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-002,True,,
IA,Wellmark BCBS,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,Wellmark Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-001,True,,
IA,Wellmark BCBS,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,Wellmark Medical Policy,Iowa_2026_PA_Audit_Report,IA-COM-WELLBCBS,88057,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,UnitedHealthcare Iowa,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,⚠️ HF 303: 48hr urgent / 10 days standard; 24hr receipt mandate; 'Advance Notification' protocols,Yes - teratogenic; cognitive; respiratory,✓ National + HF 303,92%,UHC Policy,Iowa_2026_PA_Audit,IA-COM-UHC,87726,DENY-STEP-002,True,,
IA,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans; Smart Edits,30 days each,,,Nurtec 8/30d; Ubrelvy 16/30d,Yes - CV contraindication,Yes (UHC National),≥92% approval rate,UHC Policy,Iowa_2026_PA_Audit_Report,IA-COM-UHC,87726,DENY-STEP-001,True,,
IA,Aetna,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Monthly supply,Yes,No state mandate,,Aetna Policy,Iowa_2026_PA_Audit_Report,IA-COM-AETNA,60054,DENY-STEP-002,True,,
IA,Iowa Medicaid (HHS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per IA PDL - Form 470-5554,Trial required,,,PDL limits,Yes,No,,Iowa HHS PDL,Iowa_2026_PA_Audit_Report,IA-MCD-IAHHS,STATE-IA,DENY-STEP-002,True,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 oral preventive class,≥3 months",,,Monthly supply; Aimovig/Emgality preferred; Ajovy non-preferred,Yes - Topiramate bypass (kidney stones, cognitive job),No state mandate,,BCBSNE M.14/M.29/M.30,Nebraska_2026_PA_Audit,NE-COM-NEBBCBS,10101,DENY-STEP-002,True,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; ICHD-3 definition (≥15 days/mo + ≥8 migrainous),Trial required,,,155 units/12 weeks,Yes - cite AHS 2021 for dual therapy,No state mandate,,BCBSNE Medical Policy,Nebraska_2026_PA_Audit,NE-COM-NEBBCBS,10101,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NE,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Nebraska_2026_PA_Audit,NE-COM-UHC,87726,DENY-STEP-002,True,,
NE,Nebraska Heritage Health (Medicaid),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class,≥3 months,,,Aimovig/Emgality preferred,Yes - adverse event bypass,No,,Heritage Health Policy,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,STATE-NE,DENY-STEP-002,True,,
NE,Nebraska Heritage Health (Medicaid),Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 different oral preventive classes; ICHD-3 criteria,Trial required,,,155 units/12 weeks; Dual therapy cite AHS 2021,Yes - SNAP-25/CGRP distinct mechanisms,No,,Heritage Health Medical,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,STATE-NE,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (W.S. § 26-55-112 - Medical Only),Drugs excluded from Gold Card,BCBSWY Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-002,True,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,Yes (W.S. § 26-55-112 - Medical Only),Drugs excluded,BCBSWY Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-001,True,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes,Trial required,,,155 units/12 weeks,Yes,Yes (W.S. § 26-55-112 - Medical Only),90% approval rate,BCBSWY Medical Policy,Wyoming_2026_PA_Audit,WY-COM-WYBCBS,83031,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National + State),Medical Only,UHC CGRP Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,True,,
WY,UnitedHealthcare,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1-2 triptans (plan dependent),Trial required,,,Plan dependent,Yes - CV contraindication,Yes (UHC National + State),Medical Only,UHC Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-001,True,,
WY,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes,Trial required,,,155 units/12 weeks,Yes,Yes (UHC National + State),Medical Only,UHC Medical Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 triptans acute + oral preventives,Trial required,,,Aimovig/Emgality preferred,Yes,Excluded from Gold Card,,WY Medicaid PDL,Wyoming_2026_PA_Audit,WY-MCD-WYMEDICAID,STATE-WY,DENY-STEP-002,True,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,Yes,Fail CGRP First (unique requirement),Trial required,,,155 units/12 weeks,Yes,Excluded from Gold Card,,WY Medicaid Medical,Wyoming_2026_PA_Audit,WY-MCD-WYMEDICAID,STATE-WY,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥3 oral classes per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Wyoming_2026_PA_Audit,WY-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,Anthem (Elevance),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply,Yes - CV; teratogenic,No state mandate,,Anthem IN Policy,Indiana_2026_PA_Audit_Strategy,IN-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem (Elevance),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,Anthem Medical Policy,Indiana_2026_PA_Audit_Strategy,IN-COM-ELEV,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,UnitedHealthcare Indiana,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,⚠️ SB 480: 24hr urgent / 48hr non-urgent; peer review same specialty; National Gold Card 92%,Yes - teratogenic; cognitive; respiratory; stability,✓ National Gold Card,92%,UHC Policy,Indiana_2026_PA_Audit,IN-COM-UHC,87726,DENY-STEP-002,True,,
IN,CareSource Indiana,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per FSSA PDL,Trial required,,,PDL limits,Yes,No,,CareSource IN Policy,Indiana_2026_PA_Audit_Strategy,IN-MCD-CARESOURCE,CARES,DENY-STEP-002,True,,
WI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Wisconsin_2026_PA_Audit,WI-COM-UHC,87726,DENY-STEP-002,True,,
WI,Anthem (Elevance),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes,No state mandate,,Anthem WI Policy,Wisconsin_2026_PA_Audit,WI-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,Anthem (Elevance),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes - CV; teratogenic,No state mandate,,Anthem MO Policy,Missouri_2026_PA_Audit,MO-COM-ELEV,47198,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,UnitedHealthcare Missouri,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,"PREFERRED: Aimovig, Emgality; ⚠️ Ajovy = excluded; MOH must be ruled out; ⚠️ SSM Health exit Jan 2026 = RSMo § 354.612 Continuity 90 days",Yes - teratogenic; cognitive; MOH addressed,✓ HB 618 + National,90%,UHC Policy,Missouri_2026_PA_Audit,MO-COM-UHC,87726,DENY-STEP-002,True,,
LA,Louisiana Blue (BCBSLA),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply; Dominant payer (66%),Yes - CV; teratogenic,No state mandate,,BCBSLA Policy,Louisiana_2026_PA_Audit,LA-COM-LABLUE,23738,DENY-STEP-002,True,,
LA,UnitedHealthcare Louisiana,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes (national UHC criteria),Documented,,,Strict national UM via Optum; ⚠️ Request Gold Card status for CPT 64615/J3032 under Act 432,Yes - teratogenic; cognitive; respiratory,✓ National Gold Card + Act 432 medical,92% / 90%,UHC Policy,Louisiana_2026_PA_Audit,LA-COM-UHC,87726,DENY-STEP-002,True,,
SC,Blue Cross Blue Shield SC,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply; Dominant payer (59%),Yes - CV; teratogenic,No state mandate,,BCBSSC Policy,South_Carolina_2026_PA_Audit,SC-COM-SCARBCBS,71045,DENY-STEP-002,True,,
SC,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,South_Carolina_2026_PA_Audit,SC-COM-UHC,87726,DENY-STEP-002,True,,
SC,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),,LCD DL39909,South_Carolina_2026_PA_Audit,SC-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TN,Blue Cross Blue Shield Tennessee,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes - CV; teratogenic,No state mandate,,BCBST Policy,Tennessee_2026_PA_Audit,TN-COM-TENBCBS,54828,DENY-STEP-002,True,,
TN,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Tennessee_2026_PA_Audit,TN-COM-UHC,87726,DENY-STEP-002,True,,
TN,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),,LCD DL39909,Tennessee_2026_PA_Audit,TN-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Anthem HealthKeepers,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 different oral generic classes: Antidepressants (amitriptyline/venlafaxine); Beta-blockers (propranolol/metoprolol/atenolol); Antiepileptics (topiramate/valproate); ACE/ARBs,≥1 MONTH each,,,"PREFERRED: Aimovig, Ajovy, Emgality; NON-PREFERRED: Vyepti (requires fail 2 SC mAbs first)",Yes - Disqualify beta-blockers (asthma J45.909/bradycardia/hypotension/depression); Disqualify TCAs (BPH N40.1/Beers Criteria elderly/obesity); Disqualify topiramate (kidney stones N20.0/cognitive hazard); Disqualify valproate (teratogenic - women of childbearing potential),HB 2099 - Data Collection 2026,90% threshold,VABCBS-CD-096511-25,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
VA,UnitedHealthcare Virginia,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,⚠️ ≥2 MONTHS each,,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED/EXCLUDED: Ajovy (2026); Reauth requires quantitative response ('Reduction in MHD from 12 to 5' - not vague 'improvement')",Yes - teratogenic; CV contraindication; documented intolerance,UHC National Gold Card ACTIVE,92% threshold,UHC CGRP Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-002,True,,
VA,Palmetto GBA,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks; G43.7xx codes only,Yes,N/A (Federal),,LCD DL39909,Virginia_2026_PA_Audit,VA-MAC-PALMETTO,MAC-JJ,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 oral preventive class (sometimes only 1 - UNIQUE vs 2-3 for others, varies by employer group)",≥2 months,,,Emgality/Aimovig generally preferred; Ajovy often Non-Preferred,Yes - teratogenic; CV contraindication; documented intolerance,,,Anthem Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
OH,UnitedHealthcare Ohio,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,≥8 weeks each,,,Aimovig/Emgality standard preferred; Ajovy Tier 3/4 Non-Preferred requires preferred agent failure; Gold Card opportunity eliminates PA workflow,Yes - teratogenic; CV contraindication,Yes - ACTIVE (Oct 2024),92% approval rate,UHC CGRP Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-002,True,,
OH,CareSource Ohio,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,≥3 oral preventive classes per UPDL (pharmacy carved to Gainwell),≥30 days each per UPDL,,,UPDL criteria apply; pharmacy managed by Gainwell,Yes - per UPDL contraindication criteria,HB 130 (Pending),,Ohio UPDL (via Gainwell),Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-002,True,,
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class (Beta-blocker/Antiepileptic/Antidepressant),≥8 weeks,,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy (requires Aimovig OR Emgality failure or hypersensitivity); Vyepti = Medical Benefit",Yes - teratogenic; cognitive; respiratory,⚠️ Study mandated,,CareFirst Policy,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-002,True,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 different oral classes,≥2 months each,,,"PREFERRED: Aimovig, Emgality 120mg; EXCLUDED: Ajovy; ⚠️ HB 820 AI Transparency - query compliance in appeals",Yes - teratogenic; cognitive; respiratory,✓ National voluntary,92%,UHC CGRP Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-002,True,,
MD,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Maryland_2026_PA_Audit_Defense_Kit,MD-MAC-NOVITAS,MAC-JL,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,UnitedHealthcare / RMHP,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes (Antidepressants/Beta-blockers/Anticonvulsants),≥6 weeks each (shorter than Medicaid 8 weeks),,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy (Step 2 - requires failure of Aimovig OR Emgality first); 'attestation' of oral failures acceptable but chart notes must back it up for retrospective audit",Yes - teratogenic; CV contraindication; documented intolerance; cite 'Failed Step 1 Preferred CGRP due to severe constipation/injection site reaction',HB 24-1149 ACTIVE,90%,UHC CGRP Step Therapy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-002,True,,
CO,Anthem BCBS Colorado,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class (MORE LENIENT than 2-class requirement of others),≥2 months,,,"PREFERRED: Emgality, Ajovy (National list); NON-PREFERRED/PA: Aimovig; ⚠️ Vyepti requires 2 oral agents + 1 preferred SC CGRP failure; Vyepti bypass: 'Physical disability preventing self-administration' / 'Severe needle phobia with vasovagal syncope history' / 'Cognitive impairment requiring provider-administered therapy'",Yes - teratogenic; CV contraindication; self-injection inability,HB 24-1149 ACTIVE - tracking,Tracking,Anthem CGRP Policy,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CO,Kaiser Permanente Colorado,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"Multiple oral agents + non-pharmacological interventions (biofeedback, relaxation training)",Documented failure of each,,,"PREFERRED: Topiramate, Propranolol, Amitriptyline; RESTRICTED: Aimovig, Emgality, Ajovy; ⚠️ External specialist strategy: cite Colorado Network Adequacy laws if Kaiser internal providers failed to manage migraine - patient has right to effective treatment from specialist",Yes - functional impairment; cite AHS guidelines for refractory migraine; Network Adequacy laws for external prescriptions,Internal Protocol - exemptions rare,Internal,Kaiser Internal Protocol,Colorado_2026_PA_Audit,CO-COM-KAISER,Kaiser,DENY-STEP-002,True,,
CO,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Colorado_2026_PA_Audit,CO-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
UT,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Utah_2026_PA_Audit,UT-COM-UHC,87726,DENY-STEP-002,True,,
UT,Regence BCBS Utah,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 classes,≥2 months each,,,Policy dru540; 6mo initial auth; reauth requires ≥50% reduction documentation,Yes - teratogenic; cognitive; respiratory,,,Regence dru540,Utah_2026_PA_Audit,UT-COM-REGENCE,Regence,DENY-STEP-002,True,,
UT,Molina Healthcare Utah,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per UT Medicaid PDL,Trial required,,,PDL limits; Dominant Medicaid payer (42.5%),Yes,No,,Molina UT Policy,Utah_2026_PA_Audit,UT-MCD-MOLINA,38308,DENY-STEP-002,True,,
UT,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Utah_2026_PA_Audit,UT-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MS,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Mississippi_2026_PA_Audit,MS-COM-UHC,87726,DENY-STEP-002,True,,
MS,Mississippi Medicaid (DOM),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per MS DOM PA Criteria (Form CGRP-08_25_2025),Trial required,,,PDL limits,Yes,No,,MS DOM CGRP Criteria,Mississippi_2026_PA_Audit,MS-MCD-MSDOM,STATE-MS,DENY-STEP-002,True,,
MS,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Mississippi_2026_PA_Audit,MS-MAC-NOVITAS,MAC-JH,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Documented failure,,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy, Vyepti; Vyepti requires failure of ALL viable self-injectable CGRPs before approval",Yes - teratogenic; CV contraindication; documented intolerance,NO - SB 5395 FAILED,,Regence dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-002,True,,
WA,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Washington_State_PA_Audit_2026,WA-COM-UHC,87726,DENY-STEP-002,True,,
WA,Molina Healthcare WA,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per WA HCA PDL,Trial required,,,PDL limits,Yes,No,,Molina WA Policy,Washington_State_PA_Audit_2026,WA-MCD-MOLINA,38308,DENY-STEP-002,True,,
WA,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,'Traditional methods of treatments have been tried and proven unsuccessful' - vague but audit defense = document ≥2 distinct oral preventive classes,Documented in medical record,,,LCD L35172; ⚠️ Chronic Migraine ONLY (G43.701/G43.709/G43.711/G43.719) - Episodic = 'cosmetic/investigational' = RIGID DENIAL; Diagnostic threshold: >15 HA days/mo with 4+ hours/day; ⚠️ 12-WEEK FREQUENCY STRICT - claims at 10-11 weeks = automated denial unless 'wearing off' substantiated with peer-reviewed literature (difficult); 155-200 units recognized; >200u = manual medical review,Yes - documented oral failures with adverse events,No - Federal Medicare,,LCD L35172 / Article A57186,Washington_State_PA_Audit_2026,WA-MAC-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Premera Blue Cross,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Tier 3; HCLV exclusions may apply,Yes - CV contraindication,No state mandate,,Premera Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-001,True,,
AK,Premera Blue Cross,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 categories traditional prophylaxis,Trial required,,,Monthly supply; Site of Service review for Vyepti,Yes - CV; teratogenic,No state mandate,,Premera Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-002,True,,
AK,Premera Blue Cross,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 categories prophylaxis (stricter),Trial required,,,155 units/12 weeks; 50% reduction for renewal,Yes,No state mandate,,Premera Medical Policy,Alaska_2026_PA_Audit,AK-COM-PREMBC,430,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Moda Health,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral medications,≥8 weeks each,,,Vyepti 6-month initial auth; No concurrent Botox+CGRP,Yes,No state mandate,,Moda High Performance Formulary,Alaska_2026_PA_Audit,AK-COM-MODA,MODAAK,DENY-STEP-002,True,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥1 preventive (2 mo) AND ≥2 triptans (Double Step),Trial required,,,PDL limits,Yes - CV contraindication,No,,DenaliCare PA Criteria,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-001,True,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 prophylactic classes,≥2 months each,,,No concurrent CGRP inhibitors,Yes - intolerance bypass,No,,DenaliCare PA Criteria,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-002,True,,
AK,Alaska Medicaid (DenaliCare),Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 classes; Neurologist only,Trial required,,,155 units/12 weeks,Yes,No,,DenaliCare Medical Policy,Alaska_2026_PA_Audit,AK-MCD-DENALI,STATE-AK,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 prophylactic therapies,≥2 months each,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥90% approval rate,UHC CGRP Policy,Alaska_2026_PA_Audit,AK-COM-UHC,87726,DENY-STEP-002,True,,
AK,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD L35172; JW modifier for waste,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD L35172,Alaska_2026_PA_Audit,AK-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes - CV; teratogenic,No state mandate,,BCBSAR Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-002,True,,
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,BCBSAR Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-001,True,,
AR,Blue Cross Blue Shield Arkansas,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,BCBSAR Medical Policy,Arkansas_2026_PA_Audit,AR-COM-BCBSAR,71064,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Arkansas_2026_PA_Audit,AR-COM-UHC,87726,DENY-STEP-002,True,,
AR,Arkansas Medicaid (DHS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per AR DHS PDL,Trial required,,,PDL limits,Yes,No,,AR DHS PDL,Arkansas_2026_PA_Audit,AR-MCD-ARDHS,STATE-AR,DENY-STEP-002,True,,
AR,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Arkansas_2026_PA_Audit,AR-MAC-NOVITAS,MAC-JH,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Monthly supply; Dominant payer (63%),Yes - CV; teratogenic,No state mandate,,HMSA Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-002,False,,HMSA: Commercial = 1 oral class for episodic CGRP vs 2 for chronic. QUEST Medicaid = 2 classes for both.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,HMSA Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-001,True,,
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,HMSA Medical Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA,99101,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Kaiser Permanente Hawaii,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥3 oral preventive classes (Closed Formulary),6-8 weeks each,,,Tier 4/Non-Preferred; Internal referral gates,Yes - most restrictive,No state mandate,,Kaiser HI Policy,Hawaii_2026_PA_Audit,HI-COM-KAISER,93079,DENY-STEP-002,True,,
HI,UnitedHealthcare (QUEST),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per HI QUEST PDL,Trial required,,,PDL limits,Yes,No,,UHC QUEST Policy,Hawaii_2026_PA_Audit,HI-MCD-UHC,87726,DENY-STEP-002,True,,
HI,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Hawaii_2026_PA_Audit,HI-MAC-NORIDIAN,MAC-JE,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,Blue Cross of Idaho,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply; Dominant payer (42%),Yes - CV; teratogenic,No state mandate,,BCID Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-002,True,,
ID,Blue Cross of Idaho,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,BCID Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-001,True,,
ID,Blue Cross of Idaho,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,BCID Medical Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-BCID,82024,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Idaho_2026_PA_Audit_Strategy,ID-COM-UHC,87726,DENY-STEP-002,True,,
ID,Idaho Medicaid (DHW),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per ID DHW PDL,Trial required,,,PDL limits,Yes,No,,ID DHW PDL,Idaho_2026_PA_Audit_Strategy,ID-MCD-IDDHW,STATE-ID,DENY-STEP-002,True,,
ID,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Idaho_2026_PA_Audit_Strategy,ID-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply; Dominant payer (50%),Yes - CV; teratogenic,No state mandate,,BCBSMT Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-002,True,,
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,BCBSMT Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-001,True,,
MT,Blue Cross Blue Shield Montana (HCSC),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,BCBSMT Medical Policy,Montana_2026_PA_Audit,MT-COM-BCBSMT,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Montana_2026_PA_Audit,MT-COM-UHC,87726,DENY-STEP-002,True,,
MT,Montana Medicaid (DPHHS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per MT DPHHS PDL,Trial required,,,PDL limits,Yes,No,,MT DPHHS PDL,Montana_2026_PA_Audit,MT-MCD-MTDPHHS,STATE-MT,DENY-STEP-002,True,,
MT,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Montana_2026_PA_Audit,MT-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,First-Line for Chronic Migraine (≥15 days/mo) per 2026 update,,Episodic still requires ≥2 classes,≥2 months each,Monthly supply; Dominant payer (48%),Yes - CV; teratogenic,Yes (SB 2280),90% approval rate,BCBSND 2026 Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-002,True,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥30 days each,,,Plan dependent,Yes - CV; serotonin syndrome,Yes (SB 2280),90% approval rate,BCBSND Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-001,True,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,Yes (SB 2280),90% approval rate,BCBSND Medical Policy,North_Dakota_2026_PA_Audit,ND-COM-NDAKBCBS,54384,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Sanford Health Plan,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Integrated System),Trial required,,,Direct EMR data access,Yes - CV; teratogenic,No state-specific,,Sanford Policy,North_Dakota_2026_PA_Audit,ND-COM-SANFORD,52148,DENY-STEP-002,True,,
ND,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National + State),≥92% approval rate,UHC CGRP Policy,North_Dakota_2026_PA_Audit,ND-COM-UHC,87726,DENY-STEP-002,True,,
ND,North Dakota Medicaid (DHS),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,≥30-day trial each,,,PDL limits,Yes - CV contraindication,No,,ND DHS PDL,North_Dakota_2026_PA_Audit,ND-MCD-NDDHS,STATE-ND,DENY-STEP-001,True,,
ND,North Dakota Medicaid (DHS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 drug classes,≥2 months each,,,PDL limits; Acentra Health reviews,Yes - comorbidity bypass,No,,ND DHS PA Criteria,North_Dakota_2026_PA_Audit,ND-MCD-NDDHS,STATE-ND,DENY-STEP-002,True,,
ND,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,North_Dakota_2026_PA_Audit,ND-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 oral preventive class (Topiramate, Propranolol, or Amitriptyline); lower barrier than most states",≥8 weeks,,,⚠️ NetResults often EXCLUDES Aimovig in favor of Ajovy (rebate-driven); use A1825 'Stability' override if forced switch from Aimovig to Ajovy,Yes - side effect intolerance (cognitive slowing for Topiramate); A1825 Condition 5 (Stability) if switching stable patient,A1825 Step Therapy Override,72h response or deemed approved,Horizon CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-002,True,,
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Rizatriptan, Sumatriptan, Naratriptan); documentation must include dates of service or pharmacy fill history",Documented failure,,,QL strictly enforced 16 tabs/30d; NetResults formulary highly restrictive,Yes - CV contraindication (ischemic heart disease/stroke/TIA/uncontrolled HTN/PVD) = 'Vascular Contraindication' bypass via A1825 Condition 1,A1825 Step Therapy Override,72h response or deemed approved,Horizon Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-001,True,,
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes,≥8 weeks each,N/A",,Chronic Migraine (≥15 days/mo, ≥8 migrainous, ≥3 months); OMNIA tiered structure,Yes - oral preventive contraindications; teratogenic bypass,A1825 applies,72h response or deemed approved,Horizon Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Aetna NJ,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥0-1 oral preventive class (lower barrier),≥8 weeks if required,,,Renewal often requires 50% reduction in migraine days; Cluster Headache (Emgality 300mg) requires Verapamil/Lithium failure - do NOT use migraine PA form for cluster,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies,72h response,Aetna CGRP CPB,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-STEP-002,True,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,≥8 weeks each,,,"PREFERRED: Aimovig, Emgality; Ajovy/Vyepti often NON-PREFERRED; Vyepti requires 'failure of self-injection' or 'needle phobia' or 'absorption issues'",Yes - teratogenic; CV contraindication; documented intolerance,UHC Gold Card + A1825,92% threshold,UHC CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-002,True,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per PDL,≥8 weeks each,,,PDL adherence required; ⚠️ MOH (Medication Overuse Headache) assessment documentation REQUIRED,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies to NJ FamilyCare,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-002,True,,
NJ,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,"⚠️ WISeR PILOT: Pre-Service PA MANDATORY starting Jan 1 2026; fail ≥2 classes of oral prophylaxis (Beta-blockers, Anticonvulsants, TCAs)",Documented with dates/reasons,,,"LCD L35170/L39909; AI-based review; Chronic Migraine (G43.719); ≥15 HA days with ≥8 migrainous for ≥3 months; ⚠️ HIT-6 or MIDAS score REQUIRED for AI review; renewal requires QUANTITATIVE data (e.g., 'reduced from 20 to 10 days/month') - 'patient feels better' INSUFFICIENT; ⚠️ Billing without PA = Pre-Payment Review (cash flow freeze)",Yes - documented oral failures with specific adverse events,WISeR Gold Card - earn exemption through compliance,High approval rate in initial phase,LCD L35170/L39909,New_Jersey_2026_PA_Audit,NJ-MAC-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes; ""3 drugs from 2 classes"" rule",Trial required,,,Monthly supply; Dominant payer (57-58%),Yes - CV; teratogenic,No (PA Reform excludes Rx),,BCBSRI Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-002,True,,
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent; CGRPs count as class for Botox step,Yes - CV contraindication,No (PA Reform excludes Rx),,BCBSRI Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-001,True,,
RI,Blue Cross Blue Shield Rhode Island,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No (PA Reform excludes Rx),,BCBSRI Medical Policy,Rhode_Island_2026_PA_Audit,RI-COM-RIBCBS,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Neighborhood Health Plan of RI,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Nurtec Non-Formulary; Ubrelvy preferred,Trial required,,,Restrictive; cost-containment focus,Yes - documented intolerance,No,,NHPRI Policy,Rhode_Island_2026_PA_Audit,RI-MCD-RINEIGH,NHPRI,DENY-STEP-002,True,,
RI,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; MA dominant (>30%),Trial required,,,Aimovig/Emgality preferred; Ajovy non-preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Rhode_Island_2026_PA_Audit,RI-COM-UHC,87726,DENY-STEP-002,True,,
RI,Point32Health (Tufts),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,Select formulary exclusionary logic,Trial required,,,Monthly supply,Yes,No state mandate,,Point32Health Policy,Rhode_Island_2026_PA_Audit,RI-COM-TUFTS,4271,DENY-STEP-002,True,,
RI,Novitas Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,"Per LCD DL39909; ""Conservative Tx"" requirement",Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Rhode_Island_2026_PA_Audit,RI-MAC-NOVITAS,MAC-JL,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Avera Health Plans,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Emgality/Ajovy preferred; Aimovig non-preferred,≥2 months each,,,Dominant payer (33%); needle phobia bypass for oral,Yes - needle phobia (F40.230),No (SB 158 failed),,Avera Policy,South_Dakota_2026_PA_Audit,SD-COM-AVERA,AVERA,DENY-STEP-002,True,,
SD,Avera Health Plans,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; headache diary audits,Trial required,,,155 units/12 weeks; 15+ days documented,Yes,No (SB 158 failed),,Avera Medical Policy,South_Dakota_2026_PA_Audit,SD-COM-AVERA,AVERA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Sanford Health Plan,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Aimovig preferred; Vyepti requires 2 SC CGRP fails,Trial required,,,Tier 3/4 placement,Yes - CV; teratogenic,No (SB 158 failed),,Sanford Policy,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,52148,DENY-STEP-002,True,,
SD,Sanford Health Plan,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; Dual therapy approved for refractory,Trial required,,,155 units/12 weeks,Yes - AHS 2024 synergy,No (SB 158 failed),,Sanford Medical Policy,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,52148,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,Wellmark BCBS SD,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Ajovy/Emgality preferred; Aimovig third-line,≥2 months each,Vyepti requires 2 SC CGRP fails,,Monthly supply,Yes,No (SB 158 failed),,Wellmark SD Policy,South_Dakota_2026_PA_Audit,SD-COM-WELLMARK,88057,DENY-STEP-002,True,,
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per SD DSS PDL,Trial required,,,PDL limits,Yes,No,,SD DSS PDL,South_Dakota_2026_PA_Audit,SD-MCD-SDDSS,STATE-SD,DENY-STEP-002,True,,
SD,Noridian Healthcare Solutions,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD L35170; G43.701/709/711/719 codes only,Adequate trial,,,155 units/12 weeks; JW modifier mandatory,Yes,N/A (Federal),,LCD L35170,South_Dakota_2026_PA_Audit,SD-MAC-NORIDIAN,MAC-JF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply; Dominant payer (57%),Yes - CV; teratogenic,No state mandate,,BCBSVT Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-002,True,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Trial required,,,Plan dependent,Yes - CV contraindication,No state mandate,,BCBSVT Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-001,True,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Trial required,,,155 units/12 weeks,Yes,No state mandate,,BCBSVT Medical Policy,Vermont_2026_PA_Audit,VT-COM-VERBCBS,28539,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,MVP Health Care,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Formulary updates Feb 1 2026,Trial required,,,Monthly supply,Yes,No state mandate,,MVP Policy,Vermont_2026_PA_Audit,VT-COM-MVPHEALTH,14165,DENY-STEP-002,True,,
VT,Vermont Medicaid (DVHA),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,Per VT DVHA PDL,Trial required,,,PDL limits,Yes,No,,VT DVHA PDL,Vermont_2026_PA_Audit,VT-MCD-VTDVHA,STATE-VT,DENY-STEP-002,True,,
VT,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD DL39909,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Vermont_2026_PA_Audit,VT-MAC-NGS,MAC-J6,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 different classes of standard preventives (Beta-blockers, Antidepressants, CALCIUM CHANNEL BLOCKERS, Anticonvulsants); ⚠️ CCBs (Verapamil) COUNT as valid step - if patient tried Verapamil for any reason, document it",Documented failure each,,,"PREFERRED (Formulary): Ajovy, Emgality, Nurtec ODT, Qulipta; NON-PREFERRED: Aimovig, Vyepti; ⚠️ To access Aimovig/Vyepti must fail 2 Formulary CGRPs (step-within-step); ⚠️ CRITICAL: Policy 006 (Jan 1 2026) says CGRPs are 'first-line' - USE THIS TO APPEAL step therapy denials from Policy 021",Yes - teratogenic; CV contraindication; documented intolerance; cite Policy 006 'first-line' to bypass Policy 021 step therapy,NO - H.4616 pending,,BCBSMA Policy 021/006,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-002,True,,
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,Gepants (Acute),Acute,Yes,Step 1 (Open): Naratriptan/Rizatriptan/Sumatriptan; Step 2 (PA): Almotriptan/Eletriptan/Frovatriptan/Zolmitriptan - requires 1 Step 1 agent; Step 3 (Nurtec/Ubrelvy): requires ≥2 triptan failures,Documented failure per step,,,Standard criteria; 12-month approval duration,Yes - CV contraindication (bypass all triptans),NO - H.4616 pending,,BCBSMA Policy 021,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-001,True,,
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,,,Chronic Migraine (≥15 days/month with ≥4 hours duration); ⚠️ Policy 006 explicitly states 'CGRP inhibitors as option for first-line treatment of prevention of migraine' - CONTRADICTS step therapy in Policy 021,Yes - oral preventive contraindications,NO - H.4616 pending,,BCBSMA Policy 006,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Point32Health (Harvard Pilgrim),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Trial required,,,Monthly supply,Yes,No state mandate,,Harvard Pilgrim Policy,Massachusetts_2026_PA_Audit,MA-COM-HARVARD,4271,DENY-STEP-002,True,,
MA,Point32Health (Tufts),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes; Tufts Health Together MCO exit (member reassignment),Trial required,,,Monthly supply; 90-day continuity mandate,Yes,No state mandate,,Tufts Policy,Massachusetts_2026_PA_Audit,MA-COM-TUFTS,4271,DENY-STEP-002,True,,
MA,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Trial required,,,Aimovig/Emgality preferred,Yes,Yes (UHC National),≥92% approval rate,UHC CGRP Policy,Massachusetts_2026_PA_Audit,MA-COM-UHC,87726,DENY-STEP-002,True,,
MA,MassHealth (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,'1+1 Protocol': ≥1 Beta-blocker (Atenolol/metoprolol/nadolol/propranolol/timolol) AND ≥1 Other Class Agent (Topiramate/TCA/valproic acid/venlafaxine),Documented failure each,,,Age restriction: ≥18 years (excludes pediatric approvals); PREFERRED CGRPs via UPPL; ACOs CANNOT impose stricter criteria than MHDL - appeal via 130 CMR 406.000,Yes - teratogenic; CV contraindication; documented intolerance; ACO denials using 'commercial-style' criteria = regulatory violation,NO - H.4616 pending,,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-002,True,,
MA,National Government Services,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Per LCD L33646/DL39909; G43.709/719 codes; JZ modifier if no waste,Adequate trial,,,155 units/12 weeks,Yes,N/A (Federal),,LCD DL39909,Massachusetts_2026_PA_Audit,MA-MAC-NGS,MAC-J6,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Medi-Cal Rx,Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks,≥2 SC CGRPs (Aimovig/Emgality),Documented failure/intolerance,Non-Preferred with higher PA hurdles; Medical Benefit via MCP,Yes - inability to self-inject; SC CGRP intolerance,No (State Medicaid),,Medi-Cal Rx CDL,California_2026_PA_Audit,CA-MCD-MEDICALRX,,DENY-STEP-005,True,,
CA,L.A. Care Health Plan,Medicaid MCO,Medical Benefit,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs,Documented failure,Medical Benefit; high scrutiny; must show inability to self-inject,Yes - inability to self-inject documented; SB 530 network adequacy (15 miles/30 min or 15 days),No (Medicaid),,L.A. Care Medical Benefit,California_2026_PA_Audit,CA-MCD-LACAREHEALTH,LACAR,DENY-QL-001,True,,
CA,Kaiser Permanente,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 oral preventive classes (most restrictive),≥6-8 weeks each,,,"Stopping Rule: 50% reduction required after 2 cycles (6 months) or therapy discontinued; must document baseline frequency (e.g., 20 days/mo) and current frequency; vague 'doing better' = denial",Yes - multiple documented intolerances; MIDAS Grade IV functional impairment,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Botox Policy clinical-review-botox,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Kaiser Permanente,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥3 oral preventive classes,≥6-8 weeks each,≥1 SC CGRP mAb (Aimovig/Ajovy/Emgality),Documented failure/intolerance,Last resort; requires oral + SC CGRP failures; Medical Benefit,Yes - inability to self-inject; documented SC failures,SB 306 Data Calibration 2026,Exemptions effective 2028,Kaiser Vyepti Policy,California_2026_PA_Audit,CA-COM-KAISER,93079,DENY-QL-001,True,,
CA,Anthem Blue Cross,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 prophylactic classes (Beta-blockers, Anticonvulsants, TCAs)",≥2 months each,,,Chronic Migraine (strict ICHD-3); Medical Benefit CC-0032; dual therapy (Botox+CGRP) excluded unless partial response argued with AHS 2021 Consensus,Yes - documented failures; partial responder to Botox (40% reduction but remains disabled),SB 306 Data Calibration 2026,Exemptions effective 2028,Anthem CC-0032 Botulinum Toxin,California_2026_PA_Audit,CA-COM-ANTHEMBC,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Blue Shield of California,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine (≥15 days/mo); Medical Benefit,Yes - oral preventive contraindications/intolerances,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Botox Policy PRV_MP_BotulinumToxin,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CA,Blue Shield of California,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs (Aimovig/Emgality) + Nurtec preventive,Documented failure/intolerance,Strict criteria; Feb 2026: cannot combine with another CGRP antagonist,Yes - inability to self-inject; SC CGRP failures documented,SB 306 Data Calibration 2026,Exemptions effective 2028,Blue Shield Vyepti Policy eptinezumab-jjmr,California_2026_PA_Audit,CA-COM-BSCA,88027,DENY-QL-001,True,,
CA,Health Net,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans per Centene clinical guidelines,≥4 weeks each,,,Pharmacy carved to Medi-Cal Rx for Medicaid; commercial follows Centene guidelines,Yes - CV contraindication,SB 306 Data Calibration 2026,Exemptions effective 2028,Health Net Formulary,California_2026_PA_Audit,CA-COM-HNET,68069,DENY-STEP-001,True,,
CA,Health Net,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per Centene guidelines,≥8 weeks each,,,Centene clinical criteria apply,Yes - teratogenic; CV contraindication,SB 306 Data Calibration 2026,Exemptions effective 2028,Health Net CGRP Policy,California_2026_PA_Audit,CA-COM-HNET,68069,DENY-STEP-002,True,,
CA,Noridian Healthcare Solutions,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Per LCD requirements,Documented,,,J3032; Chronic Migraine; Medical Benefit; Jurisdiction E (CA/NV/HI),Yes - inability to self-inject; documented in chart,No (Federal Medicare),,LCD DL39909,California_2026_PA_Audit,CA-PARTB-NORIDIAN,,DENY-QL-001,True,,
KS,UnitedHealthcare,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 oral preventive classes (more stringent than BCBS),≥8 weeks each,,,200 units max/12 weeks,Yes - documented intolerances,Pending (HB 2292),,UHC-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,≥2 acute episodes,,,"Nurtec 8/30d, Ubrelvy 10/30d",Yes - CV contraindication,No,,BLUEKC-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-001,True,,
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Ajovy EXCLUDED from 2026 formulary - must use Aimovig or Emgality first,,Monthly supply,Yes - teratogenic/CV contraindication,No,,BLUEKC-CGRP-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-002,True,,
KS,Blue Cross Blue Shield of Kansas City,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks standard,Yes - oral contraindications,No,,BLUEKC-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-COM-BLUEKC,47171,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Healthy Blue Kansas,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 PDL triptans,≥4 weeks each,,,KS Medicaid PDL limits apply,Yes - CV/hemiplegic contraindication,No,,HEALTHYBLUE-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-HEALTHYBLUE,47198,DENY-STEP-001,True,,
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 PDL triptans,≥4 weeks each,,,KS Medicaid PDL limits,Yes - CV contraindication,No,,SUNFLOWER-RX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-001,True,,
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155-200 units/12 weeks,Yes - oral contraindications,No,,SUNFLOWER-BOTOX-2026,Kansas_PA_Audit__Migraine_Drug_Defense,KS-MCD-SUNFLOWER,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,WPS Government Health Administrators,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful,Documented in chart,,,155-200 units/12 weeks per LCD,Yes - documented in medical record,N/A - Federal Medicare,,LCD DL39909,Kansas_PA_Audit__Migraine_Drug_Defense,KS-PARTB-WPSGHA,,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,Blue Cross Blue Shield of Minnesota,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans (sumatriptan/rizatriptan preferred),≥4 weeks each,N/A",,Non-Preferred or PA required; standard QL,Yes - vascular risk factors (uncontrolled HTN, Raynaud's, ischemic disease history),MN §62M.07 Platinum Card,Chronic condition auth does not expire,BCBSMN Commercial Formulary,Minnesota_2026_PA_Audit,MN-COM-MINNBCBS,720,DENY-STEP-001,True,,
MN,Medica,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans per formulary,≥4 weeks each,,,Non-Preferred or PA required; transitional friction with UCare legacy members Q1 2026,Yes - CV contraindication; vascular risk factors,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica Formulary 2026,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-001,True,,
MN,Medica,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Aimovig/Ajovy/Emgality preferred; acquired UCare business - watch for adjudication conflicts; 30.76% rate increase driving stricter UM,Yes - intolerance documentation; teratogenic bypass,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica CGRP Policy,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-002,True,,
MN,Medica,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine (≥15 days/mo); Medical Benefit; stricter UM due to premium pressures,Yes - documented oral preventive failures/intolerances,MN §62M.07 Platinum Card,Chronic condition auth does not expire,Medica Botox Policy,Minnesota_2026_PA_Audit,MN-COM-MEDICA,94265,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,HealthPartners,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans - automated rejection if no oral preventive history in pharmacy claims,≥4 weeks each,,,Tier 3/4; strict step therapy enforcement via claims data algorithm,Yes - CV contraindication; vascular risk factors,MN §62M.07 Platinum Card,Chronic condition auth does not expire,HealthPartners Formulary,Minnesota_2026_PA_Audit,MN-COM-PARTNERS,95052,DENY-STEP-001,True,,
MN,UCare,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes per DHS Uniform PDL,≥8 weeks each",,,⚠️ TRANSITIONING TO MEDICA - legacy runoff; Aimovig/Ajovy/Emgality preferred on PDL; Vyepti non-preferred; §62M.17 60-day continuity applies,Yes - intolerance (cognitive slowing, fatigue) bypasses trial duration,Legacy - transitioning,,DHS Uniform PDL,Minnesota_2026_PA_Audit,MN-MCD-UCARE,UCARE,DENY-STEP-002,True,,
MN,UCare,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ TRANSITIONING - D-SNP discontinued; members moving to new plans; 60-day continuity protections apply,Yes - oral preventive contraindications,Legacy - transitioning,,DHS Uniform PDL,Minnesota_2026_PA_Audit,MN-MCD-UCARE,UCARE,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,Blue Plus,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per DHS Uniform PDL,≥4 weeks each,,,Non-Preferred; Nurtec/Ubrelvy require PA,Yes - vascular risk factors; CV contraindication,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL 2026,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-001,True,,
MN,Blue Plus,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (Beta-blockers, Antidepressants, Anticonvulsants)",≥8 weeks each,,,Aimovig/Ajovy/Emgality preferred per DHS PDL; Vyepti non-preferred (higher PA hurdles); expanded Ramsey/Scott counties,Yes - intolerance documentation sufficient to bypass trial duration,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL 2026,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-002,True,,
MN,Blue Plus,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes per DHS criteria,≥8 weeks each,,,Chronic Migraine (≥15 days/mo); dual therapy with CGRP requires medical necessity appeal,Yes - oral preventive contraindications/intolerances,MN §62M.07 Platinum Card,Chronic condition auth does not expire,DHS Uniform PDL/Blue Plus Policy,Minnesota_2026_PA_Audit,MN-MCD-BLUEPLUS,720,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MN,National Government Services,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Per LCD requirements; SC CGRP failures,Documented,,,J3032; Chronic Migraine diagnosis; Medical Benefit,Yes - inability to self-inject; SC intolerance,No (Federal Medicare),,LCD DL39909,Minnesota_2026_PA_Audit,MN-PARTB-NGS,,DENY-STEP-005,True,,
TX,Blue Cross Blue Shield of Texas,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,≥2 sub-Q CGRPs (Aimovig/Emgality),Documented failure/intolerance,Per J3032 billing; Medical Benefit,Yes - inability to self-inject; SC CGRP failures,Yes (HB 3459/HB 3812),90% approval rate,Medical Benefit Policy,Texas_2026_PA_Audit,TX-COM-BCBSTX,621,DENY-GOLD-001,True,,
TX,UnitedHealthcare,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Demonstrate intolerance/failure of SC options,Documented,Medical Benefit PA required,Yes - inability to self-inject; SC intolerance,Yes (HB 3459/HB 3812),Annual evaluation Jan-Dec,UHC Medical Benefit,Texas_2026_PA_Audit,TX-COM-UHC,87726,DENY-STEP-005,True,,
TX,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans per Texas VDP (Frovatriptan often preferred),≥4 weeks each,,,>9 tabs/month requires Clinical PA proving no MOH,Yes - CV contraindication; MOH exclusion documentation required,No (Medicaid excluded HB 3459),,Texas VDP Clinical Edit,Texas_2026_PA_Audit,TX-MCD-UHC,87726,DENY-STEP-001,True,,
TX,UnitedHealthcare Community Plan,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per VDP,≥8 weeks each,PDL Prior Authorization if Non-Preferred,Must fail Preferred agents on state list,VDP quantity limits; Non-Preferred Drug Request required,Yes - standard contraindication language,No (Medicaid excluded HB 3459),,Texas VDP PDL PA Form,Texas_2026_PA_Audit,TX-MCD-UHC,87726,DENY-STEP-002,True,,
TX,Superior HealthPlan,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Medical Benefit; Chronic Migraine diagnosis required,Yes - oral preventive contraindications,No (Medicaid excluded HB 3459),,Superior Medical Benefit,Texas_2026_PA_Audit,TX-MCD-SUPERIOR,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Cigna Healthcare of Texas,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine only; Medical Benefit,Yes - documented oral failures,Yes (HB 3459/HB 3812),Biannual notifications,Cigna Botox Policy ip_0637,Texas_2026_PA_Audit,TX-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TX,Ambetter from Superior,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans or preferred formulary alternatives,≥4 weeks each,,,Qulipta/Nurtec Non-Preferred; Non-Preferred Drug Request required,Yes - CV contraindication,Yes (HB 3459/HB 3812),TDI regulated fully insured plans,Ambetter Formulary 2026,Texas_2026_PA_Audit,TX-COM-AMBET,68069,DENY-STEP-001,True,,
TX,Ambetter from Superior,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes or generic failures,≥8 weeks each,,,Non-Preferred Drug Request for restricted agents,Yes - teratogenic; CV contraindication,Yes (HB 3459/HB 3812),TDI regulated fully insured plans,Ambetter HB3459 FAQ,Texas_2026_PA_Audit,TX-COM-AMBET,68069,DENY-STEP-002,True,,
TX,Novitas Solutions,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Per LCD requirements,Documented,,,J3032; Chronic Migraine diagnosis required; Medical Benefit,Yes - inability to self-inject documented,No (Federal Medicare exempt),,LCD DL39909,Texas_2026_PA_Audit,TX-PARTB-NOVITAS,,DENY-QL-001,True,,
NY,Empire BlueCross BlueShield,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes - CAPPED at 2 per NY Chapter 20,≥2 months each (≤30 days if adverse event),,,Chronic Migraine (≥15 HA days/mo); Medical Benefit; adheres to NGS LCD L33646 for Medicare Advantage,Yes - documented adverse events; stability on current therapy per NY Ins Law §4903(c-1),Pending (S7470),N/A - pending legislation,Empire Medical Policy Botox,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Empire BlueCross BlueShield,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Failure of SC CGRPs preferred,Documented,Non-Preferred Tier 3/4; Medical Benefit,Yes - inability to self-inject; dexterity issues; cognitive impairment,Pending (S7470),N/A - pending legislation,Empire Vyepti Policy,New_York_2026_PA_Audit,NY-COM-EMPIREBCBS,13551,DENY-QL-001,True,,
NY,UnitedHealthcare (Oxford),Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,≥2 SC CGRPs (Aimovig/Emgality),Documented failure/intolerance,Non-Preferred; Medical Benefit; site of care management,Yes - inability to self-inject; SC intolerance; bioavailability argument for GI issues,Yes (Voluntary),92% approval rate,UHC Vyepti Policy,New_York_2026_PA_Audit,NY-COM-UHC,87726,DENY-STEP-005,True,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,All CGRPs (oral and injectable) require Preauthorization; Express Scripts PBM,Yes - CV contraindication,Pending (S7470),N/A - pending legislation,EmblemHealth 2026 Preauth List,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-001,True,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes - CAPPED at 2 per NY law,≥8 weeks each,N/A",,Aimovig/Emgality PREFERRED; transitioning to NYCE PPO (UHC partnership) eff 1/1/2026 - may align with stricter UHC guidelines; City employee population - emphasize 'Occupational Impact' in appeals,Yes - functional impairment affecting essential job functions (police, fire, teachers); contraindications,Pending (S7470),N/A - pending legislation,EmblemHealth CGRP Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-STEP-002,True,,
NY,EmblemHealth (GHI/HIP),Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,"≥2 oral preventive classes,≥8 weeks each",Failed self-injectables,Documented failure/intolerance,Non-Preferred; restricted to patients who failed SC or have medical reason preventing self-injection (dexterity, cognitive impairment),Yes - inability to self-inject; documented SC failures,Pending (S7470),N/A - pending legislation,EmblemHealth Vyepti Policy,New_York_2026_PA_Audit,NY-COM-EMBLEM,13141,DENY-QL-001,True,,
NY,Aetna New York,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans - strict enforcement,≥4 weeks each,,,Ubrelvy/Nurtec 16 tabs/30d (stricter than some payers); aggressive MOH denial if >10 days/month acute med use; must document 'not attributable to MOH' + concurrent preventive therapy,Yes - CV contraindication; must explicitly document NO medication overuse headache,Pending (S7470),N/A - pending legislation,Aetna Policy 3481-E,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-001,True,,
NY,Aetna New York,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Aimovig PREFERRED; standard CGRP criteria,Yes - teratogenic; CV contraindication,Pending (S7470),N/A - pending legislation,Aetna CGRP Policy,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-002,True,,
NY,Aetna New York,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; 50% REDUCTION required for reauth; Medical Benefit,Yes - documented failures,Pending (S7470),N/A - pending legislation,Aetna Botox Policy,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,Aetna New York,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥3 months preventive treatment failure,Documented,≥2 SC CGRPs (Aimovig/Emgality),Failure required per CPB 0970,J3032; Non-Preferred; requires oral + SC CGRP failures before IV option; bioavailability argument for GI stasis/malabsorption patients,Yes - severe GI stasis/malabsorption (100% bioavailability argument); SC injection failures/intolerance,Pending (S7470),N/A - pending legislation,Aetna CPB 0970,New_York_2026_PA_Audit,NY-COM-AETNA,60054,DENY-STEP-005,True,,
NY,National Government Services (NGS),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Traditional preventive methods proven unsuccessful (implies ≥2 oral classes),Documented in chart,,,155-200 units/12 weeks; LCD L33646; STRICT ICD-10: G43.701/G43.709/G43.711/G43.719 ONLY (NO R51 or episodic G43.0-/G43.1-); ≥15 HA days/mo for ≥3 months; ≥4 hours duration; document specific muscles injected + dosage per site; 12-week interval STRICT (10-11 weeks = denial); JW/JZ modifiers MANDATORY,Yes - documented in medical record with specific diagnosis codes,No - Federal Medicare,,LCD L33646,New_York_2026_PA_Audit,NY-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NY,National Government Services (NGS),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Per LCD requirements,Documented,,,J3032; Chronic Migraine; Medical Benefit; Jurisdiction K (NY/CT/MA/ME/NH/RI/VT),Yes - inability to self-inject; documented in chart,No - Federal Medicare,,LCD L33646/DL39909,New_York_2026_PA_Audit,NY-PARTB-NGS,NGS,DENY-QL-001,True,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,Regional Upstate NY BCBS; Headache Disorders pharmacy policy,Yes - CV contraindication,Pending (S7470),N/A - pending legislation,Excellus Headache Disorders Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-001,True,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Regional formulary; 2026 Part D $2000 OOP cap applies to Medicare Advantage plans,Yes - teratogenic; CV contraindication,Pending (S7470),N/A - pending legislation,Excellus CGRP Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-002,True,,
NY,Excellus BlueCross BlueShield,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; Medical Benefit,Yes - documented failures,Pending (S7470),N/A - pending legislation,Excellus Botox Policy,New_York_2026_PA_Audit,NY-COM-ECELBCBS,EXCL,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,Gepants (Acute),Acute,Yes,"""≥2 triptans (sumatriptan, rizatriptan, eletriptan)"",Failure = lack of efficacy after treating ≥3 attacks OR intolerance/contraindication",,,Standard QL; Tier 3/4; Zavzpret NON-PREFERRED,Yes - CV risk factors (CAD, uncontrolled HTN) = 'Contraindication to vasoconstrictive agents' bypasses triptan step entirely,Yes (SB 7016),>90% approval in 2025,Florida Blue Acute Migraine Policy,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-STEP-001,True,,
FL,Aetna Florida,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,⚠️ ≥3 oral preventive classes (OR 2 orals + 1 CGRP) - STRICTER than FL Blue/Sunshine 2-class requirement,≥8 weeks each,,,Chronic Migraine; restrictive dual therapy (Botox+CGRP) - must prove 'synergy' with phrase: 'Treatment-refractory chronic migraine requiring synergistic dual therapy',"Yes - document 3 distinct oral failures (e.g.,Propranolol + Topiramate + Amitriptyline)",Yes (SB 7016),Active,Aetna Botox Policy,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Florida Blue,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,PA Required,Documented,Medical Benefit (J3032); PA Required,Yes - inability to self-inject; documented SC failures,Yes (SB 7016),>90% approval in 2025,Florida Blue Medical Benefit,Florida_2026_PA_Audit,FL-COM-FLBLUECOM,47177,DENY-GOLD-001,True,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptan failures - strict enforcement,≥4 weeks each,,,Nurtec 16 tabs/30d (even for acute); Ubrelvy 10-16 tabs/30d; strict QL; to exceed QL cite 'Minimal rebound headache risk with gepants compared to triptans/opioids',Yes - CV contraindication,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Acute Gepant Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-001,True,,
FL,UnitedHealthcare of Florida,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Botox PREFERRED for migraine; must verify frequency via headache diary/log; HIT-6 scores required for functional impairment; Daxxify EXCLUDED (requires failure of all other toxins first),Yes - documented failures with HIT-6 documentation,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Botulinum Toxins A and B,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,UnitedHealthcare of Florida,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Part B Step Therapy: Fail Aimovig OR Ajovy OR Emgality first (for MA patients),Documented failure/intolerance,J3032; Part B Step Therapy REQUIRED for MA; LMN must state: 'Patient has failed SC CGRP therapy due to [specific reason]',Yes - injection site reaction; lack of SC efficacy; inability to self-inject,Yes (SB 7016),Internal Gold Card + FL state mandate,UHC Part B Step Therapy Policy,Florida_2026_PA_Audit,FL-COM-UHC,87726,DENY-GOLD-001,True,,
FL,Sunshine Health,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,"≥2 triptans (Generic: Rizatriptan, Sumatriptan) - brand triptans (Imitrex) EXCLUDED",≥4 weeks each; adherence verified via claims history,,,Nurtec ODT generally preferred over Ubrelvy/Qulipta (rebate status fluctuates); Zavzpret/Trudhesa/Tosymra NON-PREFERRED,Yes - CV contraindication; prescribing brand without documented generic trial = automatic POS rejection,Yes (SB 7016),Statutorily required for Medicaid,AHCA PDL 2026,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-001,True,,
FL,Sunshine Health,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine diagnosis; specific 'Botulinum Criteria' form required - must list specific muscles to inject + total dosage,Yes - oral preventive contraindications/intolerances,Yes (SB 7016),Statutorily required for Medicaid,Sunshine Botulinum Criteria Form,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,Sunshine Health,Medicaid MCO,Medicaid,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,Medical PA Required; J3032,Yes - inability to self-inject; documented SC failures,Yes (SB 7016),Statutorily required for Medicaid,Sunshine Medical PA,Florida_2026_PA_Audit,FL-MCD-SUNSHINE,68069,DENY-GOLD-001,True,,
FL,Aetna Florida,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,Standard QL; Policy 3481-E,Yes - CV contraindication,Yes (SB 7016),Active,Aetna Policy 3481-E,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-001,True,,
FL,Aetna Florida,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 standard oral preventive classes (Beta-blocker AND Topiramate),≥8 weeks each,,,Aimovig/Ajovy typically PREFERRED; Emgality may be EXCLUDED on some plans (requires Medical Necessity appeal); Qulipta requires step through injectable CGRP first,Yes - intolerance; contraindication; teratogenic bypass,Yes (SB 7016),Active,Aetna CGRP Policy,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-STEP-002,True,,
FL,Aetna Florida,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,Medical PA Required; J3032,Yes - inability to self-inject; SC failures,Yes (SB 7016),Active,Aetna Medical Benefit,Florida_2026_PA_Audit,FL-COM-AETNA,60054,DENY-GOLD-001,True,,
FL,First Coast Service Options (FCSO),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Medical Necessity documentation (implies ≥2 oral classes per SOC),Documented in chart,,,LCD L33274; Chronic Migraine (G43.7x) ONLY - Episodic explicitly NOT covered; 12-week interval STRICT (10-11 weeks = denial); max 200 units; JW modifier wastage monitored; 2026: CPT 64615 requires PRE-SERVICE PA in HOPD/ASC settings (Prior Authorization Demonstration expansion); injection site map required; % reduction in HA days for continuation,Yes - documented in medical record,No - Federal Medicare (preempts SB 7016),,LCD L33274,Florida_2026_PA_Audit,FL-PARTB-FCSO,FCSO,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
FL,First Coast Service Options (FCSO),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Medical Necessity (Migraine diagnosis),Documented,,,J3032; Original Medicare does NOT force Part D step therapy (no SC CGRP failure required unlike MA plans); can administer as first-line biologic if Migraine dx documented,Yes - no SC step required for Original Medicare (FFS) unlike MA plans,No - Federal Medicare,,LCD L33274 / Medical Necessity,Florida_2026_PA_Audit,FL-PARTB-FCSO,FCSO,DENY-QL-001,True,,
FL,Ambetter from Sunshine Health,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,Exchange plan - follows Centene commercial guidelines (more restrictive than AHCA PDL),Yes - CV contraindication,Yes (SB 7016),Active,Ambetter Formulary,Florida_2026_PA_Audit,FL-COM-AMBET,68069,DENY-STEP-001,True,,
FL,Ambetter from Sunshine Health,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Separate from Medicaid - follows Centene commercial formulary,Yes - teratogenic; CV contraindication,Yes (SB 7016),Active,Ambetter CGRP Policy,Florida_2026_PA_Audit,FL-COM-AMBET,68069,DENY-STEP-002,True,,
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject; oral preventive contraindications,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Policy I-11-042,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS,54154,DENY-GOLD-001,True,,
PA,Independence Blue Cross,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventives,≥6 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,IBX Medical Policy,Pennsylvania_2026_PA_Audit,PA-COM-IBX,23223,DENY-GOLD-001,True,,
PA,UPMC Health Plan,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,UPMC Medical Policy,Pennsylvania_2026_PA_Audit,PA-COM-UPMC,93692,DENY-GOLD-001,True,,
PA,UPMC For You,Medicaid MCO,Medical Benefit,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventives per UPMC For You policy,≥8 weeks each,Medical PA Required,Documented,J3032; Medical Benefit under MCO,Yes - inability to self-inject,Act 146 (Medicaid),,UPMC For You Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-UPMCHEALTH,93692,DENY-GOLD-001,True,,
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,≥2 triptans per PA DHS PDL (pharmacy carved out),≥4-6 weeks each,,,PA DHS PDL governs,Yes - CV contraindication,Act 146 (Medicaid),,PA DHS PDL,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-001,True,,
PA,AmeriHealth Caritas Pennsylvania,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives,≥8 weeks each,,,Chronic Migraine per ICHD-3,Yes - oral preventive contraindications,Act 146 (Medicaid),,AmeriHealth Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-AMERIHEALTH,AMH,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"""≥2 triptans from different chemical classes (e.g., sumatriptan + rizatriptan or naratriptan)"",≥4-6 weeks each at FDA-approved dosing (ADEQUATE trial required); failure = <50% reduction in HA intensity within 2 hours OR intolerable side effects OR contraindication,N/A,N/A,Most stringent step therapy in PA; quarterly PDL updates at papdl.com",Yes - contraindication to vasoconstrictive agents (uncontrolled HTN, ischemic heart disease, PVD, CVD, hemiplegic/basilar migraine),N/A - Medicaid FFS,,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-001,True,,
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥2 distinct classes of conventional oral preventives (beta-blockers: propranolol/metoprolol, anticonvulsants: topiramate/valproic acid, TCAs: amitriptyline/nortriptyline) at therapeutic doses",≥8 weeks each unless discontinued early for documented adverse effects; failure = <50% reduction in monthly migraine days OR intolerable adverse effects,,,Most stringent in PA; PA DHS PDL governs,Yes - documented contraindications to conventional preventives,N/A - Medicaid FFS,,PA DHS Statewide PDL,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-002,True,,
PA,Pennsylvania Medicaid FFS,Medicaid FFS,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventives (falls under medical benefit not PDL),≥8 weeks each",,,Chronic Migraine per ICHD-3 (≥15 HA days/mo for ≥3 consecutive months, ≥8 days with migraine features); headache diary or clinical note required,Yes - oral preventive contraindications,N/A - Medicaid FFS,,PA DHS Medical Policy,Pennsylvania_2026_PA_Audit,PA-MCD-FFS,PADHS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
PA,Novitas Solutions,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Per LCD requirements,Documented,,,J3032; Chronic Migraine; Medical Benefit; Jurisdiction L,Yes - inability to self-inject,No - Federal Medicare,,LCD L38809/DL39909,Pennsylvania_2026_PA_Audit,PA-MAC-NOVITAS,NOVITAS,DENY-QL-001,True,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans (Sumatriptan, Rizatriptan, Eletriptan) - payer checks claims history",Specific dates of trial required for each triptan,,,Ubrelvy 16 doses/month; override requires documentation of 'Risk of Medication Overuse Headache (MOH)',Yes - CV risk factors = 'Contraindication to vasoconstrictive agents' bypasses triptan step entirely,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs in preceding 12 months,BCBSIL Prime Performance Drug List,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-001,True,,
IL,Blue Cross Blue Shield of Illinois,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject; GI intolerance/gastroparesis,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,BCBSIL Medical Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-BCBSIL,621,DENY-STEP-005,True,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans with documented 'therapeutic failure' defined as lack of clinical response after treating ≥3 separate migraine episodes with each triptan,≥3 migraine episodes treated per triptan (nuance: single dose discontinuation may result in denial),,,Standard QL,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC Gepant Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-001,True,,
IL,UnitedHealthcare Illinois,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Intra-class step: requires Aimovig OR Emgality before Ajovy or Vyepti,Documented failure,Aimovig/Emgality preferred; Ajovy/Vyepti require step through preferred,Yes - teratogenic; CV contraindication; cognitive impairment from oral preventives,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,UHC CGRP Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-UHC,87726,DENY-STEP-002,True,,
IL,Aetna Illinois,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,≥4 weeks each,,,Standard QL; CPB criteria,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-001,True,,
IL,Aetna Illinois,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,⚠️ ≥2 distinct oral preventive classes for ≥3 MONTHS each - LONGEST trial duration (vs 8 weeks for competitors),≥3 months each (STRICTEST - common cause of 'insufficient duration of trial' denial),,,CPB 0970 - strictest standard; Site of Care restrictions for Vyepti,Yes - documented intolerances; teratogenic bypass; CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-002,True,,
IL,Aetna Illinois,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each (consistent with CPB 0970),,,Chronic Migraine; CPB criteria,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna Botox Policy,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Aetna Illinois,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,Site of Care restriction - HOPD non-preferred,Documented,"J3032; Site of Care: Home Infusion/freestanding preferred; HOPD exception requires medical necessity (difficult venous access, anaphylaxis history)",Yes - inability to self-inject; GI intolerance,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,Aetna CPB 0970,Illinois_2026_PA_Audit_Strategy,IL-COM-AETNA,60054,DENY-STEP-005,True,,
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; ⚠️ One CGRP rule applies - cannot add CGRP mAb to Botox without high-level medical necessity appeal,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,Meridian Health Plan of Illinois,Medicaid MCO,Medicaid,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical PA Required,Documented,J3032; Medical Benefit,Yes - inability to self-inject,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / Meridian Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-MERIDIAN,68069,DENY-QL-001,True,,
IL,National Government Services (NGS),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,"⚠️ ≥3 DISTINCT oral preventive classes (Beta-blockers, TCAs, Anticonvulsants) - STRICTER than commercial 2-class; chart must list specific drug/dosage/duration (2-3 months)/reason for discontinuation for EACH class",≥2-3 months each class,,,"LCD DL39909 (eff 1/1/2026); Chronic Migraine ONLY (≥15 HA days/mo for >3 mo with ≥8 migraine days) - Episodic NOT covered; must document 'migraine days' vs 'headache days' explicitly; ICD-10: G43.709/G43.719 (avoid R51.9); frequency STRICT 12 weeks (84 days) - claims <84 days = automated denial; STOPPING RULE after 2 cycles (6 months) - must show 'significant decrease' with quantified improvement (e.g., '20 days/mo → 9 days/mo')",Yes - documented 3-class failures with specific adverse events,No - Federal Medicare,,LCD DL39909,Illinois_2026_PA_Audit_Strategy,IL-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IL,National Government Services (NGS),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Usually requires failure of ≥1 self-injected CGRP unless needle phobia/cognitive impairment documented,Documented,J3032; LCD DL39909 covers BOTH Episodic and Chronic Migraine (unlike Botox); bypass SC step with 'needle phobia' or 'inability to self-administer',Yes - needle phobia; cognitive impairment; inability to self-administer,No - Federal Medicare,,LCD DL39909,Illinois_2026_PA_Audit_Strategy,IL-PARTB-NGS,NGS,DENY-QL-001,True,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per HFS PDL,≥4 weeks each,,,Specific quantity limits on triptans (differs from commercial); follows HFS PDL,Yes - CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-001,True,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per HFS PDL,≥8 weeks each,,,Follows HFS PDL; different from commercial BCBSIL,Yes - teratogenic; CV contraindication,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-002,True,,
IL,Blue Cross Community Health Plan (BCCHP),Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; follows HFS PDL for Medicaid,Yes - oral preventive contraindications,Public Act 103-0593 (July 1 2026),≥90% on ≥50 PAs,HFS PDL / BCCHP Medical,Illinois_2026_PA_Audit_Strategy,IL-MCD-ILBCBS,621,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Sumatriptan tab/nasal/inj, Rizatriptan tab/ODT, Naratriptan, Zolmitriptan tab)",Adequate trial,,,Nurtec ODT: 18 tabs/30d preventive; 8 tabs/30d acute; Ubrelvy: 10 tabs/30d (up to 16 with med necessity); UPDL applies to ALL MCOs (CareSource/Buckeye/Molina/UHC),Yes - CV disease (code I10 on PA request) waives triptan trial; 'Contraindication to vasoconstrictive agents',HB 130 (Pending),,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-STEP-001,True,,
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"⚠️ ≥3 classes of oral preventives (STRICTEST): (1) Beta-blockers: Propranolol/Metoprolol/Timolol, (2) Anticonvulsants: Topiramate/Valproic Acid, (3) TCAs/SNRIs: Amitriptyline/Venlafaxine",≥30 days each class,,,Emgality 120mg PREFERRED; Aimovig 70/140mg PREFERRED; Ajovy NON-PREFERRED (requires Emgality/Aimovig failure); Qulipta requires oral failures + preferred injectable CGRP failure,Yes - document intolerance/contraindication: Topiramate (cognitive/nephrolithiasis/glaucoma); Beta-blockers (asthma/bradycardia/depression); TCAs (weight gain/sedation/serotonin risk),HB 130 (Pending),,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-STEP-002,True,,
OH,Ohio Medicaid (ODM/Gainwell),Medicaid SPBM,Medicaid Pharmacy,Gepants (Preventive),Preventive,Yes,≥3 oral preventive classes per UPDL,≥30 days each,Must fail preferred injectable CGRP (Emgality or Aimovig),Documented failure,Qulipta requires both oral AND injectable CGRP failure unless needle phobia documented,Yes - needle phobia; inability to self-inject,HB 130 (Pending),,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-GAINWELL,ODM,DENY-QL-001,True,,
OH,CareSource Ohio,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (NOTE: Medical benefit = 2 classes vs pharmacy UPDL = 3 classes),≥2 months each,,,"J0585; Chronic Migraine (≥15 HA days/mo, ≥8 migraine days) for >3 months; managed by CareSource Medical Mgmt NOT Gainwell; headache diary/summary required",Yes - oral preventive contraindications,HB 130 (Pending),,CareSource Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,CareSource Ohio,Medicaid MCO,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,≥2 preferred triptans per UPDL (pharmacy carved to Gainwell),Per UPDL,,,UPDL quantity limits apply; pharmacy managed by Gainwell NOT CareSource,Yes - CV contraindication per UPDL,HB 130 (Pending),,Ohio UPDL (via Gainwell),Ohio_2026_PA_Audit_Strategy,OH-MCD-CARESOURCE,CSS,DENY-STEP-001,True,,
OH,CGS Administrators,Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes (Beta-blockers, Anticonvulsants, TCAs)",≥2 months each,,,"LCD L33949/DL39909 (eff Feb 15 2026); Chronic Migraine ICHD-3 strict (≥15 HA days/mo, ≥8 migraine days, ≥3 months); ⚠️ STOPPED THERAPY RULE: reauth requires documented 'significant clinical response' after 2 cycles - quantified HA day reduction (e.g., 20→12) OR HIT-6 ≥5pt reduction OR MIDAS ≥30% reduction; 'Frequent migraines' = automatic denial",Yes - documented oral preventive failures with specific adverse events,No - Federal Medicare,,LCD L33949/DL39909,Ohio_2026_PA_Audit_Strategy,OH-PARTB-CGS,CGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,CGS Administrators,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,LCD does not mandate Botox/SC CGRP failure for Original Medicare (but MA plans may overlay),Documented,J3032; 100mg IV q3mo standard; ⚠️ 300mg ONLY if documented partial/inadequate response to 100mg (starting at 300mg = denial); Site of Care review - HOPD requires 'difficult IV access' or 'hypersensitivity requiring physician oversight',Yes - needle phobia; inability to self-administer; difficult IV access,No - Federal Medicare,,LCD DL39909,Ohio_2026_PA_Audit_Strategy,OH-PARTB-CGS,CGS,DENY-QL-001,True,,
OH,Medical Mutual of Ohio,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans (Sumatriptan, Rizatriptan, Eletriptan)",Documented failure,,,Tier 2 (Preferred Brand) on most plans; Tier 3 on 'Basic' plans; Ubrelvy 10 tabs/30d; Nurtec 8 tabs/30d acute,Yes - 'Vasoconstrictor Contraindication' highly effective with MMO/ESI,Investigating,,MMO/ESI Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-001,True,,
OH,Medical Mutual of Ohio,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1-2 oral preventive classes (slightly more lenient than Medicaid),≥2 months each; strictly enforced electronically",,,Emgality/Aimovig PREFERRED; Ajovy NON-PREFERRED (requires step through BOTH Emgality AND Aimovig unless latex allergy with Aimovig autoinjector),Yes - teratogenic; CV contraindication; documented intolerance (bradycardia, cognitive dysfunction),Investigating,,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-002,True,,
OH,Medical Mutual of Ohio,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,eviCore/Cohere for PA (digital portal REQUIRED - fax rejected/delayed); Chronic Migraine (≥15 days/mo),Yes - oral preventive contraindications,Investigating,,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Medical Mutual of Ohio,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Site of Care review,Documented,J3032; Site of Care review applies,Yes - inability to self-inject; difficult IV access,Investigating,,MMO Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-MEDMUTUAL,MMO,DENY-QL-001,True,,
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Eletriptan, Naratriptan, Zolmitriptan); ⚠️ CarelonRx AUTO-DENIES if no triptan claims in 180 days",Electronic step therapy checks claims history,,,Nurtec/Ubrelvy Tier 2/3 depending on plan (Essential vs National); Zavzpret NON-PREFERRED requires triptan + oral gepant failure,Yes - CV contraindication,,,Anthem/CarelonRx Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-001,True,,
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥1 oral preventive class,≥2 months,Requires step through preferred injectable CGRP (Emgality/Aimovig) first,Documented failure,To get Qulipta as first-line CGRP must document 'Needle Phobia' (F40.231) or 'Inability to Self-Inject',Yes - needle phobia F40.231; physical inability to self-administer,,,Anthem Qulipta Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-QL-001,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,Chronic Migraine (≥15 HA days/mo),Yes - oral preventive contraindications,,,Anthem Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,Anthem Blue Cross Blue Shield Ohio,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,Must fail oral prophylaxis AND self-injected CGRP mAbs (Aimovig/Emgality/Ajovy) OR valid contraindication to self-injection,Documented,J3032; must document: 'Patient has failed Emgality due to lack of efficacy (MHD unchanged after 3 months) and is unable to self-administer due to [arthritis/tremor/anxiety]',Yes - needle phobia; arthritis; tremor; anxiety,,,Anthem Vyepti Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-ELEV,36096,DENY-QL-001,True,,
OH,UnitedHealthcare Ohio,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Ubrelvy often preferred over Nurtec for ACUTE; Nurtec preferred for preventive use (episodic); Zavzpret requires triptan + Ubrelvy/Nurtec failure,Yes - CV contraindication,Yes - ACTIVE (Oct 2024),92% approval rate,UHC/OptumRx Formulary,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-001,True,,
OH,UnitedHealthcare Ohio,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ STRICT enforcement of '15 headache days' rule - documentation must be explicit; standard Chronic Migraine criteria,Yes - oral preventive contraindications,Yes - ACTIVE (Oct 2024),92% approval rate on CPT 64615,UHC Botox Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OH,UnitedHealthcare Ohio,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Must fail SC CGRP OR document inability to self-inject,Documented,J3032; ⚠️ Site of Care review - HOPD DENIED unless medical necessity: 'difficult venous access requiring ultrasound guidance' OR 'history of anaphylaxis requiring hospital-grade resuscitation'; redirect to home infusion/office,Yes - needle phobia; difficult venous access; anaphylaxis history,Yes - ACTIVE (Oct 2024),92% approval rate on J3032,UHC Vyepti Policy,Ohio_2026_PA_Audit_Strategy,OH-COM-UHC,87726,DENY-GOLD-001,True,,
OH,Buckeye Health Plan,Medicaid MCO,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,≥2 preferred triptans per UPDL,Per UPDL,,,UPDL criteria via Gainwell,Yes - CV contraindication per UPDL,HB 130 (Pending),,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-001,True,,
OH,Buckeye Health Plan,Medicaid MCO,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,≥3 oral preventive classes per UPDL,≥30 days each per UPDL,,,UPDL criteria via Gainwell,Yes - per UPDL criteria,HB 130 (Pending),,Ohio UPDL,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-002,True,,
OH,Buckeye Health Plan,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,Medical benefit managed by MCO - 2 class standard,Yes - oral preventive contraindications,HB 130 (Pending),,Buckeye Medical Policy,Ohio_2026_PA_Audit_Strategy,OH-MCD-BUCKEYE,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan)",Documented failure = 'inadequate response' or 'intolerance/contraindication' - NOT 'patient preference',,,Ubrelvy/Nurtec NON-PREFERRED; QL typically 8-16 doses/30 days; applies to ALL CMOs via Unified PDL,Yes - CV contraindication = 'Contraindication to vasoconstrictive agents',SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-001,True,,
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (Beta-blockers: Propranolol/Metoprolol/Timolol, Anticonvulsants: Topiramate/Divalproex, Antidepressants: Amitriptyline/Venlafaxine),≥8-12 weeks each,N/A",,Aimovig/Emgality PREFERRED (Step 2 agents); Ajovy/Vyepti NON-PREFERRED,Yes - document specific intolerance (cognitive slowing, sedation, weight gain) OR contraindication (asthma precludes beta-blockers),SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-002,True,,
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine (≥15 HA days/mo); headache logs required; medical benefit may vary slightly between CMOs and FFS,Yes - oral preventive contraindications,SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Medicaid Medical,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,Georgia Medicaid (DCH),Medicaid Unified PDL,Medical Benefit,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Fail preferred CGRP mAbs (Aimovig/Emgality),Documented failure,J3032; Medical Benefit; requires step through preferred SC CGRPs,Yes - needle phobia; physical disability preventing self-injection,SB 5 (CMOs) - July 1 2026,90% threshold,Georgia Medicaid Medical,Georgia_2026_PA_Audit_Strategy,GA-MCD-DCH,DCH,DENY-QL-001,True,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 triptans; failure defined as 'no significant reduction in headache pain/intensity within 2 hours of dosing',Documented per Anthem definition,N/A",,Gepants Tier 3; CV Exception = primary bypass,Yes - CV risk factors (CAD, stroke history, uncontrolled HTN) = 'Contraindication to vasoconstrictive agents',SB 5 - Jan 1 2026 implementation,90% threshold,Anthem Commercial Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-STEP-001,True,,
GA,Anthem Blue Cross Blue Shield of Georgia,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Fail self-administered CGRP OR document inability to self-inject,Documented,J3032; Vyepti strictly reserved for patients who CANNOT self-inject; document needle phobia; arthritis; tremor; poor adherence history,Yes - needle phobia; physical disability; poor adherence to self-administered meds,SB 5 - Jan 1 2026 implementation,90% threshold,Anthem Vyepti Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-ELEV,36096,DENY-QL-001,True,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Standard criteria; Zavzpret requires triptan + oral gepant (Ubrelvy/Nurtec) failure,Yes - CV contraindication,UHC National Gold Card ACTIVE,92% on ≥10 PAs for 2 consecutive years,UHC Gepant Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-001,True,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,Must fail oral gepants (Ubrelvy OR Nurtec),Documented failure,⚠️ Highest scrutiny; bypass ONLY with documented 'Severe GI intolerance/Gastroparesis' rendering oral meds ineffective,Yes - 'Severe gastrointestinal intolerance/Gastroparesis' = only successful bypass,UHC National Gold Card,92% threshold,UHC Zavzpret Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-005,True,,
GA,UnitedHealthcare Georgia,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; 12-week rule strongly enforced; ⚠️ STRICT 'no overlap' policy with CGRPs - appeal required for dual therapy,Yes - oral preventive contraindications,UHC National Gold Card ACTIVE,92% threshold for CPT 64615,UHC Botox Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
GA,UnitedHealthcare Georgia,Medicare Advantage,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,⚠️ Part B Step Therapy (MA Plans): Must fail self-administered CGRP (Aimovig/Emgality) before Vyepti authorized,Documented SC CGRP failure,J3032; Part B Step Therapy program explicitly lists Vyepti; bypass requires documented 'Physical inability to self-administer subcutaneous injections due to [needle phobia/arthritis/tremor]',Yes - needle phobia; physical disability; arthritis; tremor; cognitive impairment,UHC National Gold Card,92% threshold on J3032,UHC Part B Step Therapy,Georgia_2026_PA_Audit_Strategy,GA-MA-UHC,87726,DENY-QL-001,True,,
GA,Palmetto GBA,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Fail standard care,Documented,LCD does not mandate SC CGRP failure for Original Medicare but MA plans overlay steps,Documented,J3032; Buy-and-bill ASP+6% (2% sequestration applies); no mandated step for Original Medicare but MA plans (UHC/Anthem) add SC CGRP requirement,Yes - needle phobia; inability to self-inject,No - Federal Medicare,,LCD L33458,Georgia_2026_PA_Audit_Strategy,GA-PARTB-PALMETTO,PGBA,DENY-QL-001,True,,
GA,Ambetter of Georgia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Narrow network + highly restrictive formulary (low premium strategy); CGRP access heavily gated,Yes - CV contraindication,SB 5 - July 1 2026,90% threshold,Ambetter Formulary,Georgia_2026_PA_Audit_Strategy,GA-COM-AMBET,68069,DENY-STEP-001,True,,
GA,Ambetter of Georgia,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8-12 weeks each,,,Restrictive formulary; branded CGRPs gated behind multiple generic failures,Yes - teratogenic; CV contraindication; documented intolerance,SB 5 - July 1 2026,90% threshold,Ambetter CGRP Policy,Georgia_2026_PA_Audit_Strategy,GA-COM-AMBET,68069,DENY-STEP-002,True,,
GA,Peach State Health Plan,Medicaid CMO,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,≥2 preferred triptans per Unified PDL,Per PDL,,,Unified PDL criteria via DCH,Yes - CV contraindication per PDL,SB 5 - July 1 2026,90% threshold,Georgia Unified PDL,Georgia_2026_PA_Audit_Strategy,GA-MCD-PEACHSTATE,68069,DENY-STEP-001,True,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medicaid Pharmacy,Gepants (Acute),Acute,Yes,"""≥2 preferred triptans (sumatriptan, rizatriptan, naratriptan); failure = lack of efficacy after treating ≥3 attacks OR intolerance/side effects"",Documented per definition,N/A",,Nurtec ODT 16 tabs/30d; Ubrelvy 16 tabs/30d; Zavzpret NON-PREFERRED requires triptan + oral gepant failure unless severe nausea/vomiting documented,Yes - CV contraindication (ischemic heart disease, uncontrolled HTN, cerebrovascular disease) = 'Contraindication to vasoconstrictive 5-HT1B/1D agonists',HB 434 CARE FIRST Act - pending,80% threshold,NC Clinical Coverage Policy,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-001,True,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medicaid Pharmacy,CGRP mAbs (SC),Preventive,Yes,"≥2 different oral prophylactic classes (Beta-blockers: propranolol/metoprolol, Antidepressants: amitriptyline/venlafaxine, Antiepileptics: topiramate/valproate, ACE/ARBs, CCBs)",≥2 months EACH (total 4+ months of failure),,,"PREFERRED: Aimovig, Ajovy, Emgality, Nurtec ODT (preventive), Qulipta; NON-PREFERRED: Vyepti (requires fail preferred mAbs + 'Medical Necessity' for infusion); MOH exclusion documentation REQUIRED - failing to document MOH ruled out = denial; pregnancy test at baseline for mAbs",Yes - teratogenic bypass for women of childbearing potential (avoid valproate/topiramate); intolerance documentation,HB 434 CARE FIRST Act - pending,80% threshold,NC Clinical Coverage Policy,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-002,True,,
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,"""⚠️ ≥3 different drug classes (Beta-blockers, CCBs, TCAs, Anticonvulsants) - STRICTER than commercial 2-class requirement"",≥3 MONTHS each class (vs 2 months for CGRPs)",,,Clinical Coverage Policy 1B; Chronic Migraine ONLY (≥15 HA days/mo, ≥8 migrainous days) for ≥3 months; Age ≥18; ⚠️ REAUTH requires reduction of ≥6 headache days/month from baseline - quantitative metric absolute (subjective 'improvement' insufficient),Yes - oral preventive contraindications documented,HB 434 CARE FIRST Act - pending,80% threshold,NC Medicaid CCP 1B,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,NC Medicaid (DHB),Medicaid Unified PDL,Medical Benefit,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral prophylactic classes,≥2 months each,Must fail ≥1 preferred self-injectable CGRP mAb,Documented failure,NON-PREFERRED; requires 'Medical Necessity' for infusion setting: needle phobia; physical inability to self-inject; failure of subcutaneous absorption,Yes - needle phobia; physical inability; absorption failure,HB 434 CARE FIRST Act - pending,80% threshold,NC Medicaid Medical,North_Carolina_2026_PA_Audit,NC-MCD-DHB,NCDHHS,DENY-QL-001,True,,
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Ubrelvy Tier 3; Nurtec ODT Tier 3; QL strictly enforced 16 tabs/30d - exceptions difficult without proving not a candidate for preventive therapy,Yes - CV contraindication (CAD/HTN),HB 434 - pending; submit data Q1 2026,80% threshold,BCBS NC Formulary,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-001,True,,
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (less restrictive than Medicaid 3-class),≥8 weeks each,,,Chronic Migraine (≥15 days/mo); Carelon may manage; dual therapy (Botox+CGRP) RESTRICTED but allows 'Medical Necessity' exception for refractory chronic migraine eff Jan 1 2026 - must submit headache logs showing partial response to monotherapy + synergistic mechanism rationale,Yes - oral preventive contraindications; dual therapy requires refractory documentation,HB 434 - pending,80% threshold for CPT 64615,BCBS NC Medical Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Blue Cross Blue Shield of North Carolina,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical Necessity documentation,Documented,NON-PREFERRED; requires medical necessity for infusion setting,Yes - needle phobia; inability to self-inject,HB 434 - pending,80% threshold,BCBS NC Medical Policy,North_Carolina_2026_PA_Audit,NC-COM-NCARBCBS,90224,DENY-QL-001,True,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure/intolerance,,,Nurtec/Ubrelvy standard criteria; Zavzpret highly restricted,Yes - CV contraindication,ACTIVE Gold Card,92% on ≥10 PAs for 2 years,UHC PA-Notification Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-001,True,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral prophylactic classes,≥8 weeks each,,,⚠️ EXCLUSION: Concurrent use of Qulipta with Aimovig/Emgality BLOCKED by edit logic - appeals for dual therapy must cite 'refractory' status + distinct mechanisms,Yes - documented intolerance; contraindication,ACTIVE Gold Card,92% threshold,UHC Qulipta Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-STEP-005,True,,
NC,UnitedHealthcare North Carolina,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Must fail 2 other CGRP mAbs (Step 3),Documented failure of Aimovig AND Emgality (or similar),J3032; Step 3 agent - highest hurdle for Vyepti among commercial payers,Yes - needle phobia; inability to self-inject; documented absorption failure,ACTIVE Gold Card,92% threshold on J3032,UHC Vyepti Policy,North_Carolina_2026_PA_Audit,NC-COM-UHC,87726,DENY-QL-001,True,,
NC,Cigna Healthcare NC,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Standard criteria; Zavzpret requires triptan + oral gepant (Ubrelvy/Nurtec) failure due to cost differentials,Yes - CV contraindication,HB 434 - pending,80% threshold,Cigna/ESI Formulary,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-001,True,,
NC,Cigna Healthcare NC,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ EMGALITY = primary preferred agent; Cigna frequently mandates Emgality trial BEFORE authorizing Aimovig or Ajovy (viewed as non-preferred within class),Yes - teratogenic; CV contraindication; documented intolerance,HB 434 - pending,80% threshold,Cigna CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-002,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
NC,Cigna Healthcare NC,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine; standard criteria,Yes - oral preventive contraindications,HB 434 - pending,80% threshold,Cigna Botox Policy,North_Carolina_2026_PA_Audit,NC-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Ambetter of North Carolina,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Standard criteria; narrow network - OON PA requests summarily denied in HMO structures,Yes - CV contraindication,HB 434 - pending,80% threshold,Ambetter Formulary,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-001,True,,
NC,Ambetter of North Carolina,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Formulary shifts frequently (rebate-driven); Ajovy/Emgality rotate as preferred; check current formulary,Yes - teratogenic; CV contraindication,HB 434 - pending,80% threshold,Ambetter CGRP Policy,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-002,True,,
NC,Ambetter of North Carolina,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ Requires specific documentation regarding MOH (medication overuse headache) evaluation prior to approval,Yes - oral preventive contraindications,HB 434 - pending,80% threshold,Ambetter Botox Policy,North_Carolina_2026_PA_Audit,NC-COM-AMBET,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Palmetto GBA (NC),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Fail 2-3 standard therapies,Documented in medical record,,,LCD L33458 (outgoing) → DL39909 (eff Feb 15 2026) = CRITICAL TRANSITION; ⚠️ DL39909 MANDATES PREEMPT PROTOCOL: 155 units across 31 FIXED sites; anatomical restrictions (frontalis/corrugator/procerus/occipitalis/temporalis/trapezius/cervical paraspinal ONLY - masseter denied); ICD-10: G43.709/G43.719 required; notes must document specific muscles + dosage per site; JW modifier for waste mandatory (200u vial - 155u used = 45u waste); JZ if zero waste,Yes - documented standard therapy failures with adverse events,No - Federal Medicare,,LCD L33458 → DL39909,North_Carolina_2026_PA_Audit,NC-PARTB-PALMETTO,PGBA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NC,Palmetto GBA (NC),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Fail standard care,Documented,LCD does not mandate SC CGRP failure for Original Medicare,Documented,J3032; Part B buy-and-bill; covered for chronic migraine,Yes - needle phobia; inability to self-inject,No - Federal Medicare,,LCD L33458,North_Carolina_2026_PA_Audit,NC-PARTB-PALMETTO,PGBA,DENY-QL-001,True,,
NC,Healthy Blue NC,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans per NC Medicaid PDL,Per state policy,,,Follows NC Medicaid Clinical Coverage Policies - cannot be stricter,Yes - CV contraindication per state policy,HB 434 - pending,80% threshold,NC Medicaid PDL,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-001,True,,
NC,Healthy Blue NC,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral prophylactic classes per NC Medicaid policy,≥2 months each per state policy,,,Follows NC Medicaid Clinical Coverage Policies - cannot be stricter,Yes - per state policy criteria,HB 434 - pending,80% threshold,NC Medicaid PDL,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-002,True,,
NC,Healthy Blue NC,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥3 drug classes per NC Medicaid policy,≥3 months each per state policy,,,Follows NC Medicaid Clinical Coverage Policy 1B - cannot be stricter,Yes - per state policy criteria,HB 434 - pending,80% threshold,NC Medicaid CCP 1B,North_Carolina_2026_PA_Audit,NC-MCD-HEALTHYBLUE,90224,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon Blue Cross Blue Shield NJ,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Medical Necessity for infusion,Documented,J3032; requires medical necessity for IV setting,Yes - needle phobia; inability to self-inject; SC CGRP failure,A1825 applies,72h response,Horizon Vyepti Policy,New_Jersey_2026_PA_Audit,NJ-COM-HORBCBS,22099,DENY-QL-001,True,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans; documentation of dates of service required; AI review checks for gaps in therapy,Documented with dates,,,Zavzpret requires DOUBLE STEP: fail triptans + oral gepants (Ubrelvy/Nurtec) unless GI contraindication documented,Yes - CV contraindication; GI bypass for Zavzpret ('Gastric Stasis' = severe nausea/vomiting),UHC Gold Card + A1825,92% threshold,UHC Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-001,True,,
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Gold Card program available; high-performing providers bypass PA; if not Gold Carded strict step therapy applies,Yes - oral preventive contraindications,UHC Gold Card ACTIVE,92% threshold for CPT 64615,UHC Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,UnitedHealthcare NJ (Oxford),Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,Justify IV infusion setting,Documented,J3032; UHC scrutinizes IV infusions; must document 'failure of self-injection' OR 'needle phobia' OR 'absorption issues',Yes - needle phobia; inability to self-inject; SC absorption failure,UHC Gold Card + A1825,92% threshold,UHC Vyepti Policy,New_Jersey_2026_PA_Audit,NJ-COM-UHC,87726,DENY-QL-001,True,,
NJ,Aetna NJ,Commercial,Commercial,Gepants (Acute),Acute,Yes (Auto-Bypass Available),"⚠️ 'Smart Edit' automation: if PBM detects 2 distinct triptan claims in patient history within 180 days, Gepant auto-pays at POS; if no claims visible, manual PA required with 'inadequate response or intolerance' attestation",Claims-based or manual attestation,,,"If patient tried samples/triptans under different insurance, system won't see it - MUST submit manual PA documenting those trials",Yes - CV contraindication; provide pharmacy fill records from previous insurers if needed,A1825 applies,72h response,Aetna Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-HEMI-001,True,,
NJ,Aetna NJ,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,CPB 0113; Chronic Migraine; coded data more important than medical necessity letter,Yes - oral preventive contraindications,A1825 applies,72h response,Aetna CPB 0113,New_Jersey_2026_PA_Audit,NJ-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,AmeriHealth NJ,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,'Select' formulary value-driven; aggressively steers to generics; often requires P2P for Tier 3 exceptions,Yes - CV contraindication,A1825 applies,72h response,AmeriHealth Gepant Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-001,True,,
NJ,AmeriHealth NJ,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Select formulary strictness),≥8 weeks each,,,High pressure to use generics; use A1825 to override,Yes - teratogenic; CV contraindication; documented intolerance,A1825 applies,72h response,AmeriHealth CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-002,True,,
NJ,AmeriHealth NJ,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Standard Chronic Migraine criteria,Yes - oral preventive contraindications,A1825 applies,72h response,AmeriHealth Botox Policy,New_Jersey_2026_PA_Audit,NJ-COM-AMERI,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Oscar Health NJ,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Digital/portal-based PA; favors clean data entry over narrative letters,Yes - CV contraindication,A1825 applies,72h response,Oscar Formulary,New_Jersey_2026_PA_Audit,NJ-COM-OSCAR,Oscar,DENY-STEP-001,True,,
NJ,Oscar Health NJ,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Digital submission preferred,Yes - teratogenic; CV contraindication,A1825 applies,72h response,Oscar CGRP Policy,New_Jersey_2026_PA_Audit,NJ-COM-OSCAR,Oscar,DENY-STEP-002,True,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per PDL,Documented failure,,,PDL adherence required; specific state fax forms,Yes - CV contraindication,A1825 applies to NJ FamilyCare,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-001,True,,
NJ,NJ FamilyCare (Medicaid),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ MOH assessment documentation REQUIRED; use specific state fax forms,Yes - oral preventive contraindications,A1825 applies,72h response,NJ FamilyCare Medical,New_Jersey_2026_PA_Audit,NJ-MCD-NJFC,NJDHS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Horizon NJ Health,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per NJ FamilyCare PDL,Per state policy,,,Uses specific state-mandated fax forms; follows NJ FamilyCare PDL,Yes - CV contraindication per PDL,A1825 applies,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-001,True,,
NJ,Horizon NJ Health,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per NJ FamilyCare,Per state policy,,,Strictly adheres to NJ FamilyCare PDL; requires MOH assessment,Yes - per state criteria,A1825 applies,72h response,NJ FamilyCare PDL,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-002,True,,
NJ,Horizon NJ Health,Medicaid MCO,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes per NJ FamilyCare,Per state policy,,,Follows NJ FamilyCare criteria; requires MOH assessment,Yes - per state criteria,A1825 applies,72h response,NJ FamilyCare Medical,New_Jersey_2026_PA_Audit,NJ-MCD-HORIZON,22099,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NJ,Novitas Solutions,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,WISeR PILOT: Pre-Service PA MANDATORY; fail ≥2 oral preventives,Documented with dates/reasons,,,LCD L39909; J3032; ⚠️ Pre-Service PA required - do NOT inject without Auth #; Chronic or Episodic Migraine; same HIT-6/MIDAS documentation requirements,Yes - documented oral failures; needle phobia; inability to self-inject,WISeR Gold Card,High approval rate,LCD L39909,New_Jersey_2026_PA_Audit,NJ-PARTB-NOVITAS,Novitas,DENY-QL-001,True,,
VA,Anthem HealthKeepers,Commercial,Commercial,Gepants (Acute),Acute,Yes,"""≥2 preferred generic triptans; hard edit at POS - if pharmacy system doesn't see 2 triptan claims, Nurtec/Ubrelvy rejects"",Claims history required,N/A",,"PREFERRED: Nurtec ODT, Ubrelvy; NON-PREFERRED: Reyvow, Zavzpret",Yes - CV bypass (HTN I10, IHD I25.9, arrhythmia I49.9) = 'Contraindication to vasoconstrictive agents'; Serotonin syndrome bypass if on SSRI/SNRI; Gastroparesis bypass for Zavzpret,HB 2099 - Data Collection 2026,90% threshold (exemptions Jan 2027),VABCBS-CD-096511-25,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-001,True,,
VA,Anthem HealthKeepers,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"≥2 oral preventive classes,≥1 month each",,,Chronic Migraine (≥15 HA days, ≥8 migrainous); ⚠️ HIT-6/MIDAS documentation for LCD compliance,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Anthem Botox Policy,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Anthem HealthKeepers,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥1 month each,Must fail 2 preferred SC CGRPs (Aimovig/Ajovy/Emgality),Documented failure,NON-PREFERRED; bypass via: 100% bioavailability argument (status migrainosus); Physical/cognitive limitation preventing self-injection (arthritis/tremor/cognitive impairment),Yes - inability to self-inject; bioavailability requirement,HB 2099 - Data Collection 2026,90% threshold,Anthem Vyepti Policy,Virginia_2026_PA_Audit,VA-COM-ELEV,36096,DENY-QL-001,True,,
VA,Sentara Health Plans,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans; failure defined as '≥2 attacks treated unsuccessfully',Documented per definition,,,Nurtec ODT 8 tabs/30d; Ubrelvy 10 tabs/30d; Zavzpret 6 sprays/30d; ⚠️ QLE for 16 tabs requires MOH risk documentation - 'Gepants do not carry same MOH risk as triptans/opioids (FDA approved for preventive EOD dosing)',Yes - CV contraindication; gastroparesis for Zavzpret,HB 2099 - Data Collection 2026,90% threshold,Sentara Drug Auth Forms,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-001,True,,
VA,Sentara Health Plans,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥1 medication from ≥2 different prophylactic classes (Anticonvulsants, Beta-blockers, Antidepressants)",⚠️ ≥2 MONTHS each (longer than Anthem 1 month),,,"PREFERRED: Aimovig, Ajovy, Emgality; NON-PREFERRED: Vyepti; ⚠️ 'Early Termination' Strategy: AE at Day 5 = trial failed (don't need full 60 days)",Yes - teratogenic; CV contraindication; documented intolerance (sedation/hypotension/paresthesia),HB 2099 - Data Collection 2026,90% threshold,Sentara CGRP Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-002,True,,
VA,Sentara Health Plans,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥2 months each,⚠️ Must fail injectable CGRP first (cannot go Topamax→Qulipta directly),Documented SC CGRP failure,PREFERRED but step edit through injectable CGRP; bypass via needle phobia (F40.231) or dexterity issues (RA/neuropathy),Yes - needle phobia F40.231; dexterity issues preventing self-injection,HB 2099 - Data Collection 2026,90% threshold,Sentara Qulipta Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-QL-001,True,,
VA,Sentara Health Plans,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,Chronic Migraine (≥15 days); standard criteria,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Sentara Botox Policy,Virginia_2026_PA_Audit,VA-COM-SENTARA,Sentara,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,UnitedHealthcare Virginia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,Standard criteria; ⚠️ Nurtec ODT denied if patient on CYP3A4 inhibitor (itraconazole/clarithromycin) - switch to Ubrelvy 50mg or justify interaction managed,Yes - CV contraindication; CYP3A4 interaction management,UHC National Gold Card ACTIVE,92% threshold,UHC Gepant Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-001,True,,
VA,UnitedHealthcare Virginia,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,⚠️ DOUBLE STEP: Must fail 2 self-injectable CGRPs (Aimovig/Ajovy/Emgality) for 3 months EACH = 6+ month delay minimum,≥3 months per SC CGRP,STRICT; bypass via: Absorption issues (bariatric surgery/malabsorption); Severe injection site reaction to SC CGRP (large induration >5cm persisting 7+ days) - re-challenging poses anaphylaxis risk,Yes - absorption issues; hypersensitivity reaction to SC CGRP,UHC National Gold Card,92% threshold,UHC Vyepti Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-QL-001,True,,
VA,UnitedHealthcare Virginia,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥2 months each,,,Chronic Migraine (≥15 days); strict criteria; quantitative response required for reauth,Yes - oral preventive contraindications,UHC National Gold Card,92% threshold for CPT 64615,UHC Botox Policy,Virginia_2026_PA_Audit,VA-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1-2 triptans,Documented failure,,,Standard criteria,Yes - CV contraindication,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0050,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-001,True,,
VA,Cigna Healthcare Virginia,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes; ⚠️ Every PA MUST include: 'Current Baseline: [X] Migraine Days Per Month' - vague 'frequent headaches' = auto-denial,⚠️ ≥3 MONTHS each (LONGEST),,,"PREFERRED: Aimovig, Ajovy; NON-PREFERRED: Emgality (requires step through Aimovig/Ajovy); ⚠️ 'Lack of Information' trap - document specific baseline headache days",Yes - teratogenic; CV contraindication; documented intolerance,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0050,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-002,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥4 migraine days/month; ≥2 oral classes,≥3 months each,No injectable CGRP step required (more accessible than Sentara),,"Renewal requires 'significant clinical benefit' - if days unchanged but severity improved, document: 'Patient reports reduction in severity and improved function (MIDAS score reduction)'",Yes - needle phobia; documented intolerance,HB 2099 - Data Collection 2026,90% threshold,Cigna IP0377,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-005,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
VA,Cigna Healthcare Virginia,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,,,Chronic Migraine (≥15 days); longest trial duration requirement,Yes - oral preventive contraindications,HB 2099 - Data Collection 2026,90% threshold,Cigna Botox Policy,Virginia_2026_PA_Audit,VA-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans per Common Core Formulary,Per CCF,,,"PREFERRED per CCF: Nurtec ODT, Ubrelvy; NON-PREFERRED: Reyvow, Zavzpret; MCO denials citing 'triptan failure required' when already failed = appeal via CCF contract compliance",Yes - CV contraindication per CCF,N/A - Medicaid,,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-001,True,,
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes per Common Core Formulary,Per CCF,,,"PREFERRED per CCF: Aimovig, Ajovy, Emgality; Qulipta 'Preferred (Step Edit Required)'; NON-PREFERRED: Vyepti; ⚠️ MCOs cannot restrict Preferred PDL drugs if DMAS criteria met - appeal: 'Denial of Preferred PDL agent when criteria met is violation of MCO contract with DMAS'",Yes - teratogenic; CV contraindication per CCF,N/A - Medicaid,,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-002,True,,
VA,Cardinal Care (VA Medicaid),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes per CCF,Per CCF,,,Chronic Migraine; follows CCF criteria,Yes - oral preventive contraindications per CCF,N/A - Medicaid,,Common Core Formulary 2026,Virginia_2026_PA_Audit,VA-MCD-CARDINAL,DMAS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Palmetto GBA (VA),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Fail standard care (≥2 oral classes implied),Documented in medical record,,,"LCD DL39909 effective Feb 15 2026; ⚠️ OBJECTIVE SCALING REQUIRED - notes saying 'patient doing well' = recoupment/denial; HIT-6 or MIDAS score MANDATORY at every visit (e.g., 'Pre-treatment HIT-6: 68. Current HIT-6: 54. Patient demonstrates functional improvement.')",Yes - documented oral failures with adverse events,No - Federal Medicare,,LCD DL39909,Virginia_2026_PA_Audit,VA-PARTB-PALMETTO,PGBA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VA,Palmetto GBA (VA),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes,Fail standard care,Documented,,,J3032; ⚠️ Site of service scrutiny - HOPD faces higher scrutiny; justify: 'Patient is high-risk for infusion reaction and requires hospital-level monitoring',Yes - inability to self-inject; infusion reaction risk,No - Federal Medicare,,LCD DL39909,Virginia_2026_PA_Audit,VA-PARTB-PALMETTO,PGBA,DENY-QL-001,True,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,"≥2 different preferred triptans (Sumatriptan, Rizatriptan, Naratriptan, Zolmitriptan)",Documented failure/intolerance,,,"NON-PREFERRED: Ubrelvy, Nurtec ODT, Reyvow, Zavzpret; QL 8-16 doses/30d depending on MCO overlay",Yes - CV contraindication (triptans are vasoconstrictive and contraindicated per FDA labeling); 'CGRP antagonists are the ONLY medically appropriate acute therapy' - triggers Contraindication exception in PA algorithm,NO - SB 5395 FAILED,,HCA Policy 67.70.10,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-001,True,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,"≥2 different categories of oral prophylactics (Beta-blockers, Antidepressants, Anticonvulsants)",≥2 MONTHS each,To access Aimovig/Vyepti: must fail BOTH Emgality AND Ajovy,Documented failure,"PREFERRED: Emgality, Ajovy; NON-PREFERRED: Aimovig, Vyepti; Qulipta/Nurtec preventive = non-preferred or require injectable failure first",Yes - teratogenicity bypass for women of childbearing potential (Topiramate/Valproate contraindicated); asthma/COPD bypass for beta-blockers; obesity bypass for Valproate (weight gain),NO - SB 5395 FAILED,,HCA Policy 67.70.10,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-002,True,,
WA,Washington Apple Health (Medicaid),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,,,Chronic Migraine (>15 days/mo) STRICT; ⚠️ Dual Therapy (Botox+CGRP) historically DENIED - appeal requires 'Refractory Chronic Migraine' + AHS 2024 Consensus citing synergistic mechanisms: 'Patient achieved partial response (30% reduction) with Botox but remains disabled with >8 migraine days/month',Yes - oral preventive contraindications,NO - SB 5395 FAILED,,MCO Medical Review,Washington_State_PA_Audit_2026,WA-MCD-APPLE,HCA,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Premera Blue Cross WA,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1 triptan (MORE LENIENT than Medicaid/others),Documented failure,,,Ubrelvy/Nurtec = Tier 2 or 3; ⚠️ MOH EXCLUSION REMOVED - can prescribe gepants to patients detoxing from analgesic overuse ('Gepants lack MOH risk'),Yes - CV contraindication; MOH patients now eligible,NO - SB 5395 FAILED,,Premera 5.01.503,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-001,True,,
WA,Premera Blue Cross WA,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 distinct categories oral prophylactics (Beta-blocker, TCA, Anticonvulsant)",Documented failure,,,"PREFERRED: Emgality, Ajovy; Aimovig often NON-PREFERRED; ⚠️ Adolescent pathway (6-17) for Qulipta/Ajovy - fail 2 pediatric-appropriate preventives (Topiramate, Amitriptyline) - formal pathway many payers deny as 'experimental'",Yes - teratogenic; CV contraindication; documented intolerance,NO - SB 5395 FAILED,,Premera 5.01.584,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-002,True,,
WA,Premera Blue Cross WA,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,,,Chronic Migraine (>15 days); Reauthorization requires documented reduction ('50% reduction in headache days' or 'clinically meaningful improvement in function'),Yes - oral preventive contraindications,NO - SB 5395 FAILED,,Premera 5.01.512,Washington_State_PA_Audit_2026,WA-COM-PREMBC,Premera,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans; ⚠️ Failure defined as 'adequate trial = treatment of at least 3 migraine episodes' - single failed dose NOT valid; notes must read: 'Patient treated 3 separate attacks with Sumatriptan 100mg without relief',≥3 attacks treated per triptan,,,Nurtec ODT/Ubrelvy require 2 triptan failures,Yes - CV contraindication,NO - SB 5395 FAILED,,Regence dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-001,True,,
WA,Regence BlueShield WA,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,,,Chronic Migraine (>15 days); standard criteria,Yes - oral preventive contraindications,NO - SB 5395 FAILED,,Regence dru006,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Regence BlueShield WA,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,Failure of ALL viable self-injectable CGRPs,Documented failure,J3032; ⚠️ SITE OF CARE RESTRICTION - HOPD NON-PREFERRED; refer to home infusion or freestanding infusion clinic; HOPD only if: 'History of difficult IV access requiring ultrasound guidance' OR 'History of severe anaphylaxis requiring hospital-grade resuscitation capabilities',Yes - inability to self-inject; anaphylaxis history,NO - SB 5395 FAILED,,Regence dru006/dru540,Washington_State_PA_Audit_2026,WA-COM-REGENCE,Regence,DENY-QL-001,True,,
WA,Kaiser Permanente Washington,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented failure,,,RESTRICTED to Neurology specialty prescribers; PCPs blocked without e-consult/formal referral,Yes - CV contraindication,NO - SB 5395 FAILED,,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-001,True,,
WA,Kaiser Permanente Washington,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,⚠️ MOST RESTRICTIVE: ≥3 oral preventive classes (Beta-blocker + TCA + Anticonvulsant) - EXCEEDS AHS 2-step standard,Documented failure all 3 classes,,,CGRPs in Tier 4/5 (Specialty) = significant coinsurance; ⚠️ Best strategy for Kaiser = External Review (IRO) citing 'Standard of Care Discrepancy' - AHS 2024 recommends CGRPs as first-line or after 1 failure; Kaiser's 3-failure requirement causes 'undue suffering and functional impairment',Yes - teratogenic; CV contraindication; documented intolerance (use IRO argument),NO - SB 5395 FAILED,,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-002,True,,
WA,Kaiser Permanente Washington,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,⚠️ ≥3 oral preventive classes (strictest in state),Documented failure all 3 classes,,,Chronic Migraine (>15 days); ⚠️ Must be administered within Kaiser facilities - external referrals almost never approved; appeal via IRO if needed,Yes - oral preventive contraindications; IRO for external referral,NO - SB 5395 FAILED,,Kaiser Clinical Review,Washington_State_PA_Audit_2026,WA-COM-KAISER,Kaiser,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WA,Noridian Healthcare Solutions,Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes (for MA plans),Medicare FFS = no strict step therapy traditionally; ⚠️ MA plans (UHC/Humana) CAN and DO apply step therapy requiring failure of Part D options before Part B Vyepti,Per MA plan policy,,,"J3032; Chronic or Episodic; ensure ICD-10 aligns with chronic criteria if treating chronic patient; ⚠️ Part D $2,100 Cap Impact: once beneficiary spends $2,100, cost drops to $0 for remainder of year - re-evaluate Medicare patients who discontinued CGRPs due to cost",Yes - inability to self-inject,No - Federal Medicare,,LCD L35172,Washington_State_PA_Audit_2026,WA-PARTB-NORIDIAN,Noridian,DENY-QL-001,True,,
MA,MassHealth (Medicaid),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,"≥2 different triptan agents (Sumatriptan, Rizatriptan, Naratriptan preferred); document inadequate response/adverse reaction/contraindication",Documented failure,,,⚠️ QL 16 units per 30 days; to exceed: document headache frequency + concurrent prophylaxis OR contraindication to prophylaxis (signals managing chronic condition),Yes - CV contraindication; Rizatriptan contraindicated if on Propranolol (drug-drug interaction); documented contraindication satisfies step per 130 CMR 406.000,NO - H.4616 pending,,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-001,True,,
MA,MassHealth (Medicaid),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 classes of oral preventives (Anti-epileptics/Beta-blockers/Antidepressants),Documented failure,,,Chronic Migraine (G43.709): ≥15 HA days/month with ≥8 migrainous days for ≥3 months; Reauthorization requires documented benefit (typically >7 days/month reduction OR significant functional improvement - return to work/school),Yes - oral preventive contraindications,NO - H.4616 pending,,MHDL Table 14,Massachusetts_2026_PA_Audit,MA-MCD-MASSHEALTH,MassHealth,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Blue Cross Blue Shield of Massachusetts,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache,Yes,"Episodic Cluster Headache; history of 5+ attacks per month; failure of standard prevention (Verapamil, Lithium, Topiramate)",Documented failure standard prevention,,,Emgality 100mg for Episodic Cluster Headache (NOT chronic cluster - often excluded),Yes - standard prevention contraindications,NO - H.4616 pending,,BCBSMA Policy 021,Massachusetts_2026_PA_Audit,MA-COM-MASSBCBS,BCBSMA,DENY-QL-001,True,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans per MNG,Documented failure,,,Standard criteria via InterQual + internal MNGs,Yes - CV contraindication,NO - H.4616 pending,,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-001,True,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 prophylactic classes (Beta-blockers/TCA-SNRI/Anticonvulsants) per MNG,Documented failure,,,"⚠️ AJOVY EXCLUSION JAN 1 2026 - moved to NON-FORMULARY; PREFERRED: Emgality, Aimovig; stable Ajovy patients face POS rejections or Tier 4/5 copays; file 'Continuity of Care' or 'Medical Necessity' exception NOW using 'Non-Medical Switching' argument: 'Switching risks immunogenicity (anti-drug antibodies) and loss of disease control; AHS advises against switching stable patients for non-medical reasons'",Yes - teratogenic; CV contraindication; Non-Medical Switching defense for stable Ajovy patients,NO - H.4616 pending,,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-002,True,,
MA,Point32Health (Harvard Pilgrim/Tufts),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,⚠️ HIGHER BAR: ≥3 prophylactic medications from 2 different classes (stricter than MassHealth's 2 classes),Documented failure,,,Chronic Migraine diagnosis,Yes - oral preventive contraindications,NO - H.4616 pending,,Point32Health MNG,Massachusetts_2026_PA_Audit,MA-COM-POINT32,Point32,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,Mass General Brigham Health Plan,Commercial/Medicaid,Commercial,CGRP mAbs (SC),Preventive,Yes,Per MassHealth UPPL for Medicaid products; internal criteria for commercial/Medicare,Per product line,,,"PREFERRED: Aimovig, Emgality; aligns with UPPL for Medicaid; 90-day PA honor for plan transitions (from Tufts SCO)",Yes - teratogenic; CV contraindication,N/A - Mixed,,MGBHP Formulary,Massachusetts_2026_PA_Audit,MA-MCD-MASSBRIGHAM,MGB,DENY-STEP-002,True,,
MA,Mass General Brigham Health Plan,Commercial/Medicaid,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,Per MassHealth UPPL for Medicaid; internal criteria for commercial,Per product line,,,⚠️ Dysport/Xeomin designated as preferred neurotoxins; Botox may require trial of preferred toxin for overlapping indications - BUT for Chronic Migraine Botox often retains exclusivity (specific FDA indication); watch for administrative friction,Yes - oral preventive contraindications; specific FDA indication defense,N/A - Mixed,,MGBHP Formulary,Massachusetts_2026_PA_Audit,MA-MCD-MASSBRIGHAM,MGB,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,National Government Services (NGS),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Standard care failures (oral preventives implied); ⚠️ LCD DL39909 mandates OBJECTIVE SCALES (MIDAS/HIT-6) at every treatment cycle; 'patient feels better' = INSUFFICIENT,Documented in medical record,,,"LCD DL39909; ⚠️ Dosage per MUSCLE GROUP required (e.g., 'Corrugator: 10 units, Procerus: 5 units') - global '155 units injected' = AUDIT RISK; must document patient continues to meet Chronic Migraine (≥15 days/mo) OR 'Chronic by History' (reduced below threshold but discontinuation would cause regression); NGS Part B FFS = POST-SERVICE review (TPE) - NO PA number required; Medicare Advantage = pre-service PA required",Yes - documented oral failures with adverse events,No - Federal Medicare,,LCD DL39909,Massachusetts_2026_PA_Audit,MA-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MA,National Government Services (NGS),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes (for MA plans),NGS Part B FFS: medical necessity (Chronic Migraine + oral preventive failures); ⚠️ NO requirement to fail SC CGRPs under NGS Part B - accessible for seniors who cannot self-inject; MA plans often require 2 oral + 1-2 SC CGRP failures before Vyepti,Documented failure orals; SC CGRP failure NOT required under NGS FFS,,,J3032; NGS FFS = no SC CGRP step (advantage for dexterity issues/cannot self-inject); Medicare Advantage = pre-service PA with SC CGRP step,Yes - inability to self-inject; dexterity issues,No - Federal Medicare,,LCD DL39909,Massachusetts_2026_PA_Audit,MA-PARTB-NGS,NGS,DENY-QL-001,True,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,"≥2 preferred triptans (Sumatriptan, Rizatriptan, Eletriptan); failure = lack of efficacy/allergy/intolerable side effects/drug-drug interactions",Documented failure,,,"NON-PREFERRED: Ubrelvy, Nurtec ODT, Reyvow; ⚠️ Eletriptan is PREFERRED (higher efficacy than Sumatriptan - strategic advantage)",Yes - CV Contraindication (vasoconstrictive agents contraindicated due to ischemic heart disease/uncontrolled HTN/significant risk factors like smoking/obesity/diabetes),N/A - Medicaid FFS exemptions vary,,HCPF PDL 01-01-26,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-001,True,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,"≥2 different oral preventive classes (Beta-blockers: Propranolol/Metoprolol, Antidepressants: Amitriptyline/Venlafaxine, Anticonvulsants: Topiramate/Divalproex)",⚠️ ≥8 WEEKS each at therapeutic dose (strict - '4-week trial' notations = denied for 'inadequate duration'),,,"PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig, Vyepti (requires failure of preferred agents or specific medical necessity like latex allergy for Aimovig or IV need for Vyepti)",Yes - 'Serious or Complex Medical Condition' bypass (Appendix P) for status migrainosus or severe functional impairment risking hospitalization; teratogenic contraindication; respiratory contraindication (asthma) to beta-blockers,N/A - Medicaid,,HCPF PDL 01-01-26,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-002,True,,
CO,Health First Colorado (Medicaid),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented failure,,,Chronic Migraine (ICHD-3): ≥15 HA days/month for >3 months with ≥8 migrainous days; ⚠️ HEADACHE DIARY MANDATORY - 'Patient reports 18 headache days in November' required; 'frequent headaches' = DENIAL,Yes - oral preventive contraindications,N/A - Medicaid,,HCPF Medical Benefit,Colorado_2026_PA_Audit,CO-MCD-HEALTHFIRST,HCPF,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,UnitedHealthcare / RMHP,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1 triptan (loosened from previous 2 triptan requirement); automated system often looks for 2 distinct claims - explicitly state 'Failure of Sumatriptan due to lack of efficacy',Documented failure,,,QL 8-12 tablets/30 days; to override: 'Acute Medication Overuse is not present' OR 'Headache frequency requires >12 doses but total monthly intake monitored to prevent rebound',Yes - CV Contraindication,⚠️ HB 24-1149 ACTIVE but 90% threshold (dispute if 80-89%),90% (exceeds statutory 80%),UHC Gepant Policy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-001,True,,
CO,UnitedHealthcare / RMHP,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes; ⚠️ prior CGRP mAb trial can count as one 'failed class' (path: Oral→CGRP→Botox),Documented failure,,,Chronic Migraine (≥15 days) NON-NEGOTIABLE - Episodic (<15 days) = automatic denial; ⚠️ 'Dual Therapy Block' - concurrent Botox+CGRP requires 'Partial Response' documentation + 'Clinical Rationale' for adding second modality,Yes - oral preventive contraindications; document 'refractory chronic migraine with partial response to CGRP blockade',HB 24-1149 ACTIVE,90%,UHC Botox Policy,Colorado_2026_PA_Audit,CO-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Anthem BCBS Colorado,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 prescription triptans (Eletriptan, Rizatriptan, Sumatriptan, Naratriptan preferred)",Documented failure,,,"NON-PREFERRED: Nurtec, Ubrelvy; ⚠️ 'Patient prefers not to take triptans' = IMMEDIATE DENIAL; must state specific contraindication: 'Contraindicated due to risk of serotonin syndrome with concurrent SSRI' or 'Vascular risk factors'",Yes - CV contraindication; serotonin syndrome risk with SSRI; documented specific contraindication required,HB 24-1149 ACTIVE - tracking,Tracking approval rates,Anthem Select Drug List,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-001,True,,
CO,Anthem BCBS Colorado,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes; ⚠️ specifically names TOPIRAMATE or DIVALPROEX as required step (amitriptyline + propranolol may NOT be enough - they want anticonvulsant failure),Documented failure,,,Chronic Migraine; ⚠️ TERATOGENICITY ARGUMENT = silver bullet: 'Contraindication to anticonvulsants due to reproductive potential' removes anticonvulsant hurdle,Yes - teratogenic contraindication to Topiramate/Valproate; nephrolithiasis (kidney stones) contraindication to Topiramate; bradycardia contraindication to beta-blockers,HB 24-1149 ACTIVE - tracking,Tracking,Anthem Botox Policy,Colorado_2026_PA_Audit,CO-COM-ELEV,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Cigna Healthcare Colorado,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥1 triptan; Express Scripts PBM has 365-day lookback - if triptan claim in last year, PA may process automatically at POS; if >1 year old, manual PA to 'remind' system",Documented failure or claims lookback,,,"PREFERRED: Sumatriptan, Rizatriptan, Zolmitriptan; NON-PREFERRED: Ubrelvy, Nurtec",Yes - 'Chest pressure and tightness (triptan sensation) mimicking angina upon triptan administration' = significant intolerance,HB 24-1149 ACTIVE,Statutory compliance,Cigna CNF_469,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-001,True,,
CO,Cigna Healthcare Colorado,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 distinct oral preventive classes,⚠️ ≥3 MONTHS each (STRICTEST - most payers 6-8 weeks),,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; ⚠️ Document SPECIFIC DATES: 'Trial of Topiramate 50mg BID from Jan 1 to April 1, 2024 (3 months) - failed due to lack of efficacy'; MIDAS/HIT-6 scores explicitly referenced in policy - include 'MIDAS Score >11' in notes",Yes - teratogenic; CV contraindication; 'Severe gastroparesis/nausea rendering oral preventives ineffective due to absorption failure - injectable therapy medically necessary',HB 24-1149 ACTIVE,Statutory compliance,Cigna CNF_333,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-002,False,8.0,Cigna: Standard episodic (4-7d) = triptan failure only for acute; High-freq episodic (≥8d) = 1 oral class for CGRP; Chronic (≥15d) = 2 oral classes. MIDAS ≥11 required for all preventives.
CO,Cigna Healthcare Colorado,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months each,,,Chronic Migraine (>15 days/mo); ⚠️ DUAL THERAPY (Botox+CGRP) HIGHLY RESTRICTED - 'duplication of therapy'; must frame as 'augmentation for partial responder' using AHS 2024 Consensus Statement: 'CGRP mAbs and OnabotulinumtoxinA have distinct pharmacological targets (ligand/receptor vs presynaptic release) - this is mechanistic augmentation not duplication',Yes - oral preventive contraindications; 'distinct pharmacological targets' argument for dual therapy,HB 24-1149 ACTIVE,Statutory compliance,Cigna Botox Policy,Colorado_2026_PA_Audit,CO-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Kaiser Permanente Colorado,Commercial,Commercial,Gepants (Acute),Acute,Yes,"≥2 generic triptans (Sumatriptan, Rizatriptan)",Documented failure,,,RESTRICTED: Nurtec/Ubrelvy strictly non-formulary or high-tier requiring 'Non-Formulary' approval; ⚠️ Only reliable bypass = SAFETY arguments ('Risk of Stroke' / 'Severe Adverse Event' / 'Serotonin syndrome risk with antidepressants') - 'better efficacy' arguments rarely work,Yes - vascular contraindication; serotonin syndrome risk; safety-based arguments only,Internal Protocol - exemptions rare,Internal,Kaiser Formulary,Colorado_2026_PA_Audit,CO-COM-KAISER,Kaiser,DENY-STEP-001,True,,
CO,Novitas Solutions (CO),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,'Conservative management' failure implied; document ≥2 oral preventive failures for audit defense,Documented in medical record,,,"LCD L38809; ⚠️ Diagnosis must code G43.709 or G43.719 (INTRACTABLE key); frequency 12 weeks STRICT - 10-11 week injections DENIED unless documented 'medical necessity for accelerated dosing' (rarely approved); must state 'Headache frequency >15 days/month, duration >4 hours/day' + list specific muscles injected with dosage per site",Yes - documented oral failures with adverse events,No - Federal Medicare,,LCD L38809,Colorado_2026_PA_Audit,CO-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CO,Novitas Solutions (CO),Medicare MAC,Part B,CGRP mAbs (IV),Chronic Migraine,Yes (for MA plans),⚠️ Original Medicare FFS = NO step therapy requiring SC CGRP failure before Vyepti (go straight to Vyepti if oral agents failed); Medicare Advantage (UHC/Anthem MA) CAN and DO enforce SC CGRP step,Oral preventive failures documented,,,"J3032; follows FDA labeling + 'conservative management' failure; ⚠️ $2,000 Part D cap = prescribe branded CGRPs (Qulipta) in January to hit cap by Q1-Q2, then $0 cost rest of year - stable year-round treatment now viable for seniors",Yes - inability to self-inject; cognitive/physical inability,No - Federal Medicare,,LCD L38809,Colorado_2026_PA_Audit,CO-PARTB-NOVITAS,Novitas,DENY-QL-001,True,,
AZ,AHCCCS Fee-For-Service,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Recent (180d) or documented,,,"NON-PREFERRED: Ubrelvy, Nurtec, Reyvow; HB 2621 form required",Yes - CV contraindication; SUD history,,,AHCCCS PDL,Arizona_2026_PA_Audit,AZ-MCD-AHCCCS,AHCCCS,DENY-STEP-001,True,,
AZ,Blue Cross Blue Shield of Arizona,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,Documented,,,QL 16/30d; Cluster Headache override difficult,Yes - CV contraindication,✓,80%,BCBSAZ Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ,BCBSAZ,DENY-STEP-001,True,,
AZ,Cigna Healthcare Arizona,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥3 months documented,,,⚠️ HEADACHE DIARY MANDATE (3mo); MOH denial if overusing acute meds,Yes - oral contraindications,Statutory,,Cigna Botox,Arizona_2026_PA_Audit,AZ-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AZ,Noridian Healthcare Solutions (AZ),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventives implied,Documented,,,⚠️ WISeR PILOT; LCD L35172/DL39909; G43.709 required; 12wk strict; JW/JZ MANDATORY,Yes - documented oral failures,,,LCD L35172/DL39909,Arizona_2026_PA_Audit,AZ-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medicaid,Gepants (Acute),Acute,Yes,≥1 triptan (harmonization toward 'rule of one'); document 2 to be safe,Recent or documented,,,PREFERRED: Nurtec ODT; NON-PREFERRED: Ubrelvy (PA + skip Nurtec reason); QL 16/30d; ⚠️ AB 463 = 2 business day response,Yes - CV contraindication,,,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-001,True,,
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medicaid,CGRP mAbs (SC),Preventive,Yes,Episodic (4-14d): 1 oral class; Chronic (≥15d): 1 oral class,≥2 months,,,"PREFERRED: Aimovig, Emgality; Ajovy requires preferred failure; Medicaid does NOT mandate Botox failure before CGRP (parallel options)",Yes - teratogenic; cognitive; respiratory,,,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-002,True,,
NV,Nevada Medicaid (sPDL),Medicaid Unified,Medical Benefit,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes + MOH ruled out,Documented,,,Chronic only (≥15d); 'frequent headaches' insufficient; ⚠️ 90-day Continuity of Care for plan switches,Yes - oral contraindications,,,Nevada sPDL,Nevada_2026_PA_Audit,NV-MCD-SPDL,NV-DHCFP,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NV,Health Plan of Nevada (UHC),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Nurtec/Ubrelvy; Smart Edits automation; QL standard,Yes - CV contraindication,,,HPN Formulary,Nevada_2026_PA_Audit,NV-COM-HPN,87726,DENY-STEP-001,True,,
NV,Health Plan of Nevada (UHC),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,≥6 weeks each,,,"PREFERRED: Aimovig, Emgality; Ajovy excluded (allergic reaction/failure of preferred required); closed HMO network",Yes - teratogenic; cognitive; respiratory,,,HPN Formulary,Nevada_2026_PA_Audit,NV-COM-HPN,87726,DENY-STEP-002,True,,
NV,Noridian Healthcare Solutions (NV),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure,Documented,,,LCD L35170; Chronic Migraine only; Episodic = off-label non-covered; 12wk spacing strict,Yes - documented oral failures,,,LCD L35170,Nevada_2026_PA_Audit,NV-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NM,Presbyterian Health Plan,Commercial/Medicaid,Commercial/Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans (failure/lack of efficacy/intolerance documented),Documented,,,Tier 3 Non-Preferred,Yes - CV contraindication,⚠️ NMAC 13.10.31.12,90% (carrier selects),Presbyterian Policy,New_Mexico_2026_PA_Audit,NM-COM-PRESBY,Presbyterian,DENY-STEP-001,True,,
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,Ubrelvy Tier 3 Preferred Brand; Nurtec Tier 3; PA still required despite 'Preferred',Yes - CV contraindication,⚠️ NMAC 13.10.31.12,90%,BCBSNM Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-STEP-001,True,,
NM,Blue Cross Blue Shield of New Mexico,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 orals + ≥1 SC CGRP failure,Documented,,,Medical benefit; ⚠️ Site of Care review (home infusion preferred over HOPD),Yes - needle phobia; dexterity; adherence issues,⚠️ NMAC 13.10.31.12,90%,BCBSNM dru540,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM,HCSC,DENY-QL-001,True,,
NM,UnitedHealthcare New Mexico,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 agents,≥8 weeks each,,,Vyepti Tier 4 requires failure of 2 preferred SC CGRPs; ⚠️ UHC acknowledges NMAC supersedes national policy,Yes - teratogenic; cognitive; respiratory,✓ NMAC acknowledged,90%,UHC CGRP,New_Mexico_2026_PA_Audit,NM-COM-UHC,87726,DENY-STEP-002,True,,
NM,Novitas Solutions (NM),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure,Documented,,,LCD L38809; ⚠️ ICD-10 G43.7 series REQUIRED (G43.9 = auto-denial); 12wk; '15+ days' + '4+ hours' documentation,Yes - documented oral failures,,,LCD L38809,New_Mexico_2026_PA_Audit,NM-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
UT,SelectHealth,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Tier 4/5 RxCore; QL Ubrelvy 16/30d; Nurtec acute 8/30d (>8 = preventive review),Yes - CV contraindication,⚠️ SB 274 (Mar 2026),Transparency reporting,SelectHealth RxCore,Utah_2026_PA_Audit,UT-COM-SELECTHEALTH,SelectHealth,DENY-STEP-001,True,,
UT,SelectHealth,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥2 months each,,,"Tier 4/5; PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig (requires preferred failure); ⚠️ New Preauth Tool may friction external providers",Yes - teratogenic; cognitive; respiratory,⚠️ SB 274,Transparency,SelectHealth RxCore,Utah_2026_PA_Audit,UT-COM-SELECTHEALTH,SelectHealth,DENY-STEP-002,True,,
UT,Regence BCBS Utah,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,⚠️ DOUBLE STEP: oral failures + 1-2 SC CGRP failures,Documented,,,Medical benefit; Site of Care dru408 (home infusion/office preferred over HOPD),Yes - needle phobia; dexterity; severe infusion reaction history,,,Regence dru540/dru408,Utah_2026_PA_Audit,UT-COM-REGENCE,Regence,DENY-QL-001,True,,
UT,Healthy U (UUHP),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,"pharm-hu-016; PREFERRED: Ajovy, Emgality; NON-PREFERRED: Aimovig (requires both preferred failure); ⚠️ Migraine NOT on 2026 Hybrid Unified PDL",Yes - teratogenic; cognitive; respiratory,,,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-STEP-002,True,,
UT,Healthy U (UUHP),Medicaid,Medicaid,Gepants (Preventive),Preventive,Yes,⚠️ Step 3: Must fail Ajovy AND Emgality AND Aimovig OR documented injection disability/phobia,Documented,,,Effectively 'last-line' option in UT Medicaid,Yes - injection phobia/disability,,,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-QL-001,True,,
UT,Healthy U (UUHP),Medicaid,Medicaid,CGRP mAbs (Cluster),Cluster Headache,Yes,⚠️ Verapamil titrated to maximum tolerated dose required first,Documented titration,,,Emgality 100mg for episodic cluster; Verapamil requirement = common PA failure point (under-dosing),Yes - Verapamil contraindication,,,pharm-hu-016,Utah_2026_PA_Audit,UT-COM-UUHP,UUHP,DENY-QL-001,True,,
UT,Noridian Healthcare Solutions (UT),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure,Documented,,,LCD L35170; ⚠️ PA Demonstration for CPT 64612/64615 (HOPD must secure PA); 12wk; '15/4' rule (≥15d + ≥4hr),Yes - documented oral failures,,,LCD L35170,Utah_2026_PA_Audit,UT-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Regence BCBS Oregon,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Policy dru540 step; QL 16/30d Ubrelvy; QL Exception requires frequency documentation,Yes - CV contraindication,⚠️ HB 3134 Transparency,,Regence dru540,Oregon_2026_PA_Audit,OR-COM-REGENCE,Regence,DENY-STEP-001,True,,
OR,Regence BCBS Oregon,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 classes (Beta-blockers/TCAs/Anticonvulsants),≥2 months each + compliance documented,,,Policy dru540; ⚠️ 'Failure' insufficient - chart notes must show COMPLIANCE during trial; Vyepti requires SC CGRP trial first,Yes - teratogenic; cognitive; respiratory,⚠️ HB 3134,,Regence dru540,Oregon_2026_PA_Audit,OR-COM-REGENCE,Regence,DENY-STEP-002,True,,
OR,Moda Health Oregon,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented (claims lookback),,,⚠️ PBM automation (Navitus) = hard stops; ST flag = auto-reject if no triptan claims 180-365d; 'New Member Trap' = preemptive PA mandatory,Yes - CV contraindication,,,Moda Formulary,Oregon_2026_PA_Audit,OR-COM-MODA,Moda,DENY-STEP-001,True,,
OR,Moda Health Oregon,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,≥2 oral preventives + objective measures (HIT-6),Documented,,,Medical benefit; HIT-6 scores emphasized,Yes - teratogenic; cognitive; respiratory,,,Moda Policy,Oregon_2026_PA_Audit,OR-COM-MODA,Moda,DENY-STEP-003,True,,
OR,Kaiser Permanente Northwest,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,⚠️ ≥3 drug class failures (stricter than 2-class standard),Documented,,,Tier 2 internal; highest barriers; closed formulary,Yes - oral contraindications,,,Kaiser Internal,Oregon_2026_PA_Audit,OR-COM-KAISER,Kaiser,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OR,Kaiser Permanente Northwest,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,Multiple oral failures + internal referral,Documented,,,⚠️ HIGHEST BARRIERS; PCPs CANNOT prescribe CGRPs - must refer to Neurology; internal protocols; ORS 743B.225 90-day Continuity shield,Yes - teratogenic; cognitive; respiratory,,,Kaiser Internal,Oregon_2026_PA_Audit,OR-COM-KAISER,Kaiser,DENY-STEP-002,True,,
OR,Noridian Healthcare Solutions (OR),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure,Documented,,,JF; LCD L35170; 12wk; HOPD PA demonstration may apply,Yes - documented oral failures,,,LCD L35170,Oregon_2026_PA_Audit,OR-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan),Documented,,,Non-Preferred Tier 3; ⚠️ Zavzpret requires oral gepant failure OR severe nausea/gastroparesis,Yes - CV contraindication; Serotonin Syndrome risk,⚠️ Study mandated,,CareFirst Formulary,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-001,True,,
MD,CareFirst BlueCross BlueShield,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,⚠️ ≥3 DIFFERENT drug classes (higher than CGRP requirement),≥2 months each,,,Policy 11.01.003; Chronic Migraine (15/8 ICHD-3); reauth requires ≥50% reduction OR ≥7 fewer days; biosimilar pressure (Dysport lacks CM indication = appeal),Yes - oral contraindications,⚠️ Study mandated,,CareFirst 11.01.003,Maryland_2026_PA_Audit,MD-COM-CAREFIRST,CareFirst,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,UnitedHealthcare Maryland,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,QL Nurtec 16/30d; Ubrelvy 16/30d; high utilization flagged for MOH review,Yes - CV contraindication,✓ National voluntary,92%,UHC Formulary,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-001,True,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,⚠️ THIRD-LINE: Oral preventives + 2 SC CGRPs (Aimovig AND Emgality),Documented failures,,,Medical Necessity; needle phobia/compliance bypass,Yes - needle phobia; inability to self-inject,✓ National voluntary,92%,UHC Vyepti Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-QL-001,True,,
MD,UnitedHealthcare Maryland,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,"⚠️ Often requires CGRP failure FIRST; Dual Therapy requires 'partial response' + 'significant disability',Documented",,,Site of Care redirection (office OK, Vyepti may redirect to home infusion),Yes - CGRP contraindication,✓ National voluntary,92%,UHC Botox Policy,Maryland_2026_PA_Audit,MD-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Kaiser Permanente Mid-Atlantic,Integrated HMO,Commercial,CGRP mAbs (SC),Preventive,Yes,⚠️ ≥3 classes (Beta-blocker/TCA/Topiramate or Valproate),Documented,,,RESTRICTED; requires Kaiser Neurologist referral; PCPs cannot prescribe,Yes - teratogenic; cognitive; respiratory,,,Kaiser Internal,Maryland_2026_PA_Audit,MD-COM-KAISER,Kaiser,DENY-STEP-002,True,,
MD,Kaiser Permanente Mid-Atlantic,Integrated HMO,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 different drug classes,≥2 months each,,,⚠️ STOPPING RULE: If <50% reduction after 2 cycles (6 months) = coverage discontinued (stricter than 30% elsewhere),Yes - oral contraindications,,,Kaiser Internal,Maryland_2026_PA_Audit,MD-COM-KAISER,Kaiser,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Maryland Medicaid (Priority Partners),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventives with specific dates documented,≥8 weeks each,,,Mirrors state PDL; Ajovy/Emgality listed; Aimovig non-preferred,Yes - teratogenic; cognitive; respiratory,,,MD PDL,Maryland_2026_PA_Audit,MD-MCD-PRIORITY,Priority Partners,DENY-STEP-002,True,,
MD,Maryland Physicians Care,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ Universal Opioid/Pain/Migraine PA Form required; ≥2 oral preventives,≥8 weeks EACH,,,Ajovy/Emgality on PDL; Aimovig non-preferred,Yes - teratogenic; cognitive; respiratory,,,MD PDL,Maryland_2026_PA_Audit,MD-MCD-MPC,MPC,DENY-STEP-002,True,,
MD,Maryland Medicaid,Medicaid,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes (lower than Kaiser's 3),Documented,,,Chronic Migraine only,Yes - oral contraindications,,,MD PDL,Maryland_2026_PA_Audit,MD-MCD-PRIORITY,MD-Medicaid,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MD,Novitas Solutions (MD),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure documented,Documented,,,LCD L38809; CPT 64615 (not 64612); 15+ days + 4+ hours; 12wk strict; ⚠️ MA plans may layer Part D SC CGRP step before Part B Vyepti,Yes - documented oral failures,,,LCD L38809,Maryland_2026_PA_Audit,MD-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS Delaware,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan),Documented,,,QL 16/30d; CV bypass = document comorbidity ICD-10; gastroparesis = Nurtec ODT absorption argument,Yes - CV contraindication; gastroparesis,✓ Voluntary 90%,90% (30+ procedures/yr),Formulary J-1207,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-001,True,,
DE,Highmark BCBS Delaware,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 agent from ≥2 different classes (Beta-blocker/Antidepressant/Anti-epileptic/Angiotensin),≥8 weeks each,,,Policy I-200-005; ⚠️ Vyepti I-222-007 requires justification why SC CGRP cannot be used,Yes - teratogenic (Topiramate/Valproate WOCBP); cognitive; respiratory; diabetes/hypotension (beta-blockers),✓ Voluntary 90%,90%,Policy I-200-005,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-002,True,,
DE,Highmark BCBS Delaware,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 prophylactic classes,≥6 weeks each,,,Policy I-11-042; Chronic only (15/8); ⚠️ Dual Therapy flagged as 'duplicate' - use AHS 2024 synergistic mechanism defense,Yes - oral contraindications,✓ Voluntary 90%,90%,Policy I-11-042,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
DE,Highmark BCBS Delaware,Commercial,Commercial,CGRP mAbs (IV),Chronic Migraine,Yes,Must justify why SC CGRP cannot be used,Documented,,,Policy I-222-007; needle phobia/inability to self-inject/SC failure = valid bypass,Yes - needle phobia; arthritis; cognitive impairment,✓ Voluntary 90%,90%,Policy I-222-007,Delaware_2026_PA_Audit,DE-COM-HIGHMARK,Highmark,DENY-QL-001,True,,
DE,Delaware First Health (Centene),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 PDL agents,Documented,,,⚠️ D-SNP Exclusive Alignment Jan 2026 = forced switches; 90-day transition fill; cite 18 Del C § 3381(a)(5) Stability Exception,Yes - stability on current regimen,,,DMAP PDL,Delaware_2026_PA_Audit,DE-MCD-DEFIRST,Centene,DENY-STEP-002,True,,
DE,Novitas Solutions (DE),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure,Documented,,,LCD L38809; JL jurisdiction; same as MD,Yes - documented oral failures,,,LCD L38809,Delaware_2026_PA_Audit,DE-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,Highmark BCBS West Virginia,Commercial,Commercial,CGRP mAbs (SC),Preventive,No,⚠️ FIRST-LINE VICTORY: NO oral failure required (effective Oct 2025),,,,Aimovig/Ajovy/Emgality = preferred; reauth = 'clinical benefit' (reduction in migraine days - not strict 50%),N/A - First-Line,⚠️ SB 833 excludes drugs,,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-FIRST-001,True,,
WV,Highmark BCBS West Virginia,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans + 1 additional acute agent (different triptan/NSAID/DHE),Documented,,,QL Ubrelvy 16/30d; Nurtec acute 8/30d; CV bypass with ICD-10 code (I10 HTN),Yes - CV contraindication (I10),⚠️ SB 833 excludes drugs,,Highmark Policy,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-STEP-001,True,,
WV,Highmark BCBS West Virginia,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,Oral preventive failure typically required (medical policy lags pharmacy),Documented,,,⚠️ DUAL THERAPY ALLOWANCE: Policy J-1207 permits Botox + CGRP if partial response (≥2 day reduction),Yes - oral contraindications,⚠️ SB 833 excludes drugs,,Highmark J-1207,West_Virginia_2026_PA_Audit,WV-COM-HIGHMARK,Highmark,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WV,The Health Plan (WV),Commercial/PEIA,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,⚠️ 720-day claims lookback,,,Tier 3 Non-Preferred; Express Scripts; ⚠️ New members = history invisible = submit records,Yes - CV contraindication,⚠️ SB 833 excludes drugs,,THP Formulary,West_Virginia_2026_PA_Audit,WV-COM-THP,THP,DENY-STEP-001,True,,
WV,The Health Plan (WV),Commercial/PEIA,PEIA,CGRP mAbs (SC),Preventive,Yes,"Oral preventive failure (PEIA = fail-first enforced, not Highmark First-Line)",Documented,,,PEIA: Aimovig/Emgality preferred; Ajovy requires preferred failure,Yes - teratogenic; cognitive; respiratory,⚠️ SB 833 excludes drugs,,THP/PEIA Formulary,West_Virginia_2026_PA_Audit,WV-COM-THP,THP,DENY-STEP-002,True,,
WV,CareSource West Virginia,Exchange/Medicaid,Exchange,Gepants (Acute),Acute,Yes,≥2 triptans + step therapy,Documented,,,"⚠️ Nurtec Tier 4 SPECIALTY (coinsurance not copay); IRA $2,100 cap critical",Yes - CV contraindication,,,CareSource Formulary,West_Virginia_2026_PA_Audit,WV-COM-CARESOURCE,CareSource,DENY-STEP-001,True,,
WV,Palmetto GBA (WV),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure + objective scales,Documented,,,⚠️ LCD DL39909 Jan 2026: OBJECTIVE FUNCTIONAL SCALES (HIT-6/MIDAS) MANDATORY at every visit; G43.709/G43.719 required,Yes - documented oral failures with objective disability scores,,,LCD DL39909,West_Virginia_2026_PA_Audit,WV-PARTB-PALMETTO,Palmetto,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
RI,Blue Cross Blue Shield RI,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Prime Therapeutics; baseline step-therapy for state,Yes - CV contraindication,⚠️ HB 5120 excludes drugs + specialists,,BCBSRI Formulary,Rhode_Island_2026_PA_Audit,RI-COM-BCBSRI,BCBSRI,DENY-STEP-001,True,,
RI,Blue Cross Blue Shield RI,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,Step therapy baseline,Yes - teratogenic; cognitive; respiratory,⚠️ HB 5120 excludes drugs,,BCBSRI Formulary,Rhode_Island_2026_PA_Audit,RI-COM-BCBSRI,BCBSRI,DENY-STEP-002,True,,
RI,Neighborhood Health Plan RI,Medicaid/Exchange,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,⚠️ UBRELVY PREFERRED over Nurtec (friction point for prescribers),Yes - CV contraindication,,,NHPRI Formulary,Rhode_Island_2026_PA_Audit,RI-MCD-NHPRI,NHPRI,DENY-STEP-001,True,,
RI,UnitedHealthcare Rhode Island,Medicare Advantage,MA,CGRP mAbs (IV),Chronic Migraine,Yes,⚠️ Part B Step Therapy: Must fail Part D SC CGRPs (Aimovig/Ajovy/Emgality) before Part B Vyepti,Documented failures,,,Needle phobia/inability to self-inject/cognitive impairment = bypass,Yes - needle phobia; dexterity; cognitive,,,UHC MA Policy,Rhode_Island_2026_PA_Audit,RI-MA-UHC,87726,DENY-QL-001,True,,
RI,National Government Services (RI),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative treatment failure,Documented,,,LCD L33646/DL39909; ⚠️ 15/8/4 rule; G43.709/G43.719 REQUIRED (G43.0/G43.1 = auto-denial); Site of Care scrutiny for HOPD,Yes - documented oral failures,,,LCD L33646/DL39909,Rhode_Island_2026_PA_Audit,RI-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
CT,Connecticut Medicaid (HUSKY),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented with dates/dosages/reasons,,,"⚠️ 2026 Clinical Criteria Pilot - dedicated 'Antimigraine Other CGRP Antagonists' PA form required; PREFERRED: Nurtec ODT, Ubrelvy; NON-PREFERRED: Zavzpret, Reyvow",Yes - CV contraindication; gastroparesis,,,CT PDL/Pilot,Connecticut_2026_PA_Audit,CT-MCD-HUSKY,CT-DSS,DENY-STEP-001,True,,
CT,Connecticut Medicaid (HUSKY),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class,≥8 weeks,,,"PREFERRED: Ajovy, Emgality 120mg, Nurtec ODT (prev), Qulipta; NON-PREFERRED: Aimovig, Vyepti; ⚠️ 90-day grace to Mar 31 2026 for established patients on non-preferred",Yes - teratogenic; cognitive; respiratory,,,CT PDL/Pilot,Connecticut_2026_PA_Audit,CT-MCD-HUSKY,CT-DSS,DENY-STEP-002,True,,
CT,Anthem BCBS Connecticut,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,"PREFERRED: Ajovy, Emgality, Qulipta; Aimovig often NON-PREFERRED; PA 25-94 Step Therapy Reform = Continuity of Care protection",Yes - teratogenic; cognitive; respiratory; PA 25-94 stability protection,,,Anthem CT Formulary,Connecticut_2026_PA_Audit,CT-COM-ANTHEM,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
CT,ConnectiCare (Molina),Exchange/MA,Exchange,CGRP mAbs (SC),Preventive,Yes,Molina policy (verify - complete integration 2026),Documented,,,⚠️ FULL Molina integration - verify existing PAs; PA 25-94 Continuity of Care critical during transition,Yes - stability on current regimen (PA 25-94),,,Molina/ConnectiCare,Connecticut_2026_PA_Audit,CT-COM-CONNECTICARE,Molina,DENY-STEP-002,True,,
CT,Cigna Healthcare Connecticut,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Express Scripts; highly restrictive; strict step therapy,Yes - CV contraindication,,,Cigna Formulary,Connecticut_2026_PA_Audit,CT-COM-CIGNA,62308,DENY-STEP-001,True,,
CT,Aetna Connecticut,Commercial,Commercial,Gepants (Acute),Acute,Yes,Precise triptan failure counts via 'step edits',Documented,,,CVS Caremark integration; specific failure counts required,Yes - CV contraindication,,,Aetna Formulary,Connecticut_2026_PA_Audit,CT-COM-AETNA,60054,DENY-STEP-001,True,,
CT,National Government Services (CT),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,JK; LCD L33646/DL39909; punitive if documentation lacking; same as RI,Yes - documented oral failures,,,LCD L33646/DL39909,Connecticut_2026_PA_Audit,CT-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans (Sumatriptan/Rizatriptan/Eletriptan),≥1 month or inadequate response,,,QL 16/30d typical; ⚠️ MOH review if exceeding QL; Zavzpret = Non-Formulary (requires oral gepant failure + severe nausea/gastroparesis),Yes - CV contraindication,✓ MCL 500.2212e,90% (fully insured only),Custom Select Drug List,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-001,True,,
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Beta-blocker/TCA/Anticonvulsant),≥2 months each,,,"PREFERRED: Aimovig, Emgality; ⚠️ Renewal requires ≥50% reduction in MMDs (quantified); 'patient doing better' insufficient; MIDAS/HIT-6 required",Yes - teratogenic; cognitive; respiratory; hypotension,✓ MCL 500.2212e,90%,BCBSM Policy,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-002,True,,
MI,Blue Cross Blue Shield Michigan,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥6 weeks each,,,Policy 2027125; Chronic (15/8 ICHD-3); ⚠️ Dual Therapy requires Letter of Medical Necessity citing AHS 2021; often restricted,Yes - oral contraindications,✓ MCL 500.2212e,90% (CPT 64615),Policy 2027125,Michigan_2026_PA_Audit,MI-COM-BCBSM,BCBSM,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MI,Priority Health Michigan,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 preferred injectable CGRPs (Aimovig/Emgality),Documented failures,,,⚠️ 'Step 3' - Qulipta positioned as third-line after injectable CGRPs,Yes - injection disability/phobia,⚠️ ASO excluded,,Priority Health Formulary,Michigan_2026_PA_Audit,MI-COM-PRIORITY,Priority Health,DENY-QL-001,True,,
MI,Michigan Medicaid (Single PDL),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,QL 16/30d; uniform across MCOs (Meridian/Molina/Blue Cross Complete),Yes - CV contraindication,,,MI Single PDL,Michigan_2026_PA_Audit,MI-MCD-MERIDIAN,Meridian,DENY-STEP-001,True,,
MI,Michigan Medicaid (Single PDL),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,≥8-12 weeks,,,"PREFERRED: Aimovig, Emgality; Ajovy/Vyepti = Non-Preferred (require preferred failure); Single PDL = uniform pharmacy criteria",Yes - teratogenic; cognitive; respiratory,,,MI Single PDL,Michigan_2026_PA_Audit,MI-MCD-MERIDIAN,Meridian,DENY-STEP-002,True,,
MI,WPS GHA (MI),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥3 drug classes documented failure,≥2 months each,,,⚠️ LCD L39909 (NEW Feb 15 2026); replaces L34635; 12-week STRICT (10-11 weeks = auto-denial); reduction ≥7 days/month OR functional improvement (MIDAS/HIT-6); maintenance without documented benefit = audit target,Yes - documented oral failures with scores,,,LCD L39909,Michigan_2026_PA_Audit,MI-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,Indiana Medicaid (SUPDL),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,,,Tier 2 Non-Preferred; ⚠️ Nurtec QL acute = 8 tabs/30d; 16 tabs = preventive PA required,Yes - CV contraindication,,,SUPDL,Indiana_2026_PA_Audit,IN-MCD-IHCP,IN-IHCP,DENY-STEP-001,True,,
IN,Indiana Medicaid (SUPDL),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 traditional oral preventive class,Documented,,,"PREFERRED: Emgality, Aimovig; Ajovy = requires preferred failure; ⚠️ MDwise exit = 90-day continuity then new PA required under new MCE",Yes - teratogenic; cognitive; respiratory,,,SUPDL,Indiana_2026_PA_Audit,IN-MCD-IHCP,IN-IHCP,DENY-STEP-002,True,,
IN,Anthem Indiana,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 generic oral preventive,≥2 months,,,"PREFERRED: Emgality (Tier 2), Aimovig (Tier 2); NON-PREFERRED: Ajovy, Vyepti (Tier 3)",Yes - teratogenic; cognitive; respiratory,,,Anthem Commercial Formulary,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem Indiana,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Generic oral preventive + preferred injectable CGRP (Aimovig/Emgality),Documented failures,,,⚠️ 'Step 3' - effectively third-line therapy,Yes - injection disability,,,Anthem Commercial Formulary,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-QL-001,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
IN,Anthem Indiana,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,,,Policy ING-CC-0032; Chronic only (15/8); ⚠️ 'Synergy Barrier' - dual therapy requires documented synergistic benefit distinct from monotherapy failure,Yes - oral contraindications,,,ING-CC-0032,Indiana_2026_PA_Audit,IN-COM-ANTHEM,36096,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IN,WPS GHA (IN),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥3 drug classes,Documented,,,Jurisdiction 5; LCD L39909 effective Feb 15 2026,Yes - documented oral failures,,,LCD L39909,Indiana_2026_PA_Audit,IN-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,Gepants (Acute),Acute,No (if dx code),Migraine diagnosis (G43.x),,,,"⚠️ PROGRESSIVE: No PA required if ICD-10 = G43.x; PREFERRED: Nurtec ODT, Ubrelvy",N/A - dx-based approval,,,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,True,,
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes (for non-preferred),PREFERRED: Emgality/Nurtec/Qulipta; NON-PREFERRED: Aimovig/Ajovy require preferred failure,,,,⚠️ 'Rule of 3' failure must be in chart; Vyepti = Non-Preferred (must fail preferred agents); 90-day Continuity for MCO transitions,Yes - preferred agent failure/intolerance,,,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,True,,
WI,Wisconsin ForwardHealth,Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,No (if dx code),Chronic Migraine diagnosis (G43.7x),,,,⚠️ No PA required if dx = G43.7x; 'Rule of 3' failure in chart documentation,N/A - dx-based approval,,,WI ForwardHealth PDL,Wisconsin_2026_PA_Audit,WI-MCD-FWH,WI-FWH,DENY-QL-001,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,Anthem BCBS Wisconsin,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Step 1; Ubrelvy often Tier 2; Nurtec Tier 3,Yes - CV contraindication,⚠️ SB 434 pending,,Anthem WI Formulary,Wisconsin_2026_PA_Audit,WI-COM-ANTHEM,36096,DENY-STEP-001,True,,
WI,Anthem BCBS Wisconsin,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral classes (Beta-blocker/Topiramate),≥8 weeks each,,,PREFERRED: Emgality; Botox may require CGRP failure or adjunctive use,Yes - teratogenic; cognitive; respiratory,⚠️ SB 434 pending,,Anthem WI Formulary,Wisconsin_2026_PA_Audit,WI-COM-ANTHEM,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
WI,Common Ground Healthcare,Exchange,Exchange,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,≥8 weeks each,≥1 preferred CGRP (Emgality/Aimovig),Documented,⚠️ Tier 4 Specialty (Non-Formulary); Step 2 = fail preferred CGRPs before others; strict EPO in-network,Yes - teratogenic; cognitive; respiratory,,,CGHC Formulary,Wisconsin_2026_PA_Audit,WI-COM-CGHC,CGHC,DENY-STEP-002,True,,
WI,Dean Health Plan (Medica),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,"PREFERRED: Emgality, Aimovig; vertically integrated",Yes - teratogenic; cognitive; respiratory,,,Dean Formulary,Wisconsin_2026_PA_Audit,WI-COM-DEAN,Dean,DENY-STEP-002,True,,
WI,Dean Health Plan (Medica),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥3 oral classes,Documented,,,Higher threshold than others (3 vs 2 classes),Yes - oral contraindications,,,Dean Policy,Wisconsin_2026_PA_Audit,WI-COM-DEAN,Dean,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WI,National Government Services (WI),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥3 drug classes,Documented,,,Jurisdiction 6 (WI/IL/MN); LCD L33646; >15 days/month; ⚠️ High documentation burden for IV necessity (Vyepti),Yes - documented oral failures,,,LCD L33646,Wisconsin_2026_PA_Audit,WI-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,Wellmark BCBS Iowa,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,QL Ubrelvy 16/30d; Nurtec 15/30d; 'Vascular Contraindication' bypass,Yes - CV contraindication (HTN/arrhythmia/family hx MI),⚠️ HF 303 pilot,90-95%,Wellmark Formulary,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-001,True,,
IA,Wellmark BCBS Iowa,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 oral class + preferred CGRPs,Documented,⚠️ Aimovig = Non-Preferred; requires BOTH Ajovy AND Emgality failure ('double-step'),Documented,"PREFERRED: Ajovy, Emgality; ⚠️ 'MOA Argument' = if failed ligand-binder (Emgality), second ligand-binder (Ajovy) is redundant - switch to receptor-binder (Aimovig)",Yes - MOA bypass argument,⚠️ HF 303 pilot,90-95%,Wellmark Formulary,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-002,True,,
IA,Wellmark BCBS Iowa,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (Beta-blocker/TCA/AED),Documented,,,15/8/4 rule; ⚠️ 'Clinically meaningful improvement' (not strict 50%); functional improvements OK (reduced ER visits/return to work),Yes - oral contraindications,⚠️ HF 303 pilot,90-95%,Wellmark Policy,Iowa_2026_PA_Audit,IA-COM-WELLMARK,Wellmark,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
IA,Iowa Medicaid (Uniform PDL),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral class,Documented,,,Uniform PDL across Iowa Total Care/Molina/Wellpoint,Yes - teratogenic; cognitive; respiratory,,,IA Uniform PDL,Iowa_2026_PA_Audit,IA-MCD-ITC,Centene,DENY-STEP-002,True,,
IA,WPS GHA (IA),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,≥3 drug classes,Documented,,,Jurisdiction 5; LCD L39909,Yes - documented oral failures,,,LCD L39909,Iowa_2026_PA_Audit,IA-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Naratriptan),Documented,,,⚠️ NO preferred gepants without step; 'SmartPA' edit; Triptans = Tier 1; Zavzpret = higher scrutiny (all orals must fail),Yes - CV contraindication; Serotonin Syndrome (SSRI/SNRI use),,,MO PDL Edit,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-STEP-001,True,,
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 prophylactic classes (Beta-blocker/TCA/AED),Documented (4+ migraine days/month),,,"PREFERRED: Ajovy, Emgality 120mg; NON-PREFERRED: Aimovig; ⚠️ Vyepti = 'Step 3' (requires 2 preferred CGRP failure)",Yes - teratogenic; cognitive (Topiramate); hypotension; asthma; glaucoma,,,MO PDL,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-STEP-002,True,,
MO,MO HealthNet (Medicaid),Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Injectable CGRP failure,Documented,,,⚠️ Nurtec preventive may require injectable failure first; needle phobia weak; injection site reactions stronger,Yes - injection site reactions; severe phobia,,,MO PDL,Missouri_2026_PA_Audit,MO-MCD-MHN,MO-MHN,DENY-QL-001,True,,
MO,Anthem Missouri,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,≥2 months,,,"PREFERRED: Emgality, Aimovig; ⚠️ Ajovy = excluded/exception required; Emgality 100mg = cluster headache indication (distinct)",Yes - teratogenic; intolerance (chest pressure/tightness/paresthesia),⚠️ HB 618 resistant,,Anthem MO Formulary,Missouri_2026_PA_Audit,MO-COM-ANTHEM,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
MO,UnitedHealthcare Missouri,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral classes,Documented,,,15/8/4 criteria; ⚠️ MOH must be explicitly ruled out; washout may be required,Yes - oral contraindications,✓ HB 618 (CPT 64615),90%,UHC Botox Policy,Missouri_2026_PA_Audit,MO-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MO,Blue Cross Blue Shield Kansas City,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes,Documented,,,⚠️ 2026 RESTRUCTURE: Ajovy EXCLUDED; Emgality moved lower tier; single-agent contracts; Continuity of Care appeals critical for non-medical switching,Yes - stability (Continuity of Care),⚠️ HB 618 applies,90%,Blue KC Premium Formulary,Missouri_2026_PA_Audit,MO-COM-BLUEKC,Blue KC,DENY-STEP-002,True,,
MO,WPS GHA (MO),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conventional therapy failure + objective scales,Documented,,,Jurisdiction 5; ⚠️ LCD L39909 effective Feb 15 2026; MIDAS/HIT-6 MANDATORY; subjective documentation = recoupment risk,Yes - documented oral failures with validated scores,,,LCD L39909,Missouri_2026_PA_Audit,MO-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
TN,BlueCross BlueShield Tennessee,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,"PREFERRED: Emgality, Aimovig (Tier 3 with PA); strict step therapy exceeds AHS guidelines",Yes - teratogenic; cognitive; respiratory,⚠️ No state mandate (API focus),,BCBST Essential Formulary,Tennessee_2026_PA_Audit,TN-COM-BCBST,BCBST,DENY-STEP-002,True,,
TN,BlueCross BlueShield Tennessee,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Step therapy maintained; biosimilar push; TCA § 53-10-205 'Mandatory Generic' statute,Yes - CV contraindication,⚠️ No state mandate,,BCBST Formulary,Tennessee_2026_PA_Audit,TN-COM-BCBST,BCBST,DENY-STEP-001,True,,
TN,TennCare (All MCOs),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,TennCare PDL; harmonized across Wellpoint/UHC CP/BlueCare; generic triptans/oral preventives = Tier 1 mandate,Yes - teratogenic; cognitive; respiratory,,,TennCare PDL,Tennessee_2026_PA_Audit,TN-MCD-WELLPOINT,Wellpoint,DENY-STEP-002,True,,
TN,TennCare (All MCOs),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,⚠️ Split-benefit: Oral gepants = OptumRx State PBM (PDL); IV Vyepti = individual MCO medical policy,Yes - CV contraindication,,,TennCare PDL,Tennessee_2026_PA_Audit,TN-MCD-WELLPOINT,Wellpoint,DENY-STEP-001,True,,
TN,Palmetto GBA (TN),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure + headache diary,Documented,,,Jurisdiction M; LCD L33458/DL39909; ⚠️ Strict 84-day (12-week) frequency cap; >15 days + >4 hours documented in diary; automated denial if even 1 day early,Yes - documented oral failures with diary,,,LCD L33458/DL39909,Tennessee_2026_PA_Audit,TN-PARTB-PALMETTO,Palmetto,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KY,Anthem Kentucky,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (generic first),≥8 weeks each,,,⚠️ 69% market = state standard; Tier 3 specialty gated; fail-first rigidly enforced,Yes - teratogenic; cognitive; respiratory,⚠️ HB 135/317 FAILED,,Anthem KY Formulary,Kentucky_2026_PA_Audit,KY-COM-ANTHEM,36096,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
KY,Anthem Kentucky,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,Documented,,,Cost differential ($0.50-$1 triptan vs $100+ gepant) drives rigid fail-first,Yes - CV contraindication,⚠️ HB 135/317 FAILED,,Anthem KY Formulary,Kentucky_2026_PA_Audit,KY-COM-ANTHEM,36096,DENY-STEP-001,True,,
KY,Kentucky Medicaid (Unified PDL),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ Unified PDL standardizes pharmacy across all MCOs (Aetna/Humana/Passport/WellCare/UHC); medical benefit = MCO-specific,Yes - teratogenic; cognitive; respiratory,,,KY Unified PDL,Kentucky_2026_PA_Audit,KY-MCD-AETNA,CVS Health,DENY-STEP-002,True,,
KY,Kentucky Medicaid (Unified PDL),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,Dual-track PA: oral Rimegepant = state PDL; IV Eptinezumab = MCO medical policy,Yes - CV contraindication,,,KY Unified PDL,Kentucky_2026_PA_Audit,KY-MCD-AETNA,CVS Health,DENY-STEP-001,True,,
KY,CGS Administrators (KY),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction 15; LCD L33949; 'reasonable and necessary' standard; bound by Social Security Act,Yes - documented oral failures,,,LCD L33949,Kentucky_2026_PA_Audit,KY-PARTB-CGS,CGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AL,Blue Cross Blue Shield Alabama,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Prime Therapeutics logic; No AI Denial rule = human review guaranteed,Yes - CV contraindication,✓ Voluntary Consensus Agreement,90%,Source+Rx Formulary,Alabama_2026_PA_Audit,AL-COM-BCBSAL,BCBSAL,DENY-STEP-001,True,,
AL,Alabama Medicaid Agency,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ 'Fail 2 Rule': 2 different oral preventive classes,≥8 weeks each,,,"'Preferred with Clinical Criteria (CC)' = PA required; PREFERRED: Aimovig, Ajovy, Emgality, Qulipta; NON-PREFERRED: Vyepti (requires SC failure); ⚠️ Form 369 MANDATORY via Acentra Health",Yes - teratogenic; cognitive; respiratory,,,Alabama PDL CC,Alabama_2026_PA_Audit,AL-MCD-AMA,AL-MCD,DENY-STEP-002,True,,
AL,Alabama Medicaid Agency,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,"PREFERRED with CC: Ubrelvy, Nurtec ODT; NON-PREFERRED: Zavzpret; verify acute vs preventive indication on Form 369",Yes - CV contraindication; Serotonin Syndrome,,,Alabama PDL CC,Alabama_2026_PA_Audit,AL-MCD-AMA,AL-MCD,DENY-STEP-001,True,,
AL,Palmetto GBA (AL),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction J; ⚠️ LCD DL39909 Feb 15 2026 'Documentation Cliff' - ICD-10 specificity required; unspecified migraine codes = denial risk,Yes - documented oral failures,,,LCD DL39909,Alabama_2026_PA_Audit,AL-PARTB-PALMETTO,Palmetto,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SC,BlueCross BlueShield SC,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ PEBA State Health Plan = CVS Caremark (NEW Jan 2026); Commercial = Prime Therapeutics; distinct formularies; 'continuation of care' denials expected Q1 2026,Yes - teratogenic; cognitive; respiratory,⚠️ S. 531 pending,,BCBSSC Formulary,South_Carolina_2026_PA_Audit,SC-COM-BCBSSC,BCBSSC,DENY-STEP-002,True,,
SC,BlueCross BlueShield SC,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Step therapy to maximize MLR; generic triptans vs high-cost specialty,Yes - CV contraindication,⚠️ S. 531 pending,,BCBSSC Formulary,South_Carolina_2026_PA_Audit,SC-COM-BCBSSC,BCBSSC,DENY-STEP-001,True,,
SC,SC Medicaid (Unified PDL),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ 'One PDL' policy = all MCOs (First Choice/Absolute/Molina/Humana/Healthy Blue) follow FFS list; no MCO flexibility; rebate maximization,Yes - teratogenic; cognitive; respiratory,,,SC Unified PDL,South_Carolina_2026_PA_Audit,SC-MCD-SCDHHS,SC-MCD,DENY-STEP-002,True,,
SC,SC Medicaid (Unified PDL),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,Unified PDL; pharmacy = Magellan Rx (FFS); medical J-codes = MCO-specific,Yes - CV contraindication,,,SC Unified PDL,South_Carolina_2026_PA_Audit,SC-MCD-SCDHHS,SC-MCD,DENY-STEP-001,True,,
SC,Palmetto GBA (SC),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction J/M; HQ Columbia SC; LCD L33458; quasi-law for Medicare Part B; documentation must meet specific LCD elements or claim denied/recouped,Yes - documented oral failures,,,LCD L33458,South_Carolina_2026_PA_Audit,SC-PARTB-PALMETTO,Palmetto,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
LA,Blue Cross Blue Shield Louisiana,Commercial,Commercial,CGRP mAbs (SC),Preventive,No,⚠️ FIRST-LINE VICTORY: No oral preventive failure required (AHS 2024 aligned),,,,~66% market share; policies = local standard of care; Act 432 applies to medical benefit (CPT 64615/J3032),N/A - First-Line,✓ Act 432 (medical only),90%,BCBSLA Policy,Louisiana_2026_PA_Audit,LA-COM-BCBSLA,BCBSLA,DENY-FIRST-001,True,,
LA,Blue Cross Blue Shield Louisiana,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (expected),Documented,,,"⚠️ Act 432 excludes 'pharmacy services' - oral gepants NOT Gold Card eligible; Part D cap ($2,000) increases payer UM on Part D drugs",Yes - CV contraindication,⚠️ Act 432 excludes pharmacy,,BCBSLA Formulary,Louisiana_2026_PA_Audit,LA-COM-BCBSLA,BCBSLA,DENY-STEP-001,True,,
LA,Louisiana Medicaid (Single PDL),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,LDH Single PDL; all MCOs (LA Healthcare Connections/Healthy Blue) follow state list; InterQual criteria where state silent,Yes - teratogenic; cognitive; respiratory,,,LA Single PDL,Louisiana_2026_PA_Audit,LA-MCD-LHC,Centene,DENY-STEP-002,True,,
LA,Louisiana Medicaid (Single PDL),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,Single PDL; MCO-specific medical policies for J-codes,Yes - CV contraindication,,,LA Single PDL,Louisiana_2026_PA_Audit,LA-MCD-LHC,Centene,DENY-STEP-001,True,,
LA,Novitas Solutions (LA),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure + functional improvement metrics,Documented,,,Jurisdiction H; LCD L38809; ⚠️ Functional improvement metrics tightened for 2026; objective documentation required,Yes - documented oral failures with improvement metrics,,,LCD L38809,Louisiana_2026_PA_Audit,LA-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AK,Premera BCBS Alaska,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,,,QL 16-18 doses/30 days; higher QL requires headache diary; Tier 3 Non-Preferred on B4/M4 formularies,Yes - CV contraindication (CAD/PVD/HTN/hemiplegic/basilar),⚠️ SB 133 effective 2027,,Policy 5.01.503,Alaska_2026_PA_Audit,AK-COM-PREMERA,Premera,DENY-STEP-001,True,,
AK,Premera BCBS Alaska,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 categories traditional prophylaxis,≥8 weeks each,,,Policy 5.01.584; Vyepti Site of Service review (HOPD denied unless medically necessary); pediatric Ajovy (12-17) available,Yes - teratogenic; cognitive; respiratory; hypotension,⚠️ SB 133 effective 2027,,Policy 5.01.584,Alaska_2026_PA_Audit,AK-COM-PREMERA,Premera,DENY-STEP-002,True,,
AK,Alaska Medicaid (DenaliCare),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,⚠️ 'Double Step Trap': 2 different triptans + 1 prophylactic,≥2 months prophylactic,,,Unusually high bar for acute meds; MOH must be ruled out; implies prevention must be optimized first,Yes - CV contraindication,,,AK PDL,Alaska_2026_PA_Audit,AK-MCD-DENALI,AK-MCD,DENY-STEP-001,True,,
AK,Alaska Medicaid (DenaliCare),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 prophylactic classes (Beta-blocker + Antiepileptic),≥2 months each,,,Episodic (4-14 days) or Chronic (15+); ⚠️ Concurrent CGRP use prohibited without refractory appeal,Yes - teratogenic; cognitive; respiratory,,,AK PDL,Alaska_2026_PA_Audit,AK-MCD-DENALI,AK-MCD,DENY-STEP-002,True,,
AK,UnitedHealthcare Alaska,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans with history of 3+ migraine episodes,Documented,,,Zavzpret excluded unless oral gepants fail (severe nausea/vomiting),Yes - CV contraindication,✓ National Gold Card,92%,UHC Policy,Alaska_2026_PA_Audit,AK-COM-UHC,87726,DENY-STEP-001,True,,
AK,Moda Health Alaska,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral medications,≥8 weeks each,,,Vyepti initial auth limited to 6 months (shorter than standard 12); renewal requires documented MMD reduction; 300mg max q3mo,Yes - teratogenic; cognitive; respiratory,,,Moda Formulary,Alaska_2026_PA_Audit,AK-COM-MODA,Moda,DENY-STEP-002,True,,
AK,Noridian Healthcare Solutions (AK),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction F; LCD L35172; J-code specific billing; JW modifiers required,Yes - documented oral failures,,,LCD L35172,Alaska_2026_PA_Audit,AK-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 distinct triptans (Sumatriptan/Rizatriptan/Eletriptan/Zolmitriptan),Documented,,,Tier 3 Non-Preferred Brand; QUEST = PA required; ⚠️ SB 226 override available,Yes - CV contraindication; gastroparesis; reproductive status,⚠️ Voluntary pilots,,HMSA Formulary,Hawaii_2026_PA_Audit,HI-COM-HMSA,HMSA,DENY-STEP-001,True,,
HI,Hawaii Medical Service Association (HMSA),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,CVS Caremark managed; SB 226 Stability Mandate = continuity if stable on therapy,Yes - teratogenic; cognitive (Topiramate); nephrolithiasis,⚠️ Voluntary pilots,,HMSA Formulary,Hawaii_2026_PA_Audit,HI-COM-HMSA,HMSA,DENY-STEP-002,False,,HMSA: Commercial = 1 oral class for episodic CGRP vs 2 for chronic. QUEST Medicaid = 2 classes for both.
HI,Kaiser Permanente Hawaii,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,Internal formulary criteria,Per Kaiser protocol,,,⚠️ Closed IDN - internal UM by employed physicians; no external PA adjudication; strict closed formulary,Per Kaiser internal criteria,N/A - Internal,,Kaiser Formulary,Hawaii_2026_PA_Audit,HI-COM-KAISER,Kaiser,DENY-STEP-002,True,,
HI,AlohaCare Hawaii,Medicaid/SNP,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Mirrors state FFS criteria with MCO overlays; QUEST + Medicare SNP focus,Yes - teratogenic; cognitive; respiratory,,,AlohaCare Policy,Hawaii_2026_PA_Audit,HI-MCD-ALOHACARE,AlohaCare,DENY-STEP-002,True,,
HI,Noridian Healthcare Solutions (HI),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction E; LCD for Botox/Vyepti,Yes - documented oral failures,,,Noridian LCD,Hawaii_2026_PA_Audit,HI-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ID,Blue Cross of Idaho,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,Documented,,,~42-44% market; MP 5.01.501; highest ROI for template alignment,Yes - CV contraindication,⚠️ HB 618 stalled,,MP 5.01.501,Idaho_2026_PA_Audit,ID-COM-BCI,BCI,DENY-STEP-001,True,,
ID,Blue Cross of Idaho,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Sets clinical policy 'thermostat' for region; Prime Therapeutics PBM,Yes - teratogenic; cognitive; respiratory,⚠️ HB 618 stalled,,MP 5.01.501,Idaho_2026_PA_Audit,ID-COM-BCI,BCI,DENY-STEP-002,True,,
ID,Regence BlueShield Idaho,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Cambia regional policies; more restrictive on 'investigational' combos; rigid pharmacy/medical separation; Ajovy procurement nuances,Yes - teratogenic; cognitive; respiratory,,,Regence Policy,Idaho_2026_PA_Audit,ID-COM-REGENCE,Regence,DENY-STEP-002,True,,
ID,SelectHealth Idaho,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,⚠️ ≥8 weeks each (stricter than 4-week competitors),,,Intermountain vertically integrated; system-wide cost-effectiveness; stricter durations,Yes - teratogenic; cognitive; respiratory,,,SelectHealth Policy,Idaho_2026_PA_Audit,ID-COM-SELECTHEALTH,SelectHealth,DENY-STEP-002,True,,
ID,Idaho Medicaid (FFS/MCO),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,Documented,,,⚠️ HB 345 DUAL-TRACK: FFS via Prime Therapeutics; MCO via Molina/UHC CP (distinct criteria divergence); QL overrides may be needed,Yes - teratogenic; cognitive; respiratory,,,ID PDL,Idaho_2026_PA_Audit,ID-MCD-DHW,ID-MCD,DENY-STEP-002,True,,
ID,Noridian Healthcare Solutions (ID),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure + objective functional metrics,Documented,,,Jurisdiction F; ⚠️ LCD DL39909 effective early 2026; subjective relief insufficient; quantifiable improvement required,Yes - documented oral failures with objective metrics,,,LCD DL39909,Idaho_2026_PA_Audit,ID-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
MT,Blue Cross Blue Shield Montana,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,>40% market; Prime Therapeutics/Carelon; 'utilization friction' strategy documented,Yes - CV contraindication,⚠️ No statutory Gold Card,,BCBSMT Formulary,Montana_2026_PA_Audit,MT-COM-BCBSMT,BCBSMT,DENY-STEP-001,True,,
MT,Blue Cross Blue Shield Montana,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,SB 449 Continuity of Care (90 days); SB 449 = statutory override for plan transitions,Yes - teratogenic; cognitive; respiratory,⚠️ No statutory Gold Card,,BCBSMT Formulary,Montana_2026_PA_Audit,MT-COM-BCBSMT,BCBSMT,DENY-STEP-002,True,,
MT,Montana Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Mountain-Pacific QIO; strict PDL adherence; SB 449 continuity applies,Yes - teratogenic; cognitive; respiratory,,,MT PDL,Montana_2026_PA_Audit,MT-MCD-DPHHS,MT-MCD,DENY-STEP-002,True,,
MT,PacificSource Montana,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,CVS Caremark vertical integration; rigorous step therapy,Yes - teratogenic; cognitive; respiratory,,,PacificSource Formulary,Montana_2026_PA_Audit,MT-COM-PACIFICSOURCE,PacificSource,DENY-STEP-002,True,,
MT,Noridian Healthcare Solutions (MT),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction F; LCD DL39909,Yes - documented oral failures,,,LCD DL39909,Montana_2026_PA_Audit,MT-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Duopoly market; ⚠️ W.S. § 26-55-112 EXCLUDES PHARMACY - oral meds NOT Gold Card eligible,Yes - CV contraindication,✓ W.S. § 26-55-112 (medical only),90%,BCBSWY Formulary,Wyoming_2026_PA_Audit,WY-COM-BCBSWY,BCBSWY,DENY-STEP-001,True,,
WY,Blue Cross Blue Shield Wyoming,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ J-code ambiguity: administration (CPT 64615) may be Gold Carded but drug product (J0585) may still need PA,Yes - teratogenic; cognitive; respiratory,✓ W.S. § 26-55-112 (medical only),90%,BCBSWY Formulary,Wyoming_2026_PA_Audit,WY-COM-BCBSWY,BCBSWY,DENY-STEP-002,True,,
WY,UnitedHealthcare Wyoming,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,'Advanced Notification' PA-lite even for Gold Card exempt services; portal Gold Card status tracking,Yes - teratogenic; cognitive; respiratory,✓ National + W.S. § 26-55-112,90%/92%,UHC Policy,Wyoming_2026_PA_Audit,WY-COM-UHC,87726,DENY-STEP-002,True,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Step therapy portability honored (no repeat if failed under previous plan); 1-year auth validity for chronic conditions,Yes - teratogenic; cognitive; respiratory,,,WY PDL,Wyoming_2026_PA_Audit,WY-MCD-DHF,WY-MCD,DENY-STEP-002,True,,
WY,Wyoming Medicaid,Medicaid FFS,Medicaid,Neurotoxins,Chronic Migraine,Yes,⚠️ 2026 REVERSAL: Must fail CGRP inhibitor BEFORE Botox,Documented CGRP failure,,,"Reversed traditional therapeutic hierarchy; CGRP first, then Botox",Yes - CGRP contraindication/failure,,,WY PDL,Wyoming_2026_PA_Audit,WY-MCD-DHF,WY-MCD,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
WY,Noridian Healthcare Solutions (WY),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction F; LCD DL39909,Yes - documented oral failures,,,LCD DL39909,Wyoming_2026_PA_Audit,WY-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans (explicit dates required),Documented failure,'Triptan Wall' - specific dates of failure required,,QL 16 tabs/30d; specialty tiering 2026,Yes - CV contraindication,,,BCBSKS Formulary,Kansas_PA_Audit,KS-COM-BCBSKS,BCBSKS,DENY-STEP-001,True,,
KS,Blue Cross Blue Shield Kansas,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Documented,,,ICHD-3 criteria; MIDAS/HIT-6 quantitative metrics required,Yes - teratogenic; cognitive; respiratory,,,BCBSKS Formulary,Kansas_PA_Audit,KS-COM-BCBSKS,BCBSKS,DENY-STEP-002,True,,
KS,Blue Cross Blue Shield Kansas City,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Documented,,,⚠️ Ajovy EXCLUDED on Premium/Select formularies; forced switch to Aimovig/Emgality; Continuity of Care appeal for stable patients,Yes - stability (Continuity),,,Blue KC Formulary,Kansas_PA_Audit,KS-COM-BLUEKC,Blue KC,DENY-STEP-002,True,,
KS,UnitedHealthcare Kansas,Commercial,Commercial,Gepants (Acute),Acute,Yes,⚠️ 'SmartPA': 2 distinct triptan fills in preceding 180 days (claims history screened),Real-time POS check,,,Automated rejection if no triptan history; proactive historical data submission required for new patients,Yes - CV contraindication,✓ Gold Card Pilot,>90%,UHC SmartPA,Kansas_PA_Audit,KS-COM-UHC,87726,DENY-STEP-001,True,,
KS,UnitedHealthcare Kansas,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,,,⚠️ Concurrent Botox+CGRP = 'duplicative therapy' denial unless 'synergistic necessity' proven via appeal,Yes - oral contraindications,✓ Gold Card Pilot,>90%,UHC Botox Policy,Kansas_PA_Audit,KS-COM-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,Healthy Blue Kansas (KanCare),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class,≥8 weeks,,,Elevance national UM guidelines; stricter than legacy criteria; objective efficacy proof (not subjective) required for renewal,Yes - teratogenic; cognitive; respiratory,,,Healthy Blue Guidelines,Kansas_PA_Audit,KS-MCD-HEALTHYBLUE,Elevance,DENY-STEP-002,True,,
KS,Healthy Blue Kansas (KanCare),Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,⚠️ ≥3 preventive classes (antihypertensive + anticonvulsant + antidepressant),Documented,,,Stricter than 2-class standard; KanCare 3.0 90-day continuity EXPIRED,Yes - oral contraindications,,,Healthy Blue Guidelines,Kansas_PA_Audit,KS-MCD-HEALTHYBLUE,Elevance,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
KS,WPS GHA (KS),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction 5; LCD DL39909; specific dx codes mandatory; rigid injection intervals; ICHD-3 15/8 alignment,Yes - documented oral failures,,,LCD DL39909,Kansas_PA_Audit,KS-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,Documented,,,Tier 2/3 Preferred; QL typical; Prime Therapeutics PBM logic,Yes - CV contraindication,⚠️ No statutory Gold Card,,BCBSNE Formulary,Nebraska_2026_PA_Audit,NE-COM-BCBSNE,BCBSNE,DENY-STEP-001,True,,
NE,Blue Cross Blue Shield Nebraska,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,Documented,,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; Medical Policy M.29 for Botox",Yes - teratogenic; cognitive; respiratory,⚠️ No statutory Gold Card,,BCBSNE Formulary,Nebraska_2026_PA_Audit,NE-COM-BCBSNE,BCBSNE,DENY-STEP-002,True,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan),Documented,,,"QL: 16/30d (Ubrelvy), 15/30d (Nurtec); Tier 1 PA Required; uniform across MCOs",Yes - CV contraindication,,,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-STEP-001,True,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 traditional preventive (Beta-blocker/TCA/Anticonvulsant),>3 months,,,Uniform PDL; step therapy required,Yes - teratogenic; cognitive; respiratory,,,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-STEP-002,True,,
NE,Nebraska Medicaid (Heritage Health),Medicaid,Medicaid,CGRP mAbs (IV),Preventive,Yes,≥2 oral classes + ≥1 SC CGRP mAb (Aimovig/Emgality),Documented failures,,,⚠️ Step 2/3 agent - requires SC CGRP failure before IV access,Yes - SC CGRP failure + oral contraindications,,,NE Uniform PDL,Nebraska_2026_PA_Audit,NE-MCD-HERITAGE,NE-MCD,DENY-QL-001,True,,
NE,WPS GHA (NE),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction 5; LCD DL39909 effective Feb 15 2026; granular injection site/dosage documentation; targeted injections required,Yes - documented oral failures,,,LCD DL39909,Nebraska_2026_PA_Audit,NE-PARTB-WPS,WPS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Standard step therapy maintained for acute,Yes - CV contraindication,✓ SB 2280 Gold Card,90%,BCBSND Formulary,North_Dakota_2026_PA_Audit,ND-COM-BCBSND,BCBSND,DENY-STEP-001,True,,
ND,Blue Cross Blue Shield North Dakota,Commercial,Commercial,CGRP mAbs (SC),Preventive,No (Chronic),⚠️ FIRST-LINE for Chronic Migraine (Jan 2026 policy update); oral step REMOVED,N/A for Chronic; Episodic may still need step,,,⚠️ MAJOR WIN: AHS 2024 aligned; cite 'January 2026 Policy Update' in appeals to override legacy PBM auto-rejections,N/A - First-Line (Chronic),✓ SB 2280 Gold Card,90%,BCBSND Policy Update Jan 2026,North_Dakota_2026_PA_Audit,ND-COM-BCBSND,BCBSND,DENY-QL-001,True,,
ND,North Dakota Medicaid,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Acentra Health PA reviews; strict,Yes - CV contraindication,,,ND PDL,North_Dakota_2026_PA_Audit,ND-MCD-DHS,ND-MCD,DENY-STEP-001,True,,
ND,North Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ Fail 2 Triptans + Fail 2 Oral Preventives,Documented,,,No liberalization like commercial; strict FFS criteria maintained,Yes - teratogenic; cognitive; respiratory,,,ND PDL,North_Dakota_2026_PA_Audit,ND-MCD-DHS,ND-MCD,DENY-STEP-002,True,,
ND,Noridian Healthcare Solutions (ND),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction F; LCD DL39909/L35172; ⚠️ 15/8 threshold RIGID; zero tolerance for 'frequent headaches' ambiguity; must specify migraine vs headache days,Yes - documented oral failures,,,LCD DL39909/L35172,North_Dakota_2026_PA_Audit,ND-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,PREFERRED: Ubrelvy; Optum/OptumRx admin,Yes - CV contraindication,,,SD PDL,South_Dakota_2026_PA_Audit,SD-MCD-DSS,SD-MCD,DENY-STEP-001,True,,
SD,South Dakota Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 traditional preventive,≥8 weeks,,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy; Nurtec preventive = TBD",Yes - teratogenic; cognitive; respiratory,,,SD PDL,South_Dakota_2026_PA_Audit,SD-MCD-DSS,SD-MCD,DENY-STEP-002,True,,
SD,Sanford Health Plan South Dakota,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Integrated pay-vider; EMR discrepancy detection; ⚠️ SB 158 FAILED - no Gold Card,Yes - teratogenic; cognitive; respiratory,⚠️ SB 158 FAILED,,Sanford Formulary,South_Dakota_2026_PA_Audit,SD-COM-SANFORD,Sanford,DENY-STEP-002,True,,
SD,Noridian Healthcare Solutions (SD),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction F; LCD DL39909,Yes - documented oral failures,,,LCD DL39909,South_Dakota_2026_PA_Audit,SD-PARTB-NORIDIAN,Noridian,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (Sumatriptan/Rizatriptan),Documented,,,QL: 16 tabs/30 days; HCSC division; Prime Therapeutics,Yes - CV contraindication,⚠️ HB 3190 continuity (60 days),,BCBSOK Formulary,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,BCBSOK,DENY-STEP-001,True,,
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral classes (Beta-blocker/TCA/Anticonvulsant),≥2 months each,,,HB 3190: 72hr urgent; HB 1808: 3-year PA validity for chronic maintenance,Yes - teratogenic; cognitive; respiratory,⚠️ HB 3190/1808 protections,,BCBSOK Formulary,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK,BCBSOK,DENY-STEP-002,True,,
OK,UnitedHealthcare Oklahoma,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventives,≥2 months,,,⚠️ Qulipta may require injectable CGRP failure first; HB 1808 criteria posting mandate,Yes - teratogenic; cognitive; respiratory,✓ National Gold Card + HB 1808,92%,UHC Policy,Oklahoma_2026_PA_Audit,OK-COM-UHC,87726,DENY-STEP-002,True,,
OK,Aetna Oklahoma,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Policy 3481-E; CVS Caremark,Yes - CV contraindication,,,Policy 3481-E,Oklahoma_2026_PA_Audit,OK-COM-AETNA,60054,DENY-STEP-001,True,,
OK,Aetna Oklahoma,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventives,60-day trial each,,,CPB 2761-E,Yes - teratogenic; cognitive; respiratory,,,CPB 2761-E,Oklahoma_2026_PA_Audit,OK-COM-AETNA,60054,DENY-STEP-002,True,,
OK,SoonerSelect (All MCOs),Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥1 oral class (typically Topiramate),≥8 weeks,,,OHCA Unified PDL governs; MCOs CANNOT impose stricter criteria than state; Aimovig/Emgality preferred,Yes - teratogenic; cognitive; respiratory,,,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,OK-MCD,DENY-STEP-002,True,,
OK,SoonerSelect (All MCOs),Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥3 preventive classes (antihypertensive + anticonvulsant + antidepressant),Documented,,,Chronic Migraine dx required; 3-class stricter than commercial 2-class,Yes - oral contraindications,,,OHCA Unified PDL,Oklahoma_2026_PA_Audit,OK-MCD-AETNA,OK-MCD,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
OK,Novitas Solutions (OK),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction H; LCD L35170; ⚠️ Chronic Migraine ONLY; >15 days/mo strict; excludes episodic use; injection site documentation,Yes - documented oral failures,,,LCD L35170,Oklahoma_2026_PA_Audit,OK-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Arkansas BCBS (ABCBS),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure of efficacy at max tolerated doses or intolerance),Documented,,,Tier 3 (ST+QL); 'Triptan Failure' definition tightened 2026,Yes - CV contraindication,✓ Act 575 Gold Card,90%,ABCBS Formulary,Arkansas_2026_PA_Audit,AR-COM-ABCBS,ABCBS,DENY-STEP-001,True,,
AR,Arkansas BCBS (ABCBS),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Aimovig/Emgality = Preferred; Vyepti = 2 oral + 1 SC mAb failure; ⚠️ 30% HA reduction at 6mo 'Stopping Rule',Yes - teratogenic; cognitive; respiratory,✓ Act 575 Gold Card,90%,ABCBS Formulary,Arkansas_2026_PA_Audit,AR-COM-ABCBS,ABCBS,DENY-STEP-002,True,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,⚠️ PREFERRED: Nurtec ODT (rebate-driven); NON-PREFERRED: Ubrelvy,Yes - CV contraindication,⚠️ Exempt from Act 575,,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-001,True,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,"PREFERRED: Aimovig, Emgality 120mg, Qulipta, Nurtec preventive; NON-PREFERRED: Ajovy, Vyepti; MOH must be ruled out for Botox",Yes - teratogenic; cognitive; respiratory,⚠️ Exempt from Act 575,,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-002,True,,
AR,Arkansas Medicaid (FFS/PASSE),Medicaid,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Chronic Migraine dx; must confirm NO medication overuse headache,Yes - oral contraindications,⚠️ Exempt from Act 575,,AR PDL,Arkansas_2026_PA_Audit,AR-MCD-DHS,AR-MCD,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Ambetter Arkansas,Commercial,ACA Exchange,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Beta-blocker/TCA/Anticonvulsant),Documented,,,Aimovig/Emgality = Tier 2/3 Preferred; Qulipta = Step 2; highly litigious on 'medical necessity',Yes - teratogenic; cognitive; respiratory,✓ Act 575 applies to J-codes,90%,Ambetter Formulary,Arkansas_2026_PA_Audit,AR-COM-AMBETTER,Centene,DENY-STEP-002,True,,
AR,Novitas Solutions (AR),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction H; LCD L39909; ⚠️ 'Headache Day' vs 'Migraine Day' math REQUIRED in notes; no state Gold Card (federal),Yes - documented oral failures,,,LCD L39909,Arkansas_2026_PA_Audit,AR-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
AR,Novitas Solutions (AR),Medicare MAC,Part B,CGRP mAbs (IV),Preventive,Yes,≥2 oral classes + ≥1 other CGRP mAb,Documented,,,Step 2 agent; TPE audit risk,Yes - documented failures,,,LCD,Arkansas_2026_PA_Audit,AR-PARTB-NOVITAS,Novitas,DENY-QL-001,True,,
MS,Blue Cross Blue Shield Mississippi,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,Near-monopoly market (~96% ASO); step therapy enforced; focus on clinical precision to trigger automated approval algorithms,Yes - CV contraindication,⚠️ SB 2140 transparency (not Gold Card),,BCBSMS Formulary,Mississippi_2026_PA_Audit,MS-COM-BCBSMS,BCBSMS,DENY-STEP-001,True,,
MS,Blue Cross Blue Shield Mississippi,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Third/fourth-line per payer vs first-line per AHS 2024; 'Deemed Authorized' if no response per SB 2140,Yes - teratogenic; cognitive; respiratory,⚠️ SB 2140 transparency,,BCBSMS Formulary,Mississippi_2026_PA_Audit,MS-COM-BCBSMS,BCBSMS,DENY-STEP-002,True,,
MS,Magnolia Health Mississippi,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Largest Medicaid MCO; strict step therapy; automated portals; ⚠️ 90-day continuity on UHC exit transition,Yes - teratogenic; cognitive; respiratory,,,Magnolia Policy,Mississippi_2026_PA_Audit,MS-MCD-MAGNOLIA,Centene,DENY-STEP-002,True,,
MS,Molina Healthcare Mississippi,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,High denial rates in initial automated pass; often requires peer-to-peer to overturn step-therapy edits,Yes - teratogenic; cognitive; respiratory,,,Molina Policy,Mississippi_2026_PA_Audit,MS-MCD-MOLINA,Molina,DENY-STEP-002,True,,
MS,TrueCare Mississippi,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,⚠️ NEW ENTRANT: 'Looser' protocols early 2026; expect UM tightening Q3/Q4 2026; Continuity of Care critical on UHC transition,Yes - teratogenic; cognitive; respiratory,,,TrueCare Policy,Mississippi_2026_PA_Audit,MS-MCD-TRUECARE,TrueCare,DENY-STEP-002,True,,
MS,Novitas Solutions (MS),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction H; LCD L38809; strict 12-week frequency; JW modifier for wastage; TPE audit risk,Yes - documented oral failures,,,LCD L38809,Mississippi_2026_PA_Audit,MS-PARTB-NOVITAS,Novitas,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ME,Anthem BCBS Maine,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,CarelonRx PBM; 'Select' formulary,Yes - CV contraindication (Golden Keyword: 'Contraindication to Vasoconstrictive Agents'),⚠️ No mandatory Gold Card,,Anthem Formulary,Maine_2026_PA_Audit,ME-COM-ANTHEM,Anthem,DENY-STEP-001,True,,
ME,Anthem BCBS Maine,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2-3 oral preventive classes (Beta-blockers/TCAs/Anticonvulsants),≥8 weeks each,,,24-A MRSA §4304-B: 90-day continuity on plan switch,Yes - Asthma/COPD (precludes Beta-blockers); Obesity (precludes TCAs); Nephrolithiasis (precludes Topiramate); Teratogenicity (strongest bypass),⚠️ No mandatory Gold Card,,Anthem Formulary,Maine_2026_PA_Audit,ME-COM-ANTHEM,Anthem,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
ME,MaineCare (DHHS),Medicaid FFS,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Rizatriptan/Sumatriptan),Documented,,,⚠️ PREFERRED: Nurtec ODT; NON-PREFERRED: Ubrelvy; Ubrelvy requires Nurtec failure first; QL 8-16 doses/30d (Form #10110 for override),Yes - CV contraindication,,,MaineCare PDL,Maine_2026_PA_Audit,ME-MCD-DHHS,ME-MCD,DENY-STEP-001,True,,
ME,MaineCare (DHHS),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,"⚠️ PREFERRED: Emgality, Ajovy; NON-PREFERRED: Aimovig; formulary preference diverges from commercial",Yes - teratogenic; cognitive; respiratory,,,MaineCare PDL,Maine_2026_PA_Audit,ME-MCD-DHHS,ME-MCD,DENY-STEP-002,True,,
ME,Community Health Options (CHO),Commercial,ACA CO-OP,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Express Scripts PBM; ⚠️ 'Chronic Illness Support Program' (CISP) = bypass for chronic migraine classification,Yes - teratogenic; cognitive; respiratory,,,CHO Formulary,Maine_2026_PA_Audit,ME-COM-CHO,CHO,DENY-STEP-002,True,,
ME,NGS (Maine),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction K; LCD for chronic migraine,Yes - documented oral failures,,,NGS LCD,Maine_2026_PA_Audit,ME-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans,Documented,,,⚠️ Vermont Blue Advantage EXITED MA 2026; Act 111 Gold Card applies,Yes - CV contraindication (Act 111 step therapy exception),✓ Act 111 Gold Card,90%,BCBSVT Formulary,Vermont_2026_PA_Audit,VT-COM-BCBSVT,BCBSVT,DENY-STEP-001,True,,
VT,Blue Cross Blue Shield Vermont,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Act 111 step therapy exception if 'expected to be ineffective' based on clinical history; 90-day continuity mandate,Yes - teratogenic (strongest); Asthma/COPD; cognitive,✓ Act 111 Gold Card,90%,BCBSVT Formulary,Vermont_2026_PA_Audit,VT-COM-BCBSVT,BCBSVT,DENY-STEP-002,True,,
VT,MVP Health Care Vermont,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Distinct CGRP preferences from BCBSVT; Act 111 applies,Yes - teratogenic; cognitive; respiratory,✓ Act 111 Gold Card,90%,MVP Formulary,Vermont_2026_PA_Audit,VT-COM-MVP,MVP,DENY-STEP-002,True,,
VT,Vermont Medicaid (DVHA),Medicaid FFS,Medicaid,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,Act 111 continuity protections apply to Medicaid plan transitions; state-administered,Yes - teratogenic; cognitive; respiratory,,,VT PDL,Vermont_2026_PA_Audit,VT-MCD-DVHA,VT-MCD,DENY-STEP-002,True,,
VT,Humana Vermont,Medicare Advantage,MA,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes,Documented,,,⚠️ One of few remaining MA plans after VT Blue Advantage + UHC exits; ~50K beneficiaries migrating,Yes - teratogenic; cognitive; respiratory,,,Humana Formulary,Vermont_2026_PA_Audit,VT-MA-HUMANA,61101,DENY-STEP-002,True,,
VT,NGS (Vermont),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,Jurisdiction K; ⚠️ ~50K beneficiaries now back to Original Medicare after MA exits; LCD governs Part B,Yes - documented oral failures,,,NGS LCD,Vermont_2026_PA_Audit,VT-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,Anthem BCBS New Hampshire,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Sumatriptan/Rizatriptan/Eletriptan/Naratriptan),Documented (inadequate response within 2hrs or intolerance),,,QL: 16 tabs/30d (Ubrelvy); 8 tabs/30d (Nurtec acute); Override: document 'Cluster-like features' or 'Menstrual Migraine',Yes - CV contraindication ('Contraindication to Vasoconstrictive Agents'); Serotonin Syndrome risk (SSRI/SNRI),⚠️ SB 561 'Deemed Approved',2 biz days,Anthem Formulary,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,Anthem,DENY-STEP-001,True,,
NH,Anthem BCBS New Hampshire,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes (Beta-blocker/Antiepileptic/TCA),≥2 months each,,,"PREFERRED: Aimovig, Emgality (Tier 3); NON-PREFERRED: Ajovy, Vyepti; Vyepti requires SC failure unless needle phobia/dexterity documented",Yes - teratogenic; cognitive; respiratory; Needle Phobia (DSM-5); Dexterity/Cognitive Impairment; Gastroparesis (Vyepti bioavailability argument),⚠️ SB 561 applies,2 biz days,Anthem Formulary,New_Hampshire_2026_PA_Audit,NH-COM-ANTHEM,Anthem,DENY-STEP-002,False,8.0,Anthem: Episodic (<8d) = 1 oral class; Episodic (≥8d) = same as chronic (1 oral class). More lenient than most payers for episodic.
NH,Harvard Pilgrim NH,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥1 triptan ('Smart PA' checks claims history for triptan fill in 180 days),Claims history or documented samples,,,Tier 3/4; 'Smart PA' logic - auto-approve if triptan claims exist; must manually document samples if no claims history,Yes - CV contraindication,⚠️ SB 561 applies,2 biz days,HPHC MNG,New_Hampshire_2026_PA_Audit,NH-COM-HARVARDPILGRIM,HPHC,DENY-STEP-001,True,,
NH,Harvard Pilgrim NH,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1-2 oral preventive classes,Documented,,,⚠️ 'AJOVY CLIFF' - Ajovy NON-FORMULARY Jan 2026; must submit Formulary Exception using MOA argument (ligand vs receptor) or adverse event history; PREFERRED: Aimovig/Emgality,Yes - ligand vs receptor MOA argument for Ajovy exception; prior adverse events to preferred agents,⚠️ SB 561 applies,2 biz days,HPHC MNG,New_Hampshire_2026_PA_Audit,NH-COM-HARVARDPILGRIM,HPHC,DENY-STEP-002,True,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,≥2 preferred triptans,Documented,,,⚠️ Triptan QL: 9 tabs/30d; MOH Risk argument for gepant access when >9 days/month acute treatment needed,Yes - CV contraindication; MOH risk,,,NH PDL,New_Hampshire_2026_PA_Audit,NH-MCD-HEALTHYFAMILIES,Centene,DENY-STEP-001,True,,
NH,NH Healthy Families,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ ≥2 different oral preventive classes,⚠️ ≥8 weeks EACH (potential 16-month delay),,,"PREFERRED: Aimovig, Emgality; NON-PREFERRED: Ajovy, Vyepti (requires failure of BOTH preferred or contraindication); Adverse Event stops 8-week clock immediately",Yes - teratogenic; cognitive (stops 8-week clock); latex allergy (autoinjectors); needle phobia (Vyepti),,,NH PDL,New_Hampshire_2026_PA_Audit,NH-MCD-HEALTHYFAMILIES,Centene,DENY-STEP-002,True,,
NH,NGS (New Hampshire),Medicare MAC,Part B,Neurotoxins,Chronic Migraine,Yes,Conservative therapy failure,Documented,,,"Jurisdiction K; LCD for chronic migraine; ⚠️ $2,100 Part D Cap means oral CGRPs now more viable for seniors (hit cap by March/April, then $0 rest of year)",Yes - documented oral failures,,,NGS LCD,New_Hampshire_2026_PA_Audit,NH-PARTB-NGS,NGS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
ALL,Medicare Part B (All MACs),Medicare MAC,Part B,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"Failed conventional cluster prevention (verapamil, lithium, topiramate)",Documented in medical record,,,Emgality 300mg monthly; ⛔ EPISODIC CLUSTER ONLY per FDA; ICD-10 must be G44.011 or G44.019,Yes - documented intolerance to verapamil or lithium,No - Federal Medicare,,LCD varies by MAC,Medicare Cluster Headache Coverage Policy,ALL-PARTB-CLUSTER,MEDICARE,DENY-CLUSTER-001,False,,⛔ CLUSTER HEADACHE - DISTINCT FROM MIGRAINE. Emgality 300mg is ONLY FDA-approved CGRP. Episodic cluster only (G44.01x).
MA,Blue Cross Blue Shield Massachusetts,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"Failure of verapamil, lithium, OR topiramate",Documented trial,,,Emgality 300mg monthly; ≥5 cluster attacks per month required,Yes - cardiac or renal/thyroid contraindications,N/A for cluster,,BCBSMA Cluster Policy,Massachusetts_2026_PA_Audit,MA-COM-BCBSMA-CLUSTER,BCBSMA,DENY-CLUSTER-001,False,,BCBSMA cluster: Emgality 300mg for episodic cluster requires verapamil/lithium/topiramate failure.
NJ,Aetna,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil OR lithium,Documented trial,,,Emgality 300mg monthly; ⚠️ Use cluster PA form NOT migraine form,Yes - documented intolerance,N/A for cluster,,Aetna Cluster Policy,New_Jersey_2026_PA_Audit,NJ-COM-AETNA-CLUSTER,60054,DENY-CLUSTER-001,False,,⚠️ Aetna cluster criteria DISTINCT from migraine. Using migraine PA form = automatic denial.
OK,Blue Cross Blue Shield Oklahoma,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"Failure of verapamil, lithium, OR topiramate",Documented trial,,,Emgality 300mg monthly; Episodic cluster only,Yes - documented contraindications,HB 1808 transparency applies,,BCBSOK Cluster Policy,Oklahoma_2026_PA_Audit,OK-COM-BCBSOK-CLUSTER,HCSC,DENY-CLUSTER-001,False,,"BCBSOK cluster: Emgality 100mg is the only indicated CGRP. Step therapy: verapamil, lithium, or topiramate."
ALL,UnitedHealthcare (National),Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"≥1 conventional cluster preventive (verapamil preferred, lithium, topiramate)",Adequate trial documented,,,Emgality 300mg monthly; Episodic cluster diagnosis required (G44.01x),Yes - cardiac/renal/thyroid contraindications,Yes (National Gold Card),≥92% approval x 2 years,UHC Cluster Policy,UHC_National_Guidelines,ALL-COM-UHC-CLUSTER,87726,DENY-CLUSTER-001,False,,UHC cluster: Requires episodic diagnosis and failure of at least one conventional preventive.
ALL,Cigna (National),Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Documented trial of verapamil AND/OR lithium at therapeutic doses,≥2 weeks each,,,Emgality 300mg monthly; ⚠️ Cluster criteria separate from migraine,Yes - document ECG abnormalities for verapamil; renal function for lithium,Yes (National Gold Card),Voluntary program,Cigna Cluster Policy,Cigna_National_Guidelines,ALL-COM-CIGNA-CLUSTER,62308,DENY-CLUSTER-001,False,,Cigna cluster: Requires verapamil and/or lithium failure. ECG documentation important.
ALL,Aetna (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class (Beta-blocker OR Anticonvulsant OR Antidepressant),≥3 months each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,,CPB 0970,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-001,True,,
ALL,Aetna (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,,,16 tablets/30 days,Yes - CV disease; Hemiplegic migraine,No,,CGRP Oral Policy 3481-E,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-001,True,,
ALL,Aetna (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (Anticonvulsant + one other),≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,,CPB 0113,National_Aetna_CPB_2026,ALL-COM-AETNA,60054,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo for ≥3 months with ≥8 migrainous days). Aetna requires ≥4 hrs/day documentation.
ALL,Cigna (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (from: Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,,IP0377,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-001,True,8.0,Cigna has tiered policy: High-freq episodic (≥8 days/mo) may have expedited access
ALL,Cigna (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (Step 1: Sumatriptan/Rizatriptan),≥30 days each,,,16 tablets/30 days,Yes - CV disease; Hemiplegic migraine,No,,Migraine Step Therapy Policy,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-001,True,,
ALL,Cigna (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,,IP0637,National_Cigna_Policy_2026,ALL-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo). Renewal requires documented reduction in headache days.
ALL,Anthem/Elevance (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥1 oral preventive class (Beta-blocker OR Anticonvulsant OR Antidepressant),≥2 months,,,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,,ING-CC-0032,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-001,True,,Anthem more lenient: requires only 1 oral failure. Prefers Emgality/Ajovy over Aimovig.
ALL,Anthem/Elevance (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 generic triptans,≥30 days each,,,16 tablets/30 days,Yes - CV disease; Uncontrolled HTN,No,,Antimigraine Policy,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-001,True,,
ALL,Anthem/Elevance (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (must include anticonvulsant: Topiramate/Divalproex),≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity bypasses anticonvulsant requirement,No,,ING-CC-0032,National_Anthem_Policy_2026,ALL-COM-ANTHEM,14163,DENY-STEP-002,False,,⛔ Chronic Migraine only. Combination ban: Botox+CGRP requires refractory documentation.
ALL,Humana (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (from: Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity,Yes,Provider Gold Card program (voluntary),,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-001,True,,
ALL,Humana (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,,,16 tablets/30 days,Yes - CV disease,Yes,Provider Gold Card program (voluntary),,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-001,True,,
ALL,Humana (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,Yes,Provider Gold Card program (voluntary),,National_Humana_Policy_2026,ALL-COM-HUMANA,61101,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo).
ALL,Kaiser Permanente (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥3 oral preventive classes: Beta-blocker (Propranolol/Atenolol) + TCA (Amitriptyline/Nortriptyline) + Anticonvulsant (Topiramate/Divalproex),≥6-8 weeks each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity; Cognitive impairment,No,,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-003,True,,"⚠️ Most restrictive: ""Step 3"" firewall requires 3 class failures. CGRPs are Tier 4/Non-Preferred."
ALL,Kaiser Permanente (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,,,16 tablets/30 days,Yes - CV disease,No,,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-001,True,,
ALL,Kaiser Permanente (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,,Kaiser Formulary 2026,National_Kaiser_Policy_2026,ALL-COM-KAISER,91051,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo). Concurrent CGRP+Botox prohibited without explicit refractory documentation.
ALL,Molina Healthcare (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (from: Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-001,True,,
ALL,Molina Healthcare (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,,,8 tablets/30 days,Yes - CV disease,No,,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-001,True,,⚠️ Molina may have stricter quantity limits (8 vs 16 tablets)
ALL,Molina Healthcare (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,,Molina Medical Policy 2026,National_Molina_Policy_2026,ALL-COM-MOLINA,20554,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo).
ALL,Centene/Ambetter (National),Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,"≥2 oral preventive classes (from: Beta-blockers, Anticonvulsants, Antidepressants)",≥8 weeks each,,,4 syringes/28 days,Yes - CV disease; Teratogenicity,No,,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-001,True,,
ALL,Centene/Ambetter (National),Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 triptans (failure/contraindication/intolerance),≥30 days each,,,16 tablets/30 days,Yes - CV disease,No,,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-001,True,,
ALL,Centene/Ambetter (National),Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,155 units/12 weeks,Yes - Teratogenicity; Severe AE,No,,Centene Medical Policy 2026,National_Centene_Policy_2026,ALL-COM-CENTENE,36273,DENY-STEP-002,False,,⛔ Chronic Migraine only (≥15 days/mo).
AL,BCBS Alabama,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Trial of injectable CGRP or oral preventive (plan dependent),≥8 weeks,,,30 tabs/30 days,Yes - standard bypasses,No,,,Alabama_2026_PA_Audit.docx,AL-COM-BCBSAL,,DENY-STEP-001,True,,Preferred Tier 2/3 but may require injectable step
AL,Alabama Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria with CC,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Alabama_2026_PA_Audit.docx,AL-MCD-ALMED,,DENY-STEP-001,True,,Listed as Preferred with Clinical Criteria
AZ,BCBS Arizona,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Failure of oral preventives,≥8 weeks,Fail injectable CGRP (Aimovig) in some plans,,30 tabs/30 days,Yes - needle phobia,No,,,Arizona_2026_PA_Audit.docx,AZ-COM-BCBSAZ,,DENY-STEP-001,True,,Preferred but gated behind injectable step in some plans
AZ,BCBS Arizona,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,,,,,,No dual therapy with CGRP acute without documentation,No,,,Arizona_2026_PA_Audit.docx,AZ-COM-BCBSAZ,,DENY-DUAL-001,True,,Dual therapy restriction - requires partial response documentation
CA,Medi-Cal,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Per CDL criteria,≥8 weeks,,,30 tabs/30 days,Continuity of care; stable on therapy,,,,California_2026_PA_Audit.docx,CA-MCD-MEDICAL,,DENY-STEP-001,True,,Non-preferred if not on CDL - PA before Jan 1 2026
CO,Multiple,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Colorado_2026_PA_Audit.docx,CO-COM-VARIOUS,,DENY-STEP-001,True,,Medicare Part D: $2000 cap eliminates donut hole
DE,Delaware First Health (Centene),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Fail oral preventives,≥6 weeks,Fail preferred CGRP mAb,,30 tabs/30 days,90-day transition fill for plan switches,,,CP.PHAR.230,Delaware_2026_PA_Audit.docx,DE-MCD-DELAWARE1ST,,DENY-STEP-001,True,,Step 3 agent - requires oral AND mAb failure
FL,Florida Blue,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail injectable CGRP first,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Florida_2026_PA_Audit.docx,FL-COM-FLBLUE,,DENY-STEP-001,True,,Usually requires step through injectable CGRP first
FL,Multiple,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - Topamax bypass for CGRP,No,,,Florida_2026_PA_Audit.docx,FL-COM-VARIOUS,,DENY-STEP-001,True,,First-line defense argument applies
KS,Blue KC,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Per UHC step therapy protocol,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Kansas_PA_Audit_Migraine_Drug_Defense.docx,KS-COM-BLUEKC,,DENY-STEP-001,True,,UHC step therapy reference
MD,CareFirst,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Skip Topiramate/Beta-blockers with justification,≥8 weeks,,,30 tabs/30 days,Yes - cognitive slowing; weight gain; hypotension,No,,,Maryland_2026_PA_Audit_Defense_Kit.docx,MD-COM-CAREFIRST,,DENY-STEP-001,True,,First-line argument for oral CGRP access
MN,HealthPartners,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail preferred injectable CGRPs (Aimovig/Emgality),≥8 weeks,,,30 tabs/30 days,Yes - needle phobia,No,,,Minnesota_2026_PA_Audit.docx,MN-COM-HEALTHPART,,DENY-STEP-001,True,,Non-Preferred - requires injectable CGRP failure
MN,BCBS Minnesota,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Oral preventive history,≥8 weeks,Injectable CGRP in some plans,,30 tabs/30 days,No dual therapy with Botox without documentation,No,,,Minnesota_2026_PA_Audit.docx,MN-COM-BCBSMN,,DENY-DUAL-001,True,,Tier 4/5 placement; dual therapy restrictions
NV,Aetna,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 2 oral classes,≥6 weeks each,Fail 1 injectable CGRP,,30 tabs/30 days,Yes - needle phobia valid bypass,No,,,Nevada_2026_PA_Audit_Report.docx,NV-COM-AETNA,,DENY-STEP-001,True,,Double step - common bottleneck
NV,Multiple,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - needle phobia; arthritis; tremor,No,,,Nevada_2026_PA_Audit_Report.docx,NV-COM-VARIOUS,,DENY-STEP-001,True,,Part D covers oral preventive
NJ,UHC NJ,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Per UHC protocol,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,New_Jersey_2026_PA_Audit.docx,NJ-COM-UHC,,DENY-STEP-001,True,,UHC PA notification applies
NY,NY Medicaid (NYRx),Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail preferred agents (Emgality/Nurtec) OR contraindication,≥8 weeks,,,30 tabs/30 days,Yes - latex allergy; adverse reaction,,,,New_York_2026_PA_Audit.docx,NY-MCD-NYRX,,DENY-STEP-001,True,,Non-Preferred - requires step through Nurtec ODT or Emgality
NY,Empire BCBS,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP (1-2 oral classes depending on plan),≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,New_York_2026_PA_Audit.docx,NY-COM-EMPIRE,,DENY-STEP-001,True,,Tier 2 Preferred - Empire is oral-forward
NY,UHC NY,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail triptans (acute history) AND oral preventives,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,New_York_2026_PA_Audit.docx,NY-COM-UHC,,DENY-STEP-001,True,,Strictly gated - triptan AND oral preventive failures
NY,Fidelis,Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Submit to NYRx not Fidelis,,,,30 tabs/30 days,,,,,New_York_2026_PA_Audit.docx,NY-MCD-FIDELIS,,DENY-STEP-001,True,,Split benefit trap - pharmacy carved to NYRx
OH,Ohio UPDL,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail oral generics AND preferred injectable CGRP,≥8 weeks,,,30 tabs/30 days,None documented,,,,Ohio_2026_PA_Audit_Strategy.docx,OH-MCD-UPDL,,DENY-STEP-001,True,,Non-Preferred with strict Step Therapy
OH,Anthem Ohio,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail preferred injectable CGRP (Emgality/Aimovig),≥8 weeks,,,30 tabs/30 days,Yes - needle phobia (F40.231); inability to self-inject,No,,,Ohio_2026_PA_Audit_Strategy.docx,OH-COM-ANTHEM,,DENY-STEP-001,True,,Double step - requires injectable CGRP step
OR,OEBB/Regence,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Oregon_2026_PA_Audit.docx,OR-COM-REGENCE,,DENY-STEP-001,True,,Non-Preferred (N) status
PA,PA DHS Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,PA DHS Statewide PDL requirements,≥8 weeks,,,30 tabs/30 days,Stability exception available,,,,Pennsylvania_2026_PA_Audit.docx,PA-MCD-PADHS,,DENY-STEP-001,True,,Pharmacy carved out to FFS PDL for MCOs
RI,BCBS RI,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 2 oral preventive classes AND injectable CGRP mAbs,≥8 weeks,,,30 tabs/30 days,Yes - needle phobia,No,,,Rhode_Island_2026_PA_Audit.docx,RI-COM-BCBSRI,,DENY-STEP-001,True,,Restricted - requires injectable CGRP failure
SD,Medicare Part D,Medicare,Part D,Gepants (Preventive),Preventive,Yes,Per formulary tier,,,,30 tabs/30 days,,No,,,South_Dakota_2026_PA_Audit.docx,SD-PARTD-VARIOUS,,DENY-STEP-001,True,,$2000 cap - hit cap early for free scripts
TX,Ambetter,Marketplace,ACA,Gepants (Preventive),Preventive,Yes,Formulary Exception required,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Texas_2026_PA_Audit.docx,TX-ACA-AMBETTER,,DENY-STEP-001,True,,Non-Preferred - frequently restricted
UT,Healthy U (Medicaid),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Fail Ajovy AND Emgality AND Aimovig OR documented disability/phobia,≥8 weeks,,,30 tabs/30 days,Yes - needle phobia with vasovagal response; documented injection disability,,,pharm-hu-016,Utah_2026_PA_Audit.docx,UT-MCD-HEALTHYU,,DENY-STEP-001,True,,LAST-LINE - must fail ALL 3 mAbs or have documented phobia
UT,SelectHealth,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail oral generics AND injectable CGRP mAbs,≥8 weeks,,,30 tabs/30 days,Yes - needle phobia,No,,,Utah_2026_PA_Audit.docx,UT-COM-SELECT,,DENY-STEP-001,True,,Step 3 positioning - similar to Healthy U
WA,Premera,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail injectables first,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,Washington_State_PA_Audit_2026.docx,WA-COM-PREMERA,,DENY-STEP-001,True,,Non-preferred - requires injectable failure
WA,Premera,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 2 pediatric-appropriate preventives,≥8 weeks,,,30 tabs/30 days,Yes - pediatric pathway available,No,,,Washington_State_PA_Audit_2026.docx,WA-COM-PREMERA-PED,,DENY-STEP-001,True,,PEDIATRIC (6-17): Specific criteria for Qulipta - formal pathway
WV,CareSource,Marketplace,ACA,Gepants (Preventive),Preventive,Yes,Per formulary,≥8 weeks,,,30 tabs/30 days,Member exception request for non-formulary,No,,,West_Virginia_2026_PA_Audit.docx,WV-ACA-CARESOURCE,,DENY-STEP-001,True,,Non-preferred - exception process for stable patients
IN,Anthem BCBS,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥1 oral preventive class (beta-blocker/TCA/anticonvulsant),≥8 weeks,Fail preferred CGRP mAb (Aimovig OR Emgality),,30 tabs/30 days,Yes - needle phobia; injection site reactions,No,,ING-CC-0032,Indiana_2026_PA_Audit.md,IN-COM-ANTHEM,,DENY-STEP-001,True,,Third-line therapy positioning
AR,Arkansas Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Fail preferred CGRP mAb (injectable),,30 tabs/30 days,Yes - CV contraindication,,,,Arkansas_2026_PA_Audit.md,AR-MCD-ARMEDIC,,DENY-STEP-001,True,,Step 2 oral preventive
CT,CT Exchange Plans,Marketplace,ACA,Gepants (Preventive),Preventive,Yes,≥1 oral preventive class,≥8 weeks,,,30 tabs/30 days,Yes - intolerance to oral preventives,No,,,Connecticut_2026_PA_Audit.md,CT-ACA-EXCHANGE,,DENY-STEP-001,True,,Preferred status - less restrictive
NC,BCBS NC,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral prophylactic classes,≥8 weeks each,,,30 tabs/30 days,Yes - CV contraindication,No,,,North_Carolina_2026_PA_Audit.md,NC-COM-BCBSNC,,DENY-STEP-001,True,,Concurrent use with Aimovig/Emgality excluded
ND,ND Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥2 months each,Fail ALL 3 CGRP mAbs (Ajovy/Emgality/Aimovig),≥3 months each,30 tabs/30 days,None documented,,,,North_Dakota_2026_PA_Audit.md,ND-MCD-NDMEDIC,,DENY-STEP-001,True,,MOST RESTRICTIVE - effectively Step 4
VA,Sentara,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventives,≥8 weeks,Fail 1 injectable CGRP (Aimovig/Ajovy/Emgality),,30 tabs/30 days,Yes - needle phobia; injection impossible,No,,IP0377,Virginia_2026_PA_Audit.md,VA-COM-SENTARA,,DENY-STEP-001,True,,Preferred but requires mAb step edit
WI,GHC/Quartz,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral classes (beta-blocker/topiramate),≥8 weeks,,,30 tabs/30 days,Yes - history of triptan use,Yes,,Gold Card,Wisconsin_2026_PA_Audit.md,WI-COM-QUARTZ,,DENY-STEP-001,True,,Gold Card bypass available
OK,UHC,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventives,≥2 months each,Fail Aimovig/Emgality,,30 tabs/30 days,Yes - needle phobia documented,No,,,Oklahoma_2026_PA_Audit.md,OK-COM-UHC,,DENY-STEP-001,True,,Double step - behind oral AND mAb
MI,BCBS MI,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventives,≥8 weeks,Fail preferred injectable CGRP (Aimovig/Emgality),,30 tabs/30 days,Yes - needle phobia,No,,,Michigan_2026_PA_Audit.md,MI-COM-BCBSMI,,DENY-STEP-001,True,,Step 2 CGRP positioning
VT,BCBS VT,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria (≥2 oral classes),≥8 weeks,,,30 tabs/30 days,Yes - standard bypasses,No,,,Vermont_2026_PA_Audit.md,VT-COM-BCBSVT,,DENY-STEP-001,True,,Preferred oral preventive option
AK,Premera,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 preventive classes,≥2 months each,,,30 tabs/30 days,Yes - CV disease,No,,,Alaska_2026_PA_Audit.md,AK-COM-PREMERA,,DENY-STEP-001,True,,Non-preferred with PA
HI,HMSA,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail preferred agent (Aimovig),,,,30 tabs/30 days,Yes - adverse effect from preferred,No,,,Hawaii_2026_PA_Audit.md,HI-COM-HMSA,,DENY-STEP-001,True,,Non-preferred status
IA,UHC IA,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral generic classes,≥2 months each,,,30 tabs/30 days,Yes - intolerance,No,,,Iowa_2026_PA_Audit.md,IA-COM-UHC,,DENY-STEP-001,True,,Higher tier or step therapy through preferred orals
LA,UHC LA,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Triptan history + oral preventive,,Preferred CGRP mAb trial (some plans),,30 tabs/30 days,Yes - vasoconstrictor contraindication,No,,,Louisiana_2026_PA_Audit.md,LA-COM-UHC,,DENY-STEP-001,True,,Exempt from Gold Carding (pharmacy benefit)
MA,MassHealth,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Massachusetts_2026_PA_Audit.md,MA-MCD-MASSHLTH,,DENY-STEP-001,True,,Listed with preventive agents
MO,UHC MO,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,Injectable CGRP failure,,30 tabs/30 days,Yes - needle phobia,No,,,Missouri_2026_PA_Audit.md,MO-COM-UHC,,DENY-STEP-001,True,,Double step pattern
MS,UHC MS,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Fail preferred injectable CGRP (Aimovig/Emgality),,30 tabs/30 days,Yes - needle phobia,No,,,Mississippi_2026_PA_Audit.md,MS-COM-UHC,,DENY-STEP-001,True,,Double step required
NE,UHC NE,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard criteria,,,,30 tabs/30 days,Yes - standard,No,,,Nebraska_2026_PA_Audit.md,NE-COM-UHC,,DENY-STEP-001,True,,Expanded indications noted
SC,UHC SC,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,No,,,South_Carolina_2026_PA_Audit.md,SC-COM-UHC,,DENY-STEP-001,True,,Self-administered - pharmacy benefit
TN,TennCare (OptumRx),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,State PDL criteria,,,,30 tabs/30 days,Per PDL,,,,Tennessee_2026_PA_Audit.md,TN-MCD-TENNCARE,,DENY-STEP-001,True,,Split benefit - follows state PDL
TN,UHC TN,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventives,≥8 weeks,Injectable CGRP failure (some plans),Varies,30 tabs/30 days,Yes - needle phobia; injection site reactions,No,,,Tennessee_2026_PA_Audit.md,TN-COM-UHC,,DENY-STEP-001,True,,Varies by plan - some post-mAb positioning
WY,Medicare Part D,Medicare,Part D,Gepants (Preventive),Preventive,Yes,Per formulary tier,,,,30 tabs/30 days,,No,,,Wyoming_2026_PA_Audit.md,WY-PARTD-VARIOUS,,DENY-STEP-001,True,,Tier 3/4 specialty
GA,Multiple (Anthem/UHC),Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,Inferred: Similar to CGRP mAb,,30 tabs/30 days,Yes - standard CGRP bypasses,No,,,Georgia_2026_PA_Audit_Strategy.md,GA-COM-VARIOUS,,DENY-STEP-001,True,,FALLBACK from CGRP mAb baseline - verify gepant-specific
GA,Georgia Medicaid (Amerigroup),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Per Unified PDL,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Georgia_2026_PA_Audit_Strategy.md,GA-MCD-AMERIGRP,,DENY-STEP-001,True,,FALLBACK - Unified PDL step therapy
ID,Blue Cross Idaho,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,Inferred: May require mAb step,,30 tabs/30 days,Yes - standard CGRP bypasses,No,,,Idaho_2026_PA_Audit_Strategy.md,ID-COM-BCIID,,DENY-STEP-001,True,,FALLBACK from CGRP mAb baseline
ID,Idaho Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail 2 oral preventive classes (strict),≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Idaho_2026_PA_Audit_Strategy.md,ID-MCD-IDMED,,DENY-STEP-001,True,,FALLBACK - strict fail-first policy
IL,BCBS Illinois,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes (strict),≥8 weeks,Inferred: May require mAb step,,30 tabs/30 days,Yes - standard CGRP bypasses,No,,,Illinois_2026_PA_Audit_Strategy.md,IL-COM-BCBSIL,,DENY-STEP-001,True,,FALLBACK - one CGRP at a time policy
IL,Illinois Medicaid (HFS),Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail 2 distinct oral preventive classes,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Illinois_2026_PA_Audit_Strategy.md,IL-MCD-ILHFS,,DENY-STEP-001,True,,FALLBACK from CGRP mAb Policy 0970
KY,Anthem Kentucky,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail oral preventives (Tier 3 specialty step),≥8 weeks,Inferred: Similar to CGRP mAb,,30 tabs/30 days,Yes - CGRP mechanism different from triptans,No,,,Kentucky_2026_PA_Audit.md,KY-COM-ANTHEM,,DENY-STEP-001,True,,FALLBACK from CGRP mAb baseline
KY,Kentucky Medicaid (Humana/Passport),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Per state PDL criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Kentucky_2026_PA_Audit.md,KY-MCD-KYMED,,DENY-STEP-001,True,,FALLBACK - step therapy logic same as CGRP mAb
ME,Anthem Maine,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 2-3 oral preventive classes,≥8 weeks,Inferred: May require mAb step,,30 tabs/30 days,Yes - teratogenic risk bypass; standard CGRP bypasses,No,,,Maine_2026_PA_Audit_Report.md,ME-COM-ANTHEM,,DENY-STEP-001,True,,FALLBACK from CGRP mAb baseline
ME,Maine Medicaid (MaineCare),Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Per state criteria,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,Maine_2026_PA_Audit_Report.md,ME-MCD-MAINECARE,,DENY-STEP-001,True,,FALLBACK - apply CGRP mAb criteria
MT,BCBS Montana,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,Inferred: May require mAb step,,30 tabs/30 days,Yes - one-and-done rule applies (no repeat step therapy),No,,,Montana_2026_PA_Audit.md,MT-COM-BCBSMT,,DENY-STEP-001,True,,FALLBACK - one-and-done rule state
MT,Montana Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail 2 oral preventive classes,≥8 weeks,,,30 tabs/30 days,Yes - standard; no repeat step therapy,,,,Montana_2026_PA_Audit.md,MT-MCD-MTMED,,DENY-STEP-001,True,,FALLBACK - state law prohibits repeat step therapy
NH,Anthem New Hampshire,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes (national baseline),≥8 weeks,Inferred: May require mAb step per national policy,,30 tabs/30 days,Yes - standard CGRP bypasses,No,,,NATIONAL_BASELINE,NH-COM-ANTHEM,,DENY-STEP-001,True,,NATIONAL BASELINE - no state audit document
NH,NH Healthy Families,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Per national Medicaid trends,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,NATIONAL_BASELINE,NH-MCD-HEALTHYFAMILIES,,DENY-STEP-001,True,,NATIONAL BASELINE - no state audit document
NM,UHC New Mexico,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 agents for 8 weeks (UHC standard),≥8 weeks,Inferred: May require self-injectable CGRP step,,30 tabs/30 days,Yes - standard CGRP bypasses,No,,,New_Mexico_2026_PA_Audit.docx,NM-COM-UHC,,DENY-STEP-001,True,,FALLBACK from CGRP mAb Step Therapy
NM,Molina New Mexico,Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Fail 2 classes per state PDL,≥8 weeks,,,30 tabs/30 days,Yes - standard,,,,New_Mexico_2026_PA_Audit.docx,NM-MCD-MOLINA,,DENY-STEP-001,True,,FALLBACK - follows state PDL
AK,Premera,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 preventive classes,≥2 months,,,16 tabs/30 days,Yes - standard CGRP bypasses,No,,,Alaska_2026_PA_Audit.md,AK-COM-PREMERA,,DENY-STEP-001,True,,High-cost preventive - accelerates OOP cap
AL,BCBS Alabama,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Similar to CGRP mAb criteria,≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Alabama_2026_PA_Audit.docx,AL-COM-BCBSAL,,DENY-STEP-001,True,,Branded preventive option
AR,Arkansas Medicaid,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,,,16 tabs/30 days,Yes - standard,No,,,Arkansas_2026_PA_Audit.md,AR-MCD-ARMEDIC,,DENY-STEP-001,True,,Preferred with preventive dosing
CA,Medi-Cal,Medicaid FFS,Medicaid,Gepants (Preventive),Preventive,Yes,Fail CGRPs (Aimovig/Emgality) + standard criteria,≥8 weeks,,,16 tabs/30 days,Unknown,No,,,California_2026_PA_Audit.docx,CA-MCD-MEDICAL,,DENY-STEP-001,True,,Requires CGRP mAb failure for preventive use
IL,BCBS Illinois,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,,,16 tabs/30 days,Unknown,No,,,Illinois_2026_PA_Audit.md,IL-COM-BCBSIL,,DENY-DUAL-001,True,,One CGRP at a time policy; cannot combine with Botox
IA,UHC Iowa,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,15-16 tabs/30 days,Yes - standard,No,,,Iowa_2026_PA_Audit.md,IA-COM-UHC,,DENY-STEP-001,True,,Preventive dosing logic applied
LA,UHC Louisiana,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Triptan history + oral preventive failure,≥8 weeks,Preferred CGRP mAb trial,,16 tabs/30 days,Yes - vasoconstrictor contraindication,No,,,Louisiana_2026_PA_Audit.md,LA-COM-UHC,,DENY-STEP-001,True,,Requires triptan AND preventive history
ME,Anthem Maine,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,,,16 tabs/30 days (vs 8 for acute),Yes - standard,No,,,Maine_2026_PA_Audit.md,ME-COM-ANTHEM,,DENY-STEP-001,True,,Quantity limit distinguishes acute vs preventive
MD,CareFirst,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Maryland_2026_PA_Audit.docx,MD-COM-CAREFIRST,,DENY-STEP-001,True,,Non-Preferred status
MN,HealthPartners,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Minnesota_2026_PA_Audit.docx,MN-COM-HEALTHPART,,DENY-STEP-001,True,,Only approved for EPISODIC migraine prevention
MS,UHC Mississippi,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral preventive classes,≥8 weeks each,Fail preferred injectable CGRP (Aimovig/Emgality),,16 tabs/30 days,Yes - needle phobia,No,,,Mississippi_2026_PA_Audit.md,MS-COM-UHC,,DENY-STEP-001,True,,Double step required; no dual CGRP therapy
MO,UHC Missouri,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Per Medicaid clinical pearl guidance,≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Missouri_2026_PA_Audit.md,MO-COM-UHC,,DENY-STEP-001,True,,Often restricted; clinical pearl for denials
MT,BCBS Montana,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 1 injectable CGRP (Aimovig/Emgality/Ajovy),≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Montana_2026_PA_Audit.md,MT-COM-BCBSMT,,DENY-STEP-001,True,,Step 2 preventive - requires mAb trial first
NC,BCBS NC,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail 2 oral prophylactic classes,≥8 weeks each,,,16 tabs/30 days,Yes - standard,No,,,North_Carolina_2026_PA_Audit.md,NC-COM-BCBSNC,,DENY-STEP-001,True,,Preferred status with preventive dosing; same QL for acute/preventive
NY,Empire BCBS,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria (less restrictive than injectable),≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,New_York_2026_PA_Audit.docx,NY-COM-EMPIRE,,DENY-STEP-001,True,,Preferred for preventive use - Empire is oral-forward
SC,UHC South Carolina,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Standard CGRP criteria,≥8 weeks,,,16 tabs/30 days (vs 8 acute),Yes - standard,No,,,South_Carolina_2026_PA_Audit.md,SC-COM-UHC,,DENY-STEP-001,True,,Quantity limit triggers preventive policy review
SD,Medicare Part D,Medicare,Part D,Gepants (Preventive),Preventive,Yes,Per formulary tier,,,,16 tabs/30 days,,No,,,South_Dakota_2026_PA_Audit.docx,SD-PARTD-VARIOUS,,DENY-STEP-001,True,,Avoid unless Aimovig/Ajovy/Emgality contraindicated
TN,TennCare (OptumRx),Medicaid MCO,Medicaid,Gepants (Preventive),Preventive,Yes,Per state PDL,,,,16 tabs/30 days,Per PDL,No,,,Tennessee_2026_PA_Audit.md,TN-MCD-TENNCARE,,DENY-STEP-001,True,,Split benefit - follows state PDL
UT,SelectHealth,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail oral generics AND injectable CGRP mAbs,≥8 weeks,,,16 tabs/30 days,Yes - needle phobia,No,,,Utah_2026_PA_Audit.docx,UT-COM-SELECT,,DENY-STEP-001,True,,Step 3 positioning - same as Qulipta
WA,Premera,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail injectables first,≥8 weeks,,,16 tabs/30 days,Yes - standard,No,,,Washington_State_PA_Audit.docx,WA-COM-PREMERA,,DENY-STEP-001,True,,Non-preferred - requires injectable failure
WI,GHC/Quartz,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,≥2 oral classes,≥8 weeks,,,16 tabs/30 days,Yes - history of triptan use,No,,,Wisconsin_2026_PA_Audit.md,WI-COM-QUARTZ,,DENY-STEP-001,True,,Preferred preventive; Gold Card may apply
WY,Medicare Part D,Medicare,Part D,Gepants (Preventive),Preventive,Yes,Per formulary tier,,,,16 tabs/30 days,,No,,,Wyoming_2026_PA_Audit.md,WY-PARTD-VARIOUS,,DENY-STEP-001,True,,Part D covers oral preventives
NY,Fidelis Care,Medicaid MCO,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil and/or lithium at therapeutic doses (verapamil ≥240mg/day),Documented trial,,,Emgality 300mg monthly; ⚠️ The 'Cluster' Loophole: Emgality 300mg is ONLY FDA-approved for episodic cluster - migraine preventive step therapy is clinically invalid for cluster dx,"Yes - documented intolerance to verapamil (bradycardia, heart block, hypotension) or lithium (renal impairment, thyroid dysfunction)",N/A for cluster,,Fidelis Cluster Policy,New_York_2026_PA_Audit,NY-MCD-FIDELIS-CLUSTER,CENTENE,DENY-CLUSTER-001,False,,⚠️ CLUSTER HEADACHE - DISTINCT FROM MIGRAINE. Topiramate failure is NOT required as it's a migraine drug. Emgality 300mg = ONLY FDA-approved CGRP for cluster.
NY,NYRx (Magellan),Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"Failure of ≥1 conventional cluster preventive (verapamil preferred, then lithium)",Documented trial at therapeutic doses,,,Emgality 300mg monthly; Carved out to state - submit PA to NYRx NOT MCO; ICD-10: G44.011 or G44.019 only,Yes - documented contraindications to verapamil/lithium,,,NYRx Cluster Criteria,New_York_2026_PA_Audit,NY-MCD-NYRX-CLUSTER,MAGELLAN,DENY-CLUSTER-001,False,,"NYRx cluster: Carve-out applies - submit to state Magellan portal, not Fidelis/MCO. Distinct from migraine criteria."
CA,L.A. Care Health Plan,Medicaid MCO,Medical Benefit,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil ≥240mg/day or lithium (therapeutic serum level 0.6-1.2 mEq/L),Documented trial,,,Emgality 300mg monthly; ⛔ EPISODIC CLUSTER ONLY (G44.01x); L.A. Care retains medical benefit control even with pharmacy carve-out,Yes - documented cardiac contraindication to verapamil; renal/thyroid contraindication to lithium,Gold Card tracking begins 2026 per SB 306,Data calibration year,L.A. Care Cluster Policy,California_2026_PA_Audit,CA-MCD-LACARE-CLUSTER,LACARE,DENY-CLUSTER-001,False,,L.A. Care cluster: Medical benefit NOT carved out to Medi-Cal Rx. Submit cluster PA directly to L.A. Care.
CA,Medi-Cal Rx (DHCS),Medicaid FFS,Medicaid Pharmacy,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil AND/OR lithium; transitional corticosteroid course may count,Documented trial,,,Emgality 300mg monthly; State-managed pharmacy benefit; ⚠️ Medical benefit (J3590) may require separate LA Care/MCP PA,Yes - standard cluster preventive contraindications,No state Gold Card,,Medi-Cal Rx Cluster Criteria,California_2026_PA_Audit,CA-MCD-MEDICALRX-CLUSTER,DHCS,DENY-CLUSTER-001,False,,Medi-Cal Rx cluster: Central FFS pharmacy benefit. Episodic cluster only per FDA label.
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil (titrated to ≥240mg or max tolerated) OR lithium at therapeutic serum level,Documented trial,,,Emgality 300mg monthly; Act 146 Gold Card tracking applies; ICD-10: G44.011/G44.019,"Yes - bradycardia, heart block, asthma (verapamil); renal impairment, thyroid disorder (lithium)",Act 146 (2026 measurement year),≥90% approval; exemptions begin 1/1/2027,Highmark Cluster Policy,Pennsylvania_2026_PA_Audit,PA-COM-HIGHBCBS-CLUSTER,54154,DENY-CLUSTER-001,False,,Highmark cluster: Step therapy is DISTINCT from migraine. Topiramate/beta-blocker failures do NOT count.
DE,Highmark BCBS DE,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil OR lithium at therapeutic doses,Documented trial,,,Emgality 300mg monthly; Episodic cluster only; Voluntary Gold Card available,Yes - cardiac/renal/thyroid contraindications,Yes (Voluntary),90% approval rate,Highmark DE Cluster Policy,Delaware_2026_PA_Audit,DE-COM-HIGHBCBS-CLUSTER,65093,DENY-CLUSTER-001,False,,Highmark DE cluster: Delaware 18 Del. C. § 3381 step therapy exemption applies if conventional tx likely ineffective.
WI,ForwardHealth (WI Medicaid),Medicaid FFS,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil (titrated per AHS guidelines) AND/OR lithium,Documented titration,,,Emgality 300mg monthly; ForwardHealth portal PA; ⛔ Episodic cluster only (G44.01x),Yes - documented contraindications per AHS 2016 cluster guidelines,N/A for Medicaid,,ForwardHealth Cluster Policy,Wisconsin_2026_PA_Audit,WI-MCD-FORWARD-CLUSTER,FORWARD,DENY-CLUSTER-001,False,,ForwardHealth cluster: WI SB 434 pending - may affect 2027 PA landscape.
TX,Texas Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of ≥1 conventional cluster preventive (verapamil or lithium),Documented trial,,,Emgality 300mg monthly; State PDL applies; ⚠️ Claims often require NDC override for 300mg vs 120mg,Yes - standard contraindications documented,N/A for Medicaid,,TX Medicaid Cluster Policy,Texas_2026_PA_Audit,TX-MCD-TXMEDICAID-CLUSTER,TXMEDICAID,DENY-CLUSTER-001,False,,Texas Medicaid cluster: Verify NDC for 300mg cluster dose vs 120mg migraine dose on PA.
FL,Florida Medicaid (Statewide),Medicaid MCO,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil ≥240mg/day or lithium therapeutic level,Documented trial,,,Emgality 300mg monthly; FL SMMC unified PDL applies; Episodic cluster only,Yes - cardiac/renal/thyroid contraindications,N/A for Medicaid,,FL Medicaid Cluster Policy,Florida_2026_PA_Audit,FL-MCD-FLMEDICAID-CLUSTER,AHCA,DENY-CLUSTER-001,False,,Florida Medicaid cluster: Statewide PDL governs across all MCOs.
AZ,BCBS Arizona,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil AND/OR lithium; topiramate optional per physician discretion,Documented trial,,,Emgality 300mg monthly; ⚠️ Cluster Headache override can be difficult - document episodic pattern clearly,Yes - standard contraindications,Yes (Gold Card Program),80% approval,BCBSAZ Cluster Policy,Arizona_2026_PA_Audit,AZ-COM-BCBSAZ-CLUSTER,BCBSAZ,DENY-CLUSTER-001,False,,BCBSAZ cluster: Distinct criteria from migraine. Document ≥5 attacks in a cluster period.
OH,Buckeye Health Plan,Medicaid MCO,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil (titrated appropriately) OR lithium,Documented trial,,,Emgality 300mg monthly; OH Medicaid unified PDL applies; Episodic cluster only (G44.01x),Yes - documented cardiac/renal contraindications,N/A for Medicaid,,Buckeye Cluster Policy,Ohio_2026_PA_Audit,OH-MCD-BUCKEYE-CLUSTER,CENTENE,DENY-CLUSTER-001,False,,"OH Medicaid cluster: HB 122 Gold Card law applies to commercial only, not Medicaid."
VA,Anthem HealthKeepers,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,"Failure of ≥1 conventional cluster preventive (verapamil, lithium, or topiramate)",Documented trial,,,Emgality 300mg monthly; VA § 38.2-3407.15:8 Gold Card eligibility tracking applies,Yes - documented contraindications to all three conventional agents,VA Gold Card Law (2027 implementation),Per HB 2099,Anthem HealthKeepers Cluster Policy,Virginia_2026_PA_Audit,VA-COM-ANTHEM-CLUSTER,36096,DENY-CLUSTER-001,False,,Anthem VA cluster: Document episodic pattern (attacks in bouts with remission periods ≥3 months).
WA,Premera BCBS WA,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil or lithium at therapeutic doses,Documented trial,,,Emgality 300mg monthly; Policy 5.01.503 covers cluster; Episodic cluster only per FDA,Yes - cardiac (verapamil) or renal/thyroid (lithium) contraindications,N/A for cluster,,Premera WA Cluster Policy,Washington_State_PA_Audit,WA-COM-PREMERA-CLUSTER,PREMERA,DENY-CLUSTER-001,False,,"Premera WA cluster: Per policy 5.01.503, cluster criteria are separate from migraine."
OR,Moda Health,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil ≥240mg/day (or max tolerated dose),Documented titration,,,Emgality 300mg monthly; ⚠️ Moda requires documented titration schedule for verapamil,Yes - documented intolerance or contraindication,N/A for cluster,,Moda Cluster Policy,Oregon_2026_PA_Audit,OR-COM-MODA-CLUSTER,MODA,DENY-CLUSTER-001,False,,Moda cluster: Document specific verapamil titration - 'tried 120mg' will be denied.
AK,Premera BCBS AK,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil or lithium at therapeutic doses per AHS cluster guidelines,Documented trial,,,Emgality 300mg monthly; Policy 5.01.503 applies; SB 133 PA reform effective 2027,Yes - documented cardiac/renal/thyroid contraindications,SB 133 future,,Premera AK Cluster Policy,Alaska_2026_PA_Audit,AK-COM-PREMERA-CLUSTER,PREMERA,DENY-CLUSTER-001,False,,"Premera AK cluster: Per policy 5.01.503, cluster headache criteria are distinct from migraine criteria."
HI,HMSA,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil (≥240mg/day) and/or lithium; may also require Noridian alignment for Part B,Documented trial,,,Emgality 300mg monthly; HMSA medical policy aligns with Noridian JE LCD,Yes - cardiac/renal/thyroid contraindications,N/A for cluster,,HMSA Cluster Policy,Hawaii_2026_PA_Audit,HI-COM-HMSA-CLUSTER,HMSA,DENY-CLUSTER-001,False,,HMSA cluster: May require concurrent Noridian MAC documentation for Medicare crossover patients.
NV,Nevada Medicaid (DHCFP),Medicaid FFS,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil (appropriately titrated) OR lithium at therapeutic serum level,Documented trial,,,Emgality 300mg monthly; State PDL criteria; Episodic cluster only (G44.01x),Yes - documented cardiac/renal/thyroid contraindications,N/A for Medicaid,,NV Medicaid Cluster Policy,Nevada_2026_PA_Audit,NV-MCD-NVMEDICAID-CLUSTER,DHCFP,DENY-CLUSTER-001,False,,NV Medicaid cluster: Verify PDL status for Emgality 300mg vs 120mg dosing.
CO,Colorado Medicaid,Medicaid FFS,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of ≥1 conventional cluster preventive (verapamil or lithium),Documented trial,,,Emgality 300mg monthly; CO Gold Card exemptions (commercial) per SB21-023 do NOT apply to Medicaid,Yes - documented contraindications,N/A for Medicaid,,CO Medicaid Cluster Policy,Colorado_2026_PA_Audit,CO-MCD-COMEDICAID-CLUSTER,HCPF,DENY-CLUSTER-001,False,,CO Medicaid cluster: Commercial Gold Card exemptions do not apply to Medicaid cluster headache PAs.
NM,BCBS New Mexico,Commercial,Commercial,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil OR lithium at therapeutic doses,Documented trial,,,Emgality 300mg monthly; Episodic cluster diagnosis required; HB 246 step therapy law applies,Yes - documented cardiac/renal contraindications,Yes per HB 246,TBD 2027,BCBSNM Cluster Policy,New_Mexico_2026_PA_Audit,NM-COM-BCBSNM-CLUSTER,HCSC,DENY-CLUSTER-001,False,,BCBS NM cluster: HB 246 step therapy reform may provide additional cluster bypass options.
KS,Sunflower Health Plan,Medicaid MCO,Medicaid,CGRP mAbs (Cluster),Cluster Headache Prevention,Yes,Failure of verapamil at ≥240mg/day or therapeutic dose per cardiology consultation,Documented titration,,,Emgality 300mg monthly; KS KDHE PDL applies; ⚠️ KDHE 2026 criteria update pending verification,Yes - documented cardiac contraindication,N/A for Medicaid,,Sunflower Cluster Policy,Kansas_PA_Audit,KS-MCD-SUNFLOWER-CLUSTER,CENTENE,DENY-CLUSTER-001,False,,Sunflower KS cluster: Verify KDHE PDL criteria for 2026 - criteria may have updated.
PA,Highmark Blue Cross Blue Shield,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail injectable CGRP (Aimovig/Ajovy),≥8 weeks,,,30 tabs/30 days,Yes - needle phobia; severe arthritis; tremor; anxiety; elderly/disabled alone,No,,,Pennsylvania_2026_PA_Audit.docx,PA-COM-HIGHBCBS,,DENY-STEP-001,True,,Injectable failure step with documented bypass options
PA,Independence Blue Cross,Commercial,Commercial,Gepants (Preventive),Preventive,Yes,Fail injectable CGRP (Aimovig/Ajovy),≥6 weeks,,,30 tabs/30 days,Yes - needle phobia; severe arthritis; tremor; anxiety; elderly/disabled alone,No,,,Pennsylvania_2026_PA_Audit.docx,PA-COM-IBX,,DENY-STEP-001,True,,Injectable failure step with documented bypass options
NH,Harvard Pilgrim NH,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,Documented,,,"Chronic Migraine dx (≥15 HA days/mo, ≥8 migraine days); 155 units/12 weeks",Yes - documented oral failures,⚠️ SB 561 applies,2 biz days,HPHC MNG,New_Hampshire_2026_Prior_Authorization_Audit,NH-COM-HARVARDPILGRIM,HPHC,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,NH Healthy Families,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (strict PDL),≥8 weeks each,,,"Chronic Migraine dx (≥15 HA days/mo, ≥8 migraine days); 155 units/12 weeks; Centene MCO approval",Yes - documented oral failures,N/A - Medicaid,,NH PDL,New_Hampshire_2026_Prior_Authorization_Audit,NH-MCD-HEALTHYFAMILIES,Centene,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. Episodic (4-14 days/month) = automatic denial. ICD-10 must be G43.7xx series.
NH,AmeriHealth Caritas NH,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with AmeriHealth PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-AMERIHEALTH,77003,DENY-STEP-001,True,,⚠️ NEEDS MANUAL REVIEW — AmeriHealth not in NH audit
NH,AmeriHealth Caritas NH,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with AmeriHealth PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-AMERIHEALTH,77003,DENY-STEP-002,True,,⚠️ NEEDS MANUAL REVIEW — AmeriHealth not in NH audit
NH,AmeriHealth Caritas NH,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with AmeriHealth PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-AMERIHEALTH,77003,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Well Sense Health Plan NH,Medicaid MCO,Medicaid,Gepants (Acute),Acute,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with WellSense PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-WELLSENSE,WLSNS,DENY-STEP-001,True,,⚠️ NEEDS MANUAL REVIEW — WellSense not in NH audit
NH,Well Sense Health Plan NH,Medicaid MCO,Medicaid,CGRP mAbs (SC),Preventive,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with WellSense PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-WELLSENSE,WLSNS,DENY-STEP-002,True,,⚠️ NEEDS MANUAL REVIEW — WellSense not in NH audit
NH,Well Sense Health Plan NH,Medicaid MCO,Medicaid,Neurotoxins,Chronic Migraine,Yes,⚠️ FLAG: Inferred from NH Medicaid baseline — verify with WellSense PA criteria,Verify,,,Per NH Medicaid PDL,Yes - standard,N/A - Medicaid,,⚠️ NEEDS VERIFICATION,INFERRED — Not in NH Audit (audit covers Centene only),NH-MCD-WELLSENSE,WLSNS,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Aetna NH,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (national Aetna baseline),Trial required,,,Per national Aetna formulary,Yes - CV contraindication,⚠️ SB 561 applies,2 biz days,National Aetna Policy,NATIONAL_BASELINE — Aetna not profiled in NH audit,NH-COM-AETNA,60054,DENY-STEP-001,True,,NATIONAL BASELINE — verify with state-specific filing
NH,Aetna NH,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national Aetna baseline),≥8 weeks each,,,Per national Aetna formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,National Aetna Policy,NATIONAL_BASELINE — Aetna not profiled in NH audit,NH-COM-AETNA,60054,DENY-STEP-002,True,,NATIONAL BASELINE — verify with state-specific filing
NH,Aetna NH,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Per national Aetna formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,National Aetna Policy,NATIONAL_BASELINE — Aetna not profiled in NH audit,NH-COM-AETNA,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Cigna NH,Commercial,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (national Cigna/ESI baseline),Trial required,,,Per national Cigna/Express Scripts formulary,Yes - CV contraindication,⚠️ SB 561 applies,2 biz days,National Cigna/ESI Policy,NATIONAL_BASELINE — Cigna mentioned in NH audit §1.3 but no deep-dive,NH-COM-CIGNA,62308,DENY-STEP-001,True,,NATIONAL BASELINE — verify with state-specific filing
NH,Cigna NH,Commercial,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national Cigna/ESI baseline),≥8 weeks each,,,Per national Cigna/Express Scripts formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,National Cigna/ESI Policy,NATIONAL_BASELINE — Cigna mentioned in NH audit §1.3 but no deep-dive,NH-COM-CIGNA,62308,DENY-STEP-002,True,,NATIONAL BASELINE — verify with state-specific filing
NH,Cigna NH,Commercial,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Per national Cigna/Express Scripts formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,National Cigna/ESI Policy,NATIONAL_BASELINE — Cigna mentioned in NH audit §1.3 but no deep-dive,NH-COM-CIGNA,62308,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Ambetter New Hampshire,ACA Exchange,Commercial,Gepants (Acute),Acute,Yes,≥2 preferred triptans (Centene/Ambetter baseline),Trial required,,,Per Centene/Ambetter formulary,Yes - CV contraindication,⚠️ SB 561 applies,2 biz days,Centene/Ambetter Policy,NATIONAL_BASELINE — NH audit §1.3 mentions Ambetter but no deep-dive,NH-COM-AMBETTER,68069,DENY-STEP-001,True,,NATIONAL BASELINE — same Centene infrastructure as NH Healthy Families
NH,Ambetter New Hampshire,ACA Exchange,Commercial,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (Centene baseline),≥8 weeks each,,,Per Centene/Ambetter formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,Centene/Ambetter Policy,NATIONAL_BASELINE — NH audit §1.3 mentions Ambetter but no deep-dive,NH-COM-AMBETTER,68069,DENY-STEP-002,True,,NATIONAL BASELINE — same Centene infrastructure as NH Healthy Families
NH,Ambetter New Hampshire,ACA Exchange,Commercial,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes,≥8 weeks each,,,Per Centene/Ambetter formulary,Yes - standard,⚠️ SB 561 applies,2 biz days,Centene/Ambetter Policy,NATIONAL_BASELINE — NH audit §1.3 mentions Ambetter but no deep-dive,NH-COM-AMBETTER,68069,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,NH Healthy Kids (CHIP),CHIP,CHIP,Gepants (Acute),Acute,Yes,≥2 preferred triptans (NH PDL via Centene),Documented,,,Per NH Medicaid PDL — CHIP inherits MCO criteria,Yes - standard,N/A - CHIP,,NH PDL (CHIP),INFERRED — CHIP uses NH Healthy Families (Centene) MCO policies,NH-CHIP-NHHF,NHHF-NH-CHIP,DENY-STEP-001,True,,⚠️ CHIP/Pediatric — verify age limits with NH DHHS
NH,NH Healthy Kids (CHIP),CHIP,CHIP,CGRP mAbs (SC),Preventive,Yes,≥2 different oral preventive classes (NH PDL),≥8 weeks each,,,Per NH Medicaid PDL — CHIP inherits MCO criteria,Yes - standard,N/A - CHIP,,NH PDL (CHIP),INFERRED — CHIP uses NH Healthy Families (Centene) MCO policies,NH-CHIP-NHHF,NHHF-NH-CHIP,DENY-STEP-002,True,,⚠️ CHIP/Pediatric — verify age limits with NH DHHS
NH,NH Healthy Kids (CHIP),CHIP,CHIP,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes (NH PDL),≥8 weeks each,,,Per NH Medicaid PDL — CHIP inherits MCO criteria,Yes - standard,N/A - CHIP,,NH PDL (CHIP),INFERRED — CHIP uses NH Healthy Families (Centene) MCO policies,NH-CHIP-NHHF,NHHF-NH-CHIP,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA. ⚠️ PEDIATRIC: Age restrictions may apply.
NH,Aetna Medicare NH,Medicare Advantage,MA,Gepants (Acute),Acute,Yes,≥1-2 preferred triptans (national Aetna MA baseline),Trial required,,,"Per CVS Caremark MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - CV contraindication,N/A - Federal/MA,,National Aetna MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-AETNACARE,60054,DENY-STEP-001,True,,NATIONAL BASELINE — verify with CVS Caremark MA formulary
NH,Aetna Medicare NH,Medicare Advantage,MA,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national Aetna MA baseline),≥8 weeks each,,,"Per CVS Caremark MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Aetna MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-AETNACARE,60054,DENY-STEP-002,True,,NATIONAL BASELINE — verify with CVS Caremark MA formulary
NH,Aetna Medicare NH,Medicare Advantage,MA,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes + chronic migraine dx,Documented,,,"Per CVS Caremark MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Aetna MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-AETNACARE,60054,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Anthem MA NH,Medicare Advantage,MA,Gepants (Acute),Acute,Yes,≥1-2 preferred triptans (national Anthem MA baseline),Trial required,,,"Per CarelonRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - CV contraindication,N/A - Federal/MA,,National Anthem MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-ELEV,47198,DENY-STEP-001,True,,NATIONAL BASELINE — verify with CarelonRx MA formulary
NH,Anthem MA NH,Medicare Advantage,MA,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national Anthem MA baseline),≥8 weeks each,,,"Per CarelonRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Anthem MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-ELEV,47198,DENY-STEP-002,True,,NATIONAL BASELINE — verify with CarelonRx MA formulary
NH,Anthem MA NH,Medicare Advantage,MA,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes + chronic migraine dx,Documented,,,"Per CarelonRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Anthem MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-ELEV,47198,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,Humana MA NH,Medicare Advantage,MA,Gepants (Acute),Acute,Yes,≥1-2 preferred triptans (national Humana MA baseline),Trial required,,,"Per Humana Pharmacy Solutions MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - CV contraindication,N/A - Federal/MA,,National Humana MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-HUMANA,61101,DENY-STEP-001,True,,NATIONAL BASELINE — verify with Humana Pharmacy Solutions MA formulary
NH,Humana MA NH,Medicare Advantage,MA,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national Humana MA baseline),≥8 weeks each,,,"Per Humana Pharmacy Solutions MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Humana MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-HUMANA,61101,DENY-STEP-002,True,,NATIONAL BASELINE — verify with Humana Pharmacy Solutions MA formulary
NH,Humana MA NH,Medicare Advantage,MA,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes + chronic migraine dx,Documented,,,"Per Humana Pharmacy Solutions MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National Humana MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-HUMANA,61101,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
NH,UnitedHealthcare MA NH,Medicare Advantage,MA,Gepants (Acute),Acute,Yes,≥1-2 preferred triptans (national UnitedHealthcare MA baseline),Trial required,,,"Per OptumRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - CV contraindication,N/A - Federal/MA,,National UnitedHealthcare MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-UHC,87726,DENY-STEP-001,True,,NATIONAL BASELINE — verify with OptumRx MA formulary
NH,UnitedHealthcare MA NH,Medicare Advantage,MA,CGRP mAbs (SC),Preventive,Yes,≥2 oral preventive classes (national UnitedHealthcare MA baseline),≥8 weeks each,,,"Per OptumRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National UnitedHealthcare MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-UHC,87726,DENY-STEP-002,True,,NATIONAL BASELINE — verify with OptumRx MA formulary
NH,UnitedHealthcare MA NH,Medicare Advantage,MA,Neurotoxins,Chronic Migraine,Yes,≥2 oral preventive classes + chronic migraine dx,Documented,,,"Per OptumRx MA formulary; ⚠️ $2,100 Part D OOP Cap (IRA) — oral CGRPs more viable post-cap",Yes - standard,N/A - Federal/MA,,National UnitedHealthcare MA Policy,"NATIONAL_BASELINE — NH audit mentions $2,100 cap impact (§2.1) but no MA-specific deep-dive",NH-MA-UHC,87726,DENY-STEP-002,False,,⛔ BOTOX = CHRONIC MIGRAINE ONLY per FDA.
